Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Conditions
Keywords
HER2, IMAB362, leucovorin, fluorouracil, Gastric cancer, claudiximab, zolbetuximab, oxaliplatin, adenocarcinoma, Gastro-Esophageal Junction cancer, HER2 Negative mFOLFOX6
Brief summary
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advanced stomach cancer or GEJ cancer will either be given zolbetuximab with chemotherapy or a placebo with chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. Zolbetuximab with chemotherapy has already been approved to treat gastric cancer and GEJ cancer in some countries. This study is being done in countries where zolbetuximab has not yet been approved for use. If zolbetuximab becomes approved for use in those countries taking part in this study, the study doctor will switch study treatment in those countries to the licensed zolbetuximab. If this happens, people taking part in those countries will leave this study and receive licensed zolbetuximab. The main aim of the study is to check if zolbetuximab and chemotherapy can prevent or delay the worsening of people's gastric cancer and GEJ cancer compared to placebo and chemotherapy. Adults with advanced stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample of their cancer will also have the Claudin 18.2 protein. They may have been previously treated with certain standard therapies, but have not been treated with chemotherapy for their cancer. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections. The study treatments are either zolbetuximab with chemotherapy, or placebo with chemotherapy. People who take part will receive just 1 of the study treatments by chance. Study treatment will be double-blinded. That means that the people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in cycles. The study treatment is given to people slowly through a tube into a vein. This is called an infusion. People will have 4 infusions in 6-week (42-day) cycles as follows: * Zolbetuximab or placebo - 2 infusions in a cycle. * Chemotherapy (called modified FOLFOX6 or mFOLFOX6) - 3 infusions in a cycle. The first infusion is combined with zolbetuximab or placebo on day 1 of each cycle. People may receive zolbetuximab or placebo until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will receive mFOLFOX6 for up to 6 months (4 study treatment cycles). After the 6 months people may receive chemotherapy containing folinic acid and fluorouracil instead of mFOLFOX6. People may receive folinic acid and fluorouracil chemotherapy for more than 6 months, or until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will visit the clinic on certain days during their study treatment. The study doctors will check if people had any medical problems from taking zolbetuximab or the other study treatments. Also, people in the study will have health checks. On some visits they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample after their study treatment has finished. People will visit the clinic after they stop their study treatment. People who start treatment with licensed zolbetuximab or mFOLFOX6 outside of this study will not need to visit the clinic. People will be asked about any medical problems and will have a health check. People will visit the clinic at 1 month after they stop their study treatment. People will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. People will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their study treatment or not.
Detailed description
After the marketing approval in Japan on 26 Mar 2024, this study continued as "post marketing clinical study" in Japan. In the rest of the countries which participated in this study, this study continued as clinical study.
Interventions
DRUGzolbetuximab
Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.
DRUGplacebo
Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.
DRUGoxaliplatin
Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.
DRUGfolinic acid
Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
DRUGfluorouracil
Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
Sponsors
Astellas Pharma Global Development, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female subject eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin and a demonstrated non-pregnant status through additional testing are eligible) and at least one of the following conditions applies: * Not a woman of child-bearing potential (WOCBP) OR * WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs * Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration. * Female subject must not donate ova starting at screening and throughout the study period, and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs. * A sexually active male subject with a female partner(s) who is of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration. * Male subject must agree not to donate sperm starting at screening and throughout the study period, and for 6 months after the final study drug administration. * Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration. * Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma. * Subject has radiologically confirmed locally advanced unresectable or metastatic disease within 28 days prior to randomization. * Subject has radiologically evaluable disease (measurable and/or non-measurable disease according to RECIST 1.1), per local assessment, ≤ 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy. * Subject's tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing. * Subject has a HER2-Negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ tumor.) * Subject has ECOG performance status 0 to 1. * Subject has predicted life expectancy ≥ 12 weeks. * Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility. * Hemoglobin (Hgb) ≥ 9 g/dL. Subjects requiring transfusions are eligible if they have a post-transfusion Hgb ≥ 9 g/dL. * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Albumin ≥ 2.5 g/dL * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) without liver metastases (or \< 3.0 x ULN if liver metastases are present) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (or ≤ 5 x ULN if liver metastases are present) * Estimated creatinine clearance ≥ 30 mL/min * Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)
Exclusion criteria
* Subject has received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, subject may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies, as long as it was completed at least 6 months prior to randomization. Subject may have received treatment with herbal medications that have known antitumor activity \> 28 days prior to randomization. * Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity. * Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed. * Subject has received other investigational agents or devices within 28 days prior to randomization. * Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies. * Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment. * Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6. * Subject has known dihydropyrimidine dehydrogenase deficiency. * Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting. * Subject has significant gastric bleeding and/or untreated gastric ulcers that would exclude the subject from participation. * Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements. * For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded. * Subjects with positive hepatitis C virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test are eligible. * Subjects treated for HCV with undetectable viral load results are eligible. * Subject has an active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization. * Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization. * Subject has significant cardiovascular disease, including any of the following: * Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months prior to randomization. * History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes) * QTc interval \> 450 msec for male subjects; QTc interval \> 470 msec for female subjects * History or family history of congenital long QT syndrome * Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for \> 1 month prior to randomization are eligible). * Subject has a history of central nervous system metastases and/or carcinomatous meningitis from gastric/GEJ cancer. * Subject has known peripheral sensory neuropathy \> Grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality. * Subject has had a major surgical procedure ≤ 28 days prior to randomization. * Subject is without complete recovery from a major surgical procedure ≤ 14 days prior to randomization. * Subject has psychiatric illness or social situations that would preclude study compliance. * Subject has another malignancy for which treatment is required. * Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From date of randomization until the date of first documented radiological progression or date of death from any cause, whichever occurred first (up to 62 months and 18 days) | PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan -Meier (KM) estimates was used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From the date of randomization until 62 months and 18 days | OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used. |
| Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | From the date of randomization until 62 months and 18 days | TTCD: time from randomization to first clinically meaning full deterioration (CMD) that was confirmed at next scheduled visit. EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical,role,emotional,social \& cognitive), 9 symptom scales (fatigue, nausea/vomiting,general pain,dyspnea,insomnia,appetite loss,constipation,diarrhea,financial difficulties) \& global health status scale. Most items were scored 1(not at all) to 4(very much) except for items contributing to global health status/QoL, which were scored 1(very poor) to 7(excellent). All raw domain scores were linearly transformed to 0-100scale with higher scores on symptoms indicate worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -13. This was derived from an Exit Survey conducted using Patient Global Impression of Severity/Change(PGIS/PGIC) questionnaires as an anchor for estimating meaningful change. KM estimates was used. |
| Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 | From the date of randomization until 62 months and 18 days | TTCD: time from randomization to first CMD that was confirmed at next scheduled visit. EORTC QLQ-OG25 evaluated gastric and GEJ cancer specific symptoms. A 25 item instrument with 6 scales: dysphagia (3 items), eating restrictions (4 ), reflux (2), odynophagia (2), pain and discomfort (2), anxiety (2), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight and hair loss. Items were scored:1: not at all; 2: a little, 3: quite a bit, 4: very much, and were transformed linearly into scores (0 to 100) with higher scores indicating worse symptoms. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of 16.67. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used. |
| Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | From the date of randomization until 62 months and 18 days | TTCD: time from randomization to first CMD that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items were scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which were scored 1 ("very poor") to 7 ("excellent"). All raw domain scores were linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -10. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used. |
| Objective Response Rate (ORR) | From the date of randomization until 62 months and 18 days | ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. |
| Duration Of Response (DOR) | From date of first response (CR/PR) until 62 months and 18 day | DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.PD was defined as development of new, or progression of existing metastases to the primary cancer under the sudy. |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose until 62 months and 18 days | An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or notconsidered related to the medicinal product. TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose. |
| Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline, cycle (C) 1 day (D) 22, D1 and D22 of C2 through C39 | ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead. |
| Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up | The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. |
| Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up | The EORTC-QLQ-OG25 consists of a 25-item instrument that evaluates gastric and GEJ cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. This module consists of 6 scales: dysphagia (3 items), eating restrictions (4 items), reflux (2 items), odynophagia (2 items), pain and discomfort (2 items) and anxiety (2 items), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. All questions have four response alternatives (1:not at all; 2:a little, 3:quite a bit, 4:very much). Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 For symptom scales/items, higher scores indicate worse symptoms. |
| Change From Baseline in HRQoL Measured by Global Pain (GP) | Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up | The GP instrument is a single assessment of overall pain. Participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain. |
| Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up | EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples. |
| Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | Predose on C1D22, C3D1, C5D1, C7D1, C9D1 | Ctrough was defined as the predose concentration at the end of dosing interval. |
| Number of Participants With Anti-drug Antibodies (ADA) | Predose on C1D1, C1D22, C3D1, C5D1, C7D1, C9D1, 30-day follow up, 90-day follow up | Immunogenicity will be measured by the number of participants that are ADA positive. |
Countries
Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Mexico, Peru, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
Contacts
STUDY_DIRECTORGlobal Medical Lead
Astellas Pharma Global Development, Inc.
Participant flow
Recruitment details
Participants with claudin (CLDN)18.2-positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Pre-assignment details
Participants who met all inclusion criteria and none of the exclusion criteria were enrolled in the study. Randomization was stratified by region (Asia vs Non-Asia), number of organs with metastatic sites (0 to 2 vs ≥ 3) and prior gastrectomy (Yes or No).
Participants by arm
| Arm | Count |
|---|---|
| mFOLFOX6 + Zolbetuximab Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Participants also received up to 12 treatments of 5-fluorouracil, folinic acid and oxaliplatin (mFOLFOX6) (or components of mFOLFOX6 if some components were discontinued due to toxicity) over 4 or more cycles in which mFOLFOX6 was administered on Days 1, 15 and 29 of each cycle (5-fluorouracil administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid administered 400 mg/m\^2 IV infusion over 2 hours; oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours). A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants could continue to receive 5-FU and folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days. | 283 |
| mFOLFOX6+Placebo Participants received an IV infusion (minimum 2-hour infusion) of placebo matched to zolbetuximab on C1D1, followed by subsequent doses every 3 weeks starting from C1D22 until study treatment discontinuation criteria were met. Participants also received up to 12 treatments of mFOLFOX6 (or components if some were discontinued due to toxicity) over 4 or more cycles. mFOLFOX6 was administered on Days 1, 15, and 29 of each cycle (5-fluorouracil: 400 mg/m\^2 IV bolus over 5-15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid: 400 mg/m\^2 IV infusion over 2 hours; oxaliplatin: 85 mg/m\^2 IV infusion over 2 hours). A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants could continue to receive 5-FU and folinic acid on Days 1, 15, and 29 of each cycle at the investigator's discretion or until study treatment discontinuation criteria were met. Each cycle was approximately 42 days. | 282 |
| Total | 565 |
Baseline characteristics
| Characteristic | Total | mFOLFOX6+Placebo | mFOLFOX6 + Zolbetuximab |
|---|---|---|---|
| Age, Continuous | 59.3 Years STANDARD_DEVIATION 12.4 | 58.8 Years STANDARD_DEVIATION 13 | 59.7 Years STANDARD_DEVIATION 11.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 73 Participants | 37 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 438 Participants | 213 Participants | 225 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 54 Participants | 32 Participants | 22 Participants |
| Number of organs with metastatic sites 0-2 metastatic sites | 438 Participants | 219 Participants | 219 Participants |
| Number of organs with metastatic sites >=3 metastatic sites | 127 Participants | 63 Participants | 64 Participants |
| Prior Gastrectomy NO | 399 Participants | 200 Participants | 199 Participants |
| Prior Gastrectomy YES | 166 Participants | 82 Participants | 84 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 17 Participants | 8 Participants | 9 Participants |
| Race (NIH/OMB) Asian | 193 Participants | 97 Participants | 96 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 2 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 74 Participants | 41 Participants | 33 Participants |
| Race (NIH/OMB) White | 274 Participants | 134 Participants | 140 Participants |
| Region (Asia vs Non-Asia) Asia | 177 Participants | 89 Participants | 88 Participants |
| Region (Asia vs Non-Asia) Non- Asia | 388 Participants | 193 Participants | 195 Participants |
| Sex: Female, Male Female | 214 Participants | 107 Participants | 107 Participants |
| Sex: Female, Male Male | 351 Participants | 175 Participants | 176 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 197 / 283 | 414 / 565 | 414 / 565 | 414 / 565 | 217 / 282 |
| other Total, other adverse events | 276 / 279 | 550 / 557 | 550 / 557 | 550 / 557 | 274 / 278 |
| serious Total, serious adverse events | 133 / 279 | 262 / 557 | 262 / 557 | 262 / 557 | 129 / 278 |
Outcome results
Primary
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan -Meier (KM) estimates was used.
Time frame: From date of randomization until the date of first documented radiological progression or date of death from any cause, whichever occurred first (up to 62 months and 18 days)
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Progression Free Survival (PFS) | 11.04 Months |
| mFOLFOX6+ Placebo | Progression Free Survival (PFS) | 8.94 Months |
p-value: 0.002495% CI: [0.591, 0.91]Log Rank
Secondary
Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire
The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 (not at all) to 4 (very much) except for the items contributing to the global health status/QoL, which are scored 1 (very poor) to 7 (excellent). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C5D1 | -4.03 units on Scale | Standard Deviation 21.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C18D1 | 3.46 units on Scale | Standard Deviation 21.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C14D1 | -1.71 units on Scale | Standard Deviation 22.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss Baseline | 32.81 units on Scale | Standard Deviation 32.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C14D22 | -3.13 units on Scale | Standard Deviation 21.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C15D1 | 3.24 units on Scale | Standard Deviation 18.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C5D22 | -4.35 units on Scale | Standard Deviation 23.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C1D22 | 9.04 units on Scale | Standard Deviation 33.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C6D1 | -5.42 units on Scale | Standard Deviation 24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C7D1 | 4.09 units on Scale | Standard Deviation 21.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C6D22 | -2.27 units on Scale | Standard Deviation 23.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C2D1 | -4.99 units on Scale | Standard Deviation 36.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C7D1 | -2.49 units on Scale | Standard Deviation 19.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C15D22 | 3.56 units on Scale | Standard Deviation 18.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C7D22 | -2.06 units on Scale | Standard Deviation 18.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C2D22 | -1.33 units on Scale | Standard Deviation 34.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C8D1 | -3.75 units on Scale | Standard Deviation 21.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C19D1 | -3.62 units on Scale | Standard Deviation 24.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C8D22 | 1.16 units on Scale | Standard Deviation 22.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C3D1 | -8.07 units on Scale | Standard Deviation 34.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C9D1 | -0.67 units on Scale | Standard Deviation 22.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C16D1 | 3.43 units on Scale | Standard Deviation 20.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C9D22 | -1.67 units on Scale | Standard Deviation 24.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C10D1 | -0.25 units on Scale | Standard Deviation 23.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C3D22 | 2.19 units on Scale | Standard Deviation 35.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C10D22 | -1.17 units on Scale | Standard Deviation 19.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C1D22 | -6.78 units on Scale | Standard Deviation 25.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C11D1 | 2.12 units on Scale | Standard Deviation 19.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C4D1 | -6.08 units on Scale | Standard Deviation 38.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C11D22 | -2.27 units on Scale | Standard Deviation 15.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C16D22 | 5.29 units on Scale | Standard Deviation 19.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C12D1 | 0.00 units on Scale | Standard Deviation 18.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C4D22 | 1.90 units on Scale | Standard Deviation 38.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C12D22 | -1.75 units on Scale | Standard Deviation 19.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C19D22 | -4.58 units on Scale | Standard Deviation 20.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C13D1 | 1.04 units on Scale | Standard Deviation 18.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C5D1 | -4.03 units on Scale | Standard Deviation 35.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C14D1 | 4.27 units on Scale | Standard Deviation 17.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C13D22 | -1.22 units on Scale | Standard Deviation 20.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C15D1 | -4.76 units on Scale | Standard Deviation 23.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C5D22 | -0.30 units on Scale | Standard Deviation 37.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C14D1 | 0.43 units on Scale | Standard Deviation 18.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C7D22 | 4.94 units on Scale | Standard Deviation 19.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C14D22 | -4.17 units on Scale | Standard Deviation 21.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C6D1 | -6.50 units on Scale | Standard Deviation 37.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C14D22 | 0.42 units on Scale | Standard Deviation 19.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C15D1 | -1.43 units on Scale | Standard Deviation 24.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C15D22 | -3.33 units on Scale | Standard Deviation 20.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C6D22 | -6.15 units on Scale | Standard Deviation 39.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C15D22 | -0.56 units on Scale | Standard Deviation 17.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C20D1 | -2.54 units on Scale | Standard Deviation 24.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C16D1 | -6.67 units on Scale | Standard Deviation 27.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C7D1 | -9.65 units on Scale | Standard Deviation 36.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C16D22 | 0.00 units on Scale | Standard Deviation 25.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C2D22 | -0.67 units on Scale | Standard Deviation 20.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C16D1 | 1.43 units on Scale | Standard Deviation 18.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C7D22 | -4.94 units on Scale | Standard Deviation 39.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C16D22 | -1.15 units on Scale | Standard Deviation 18.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C17D1 | 3.78 units on Scale | Standard Deviation 25.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C17D1 | -0.56 units on Scale | Standard Deviation 25.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C8D1 | -8.75 units on Scale | Standard Deviation 35.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C17D22 | -2.17 units on Scale | Standard Deviation 23.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C20D22 | -3.70 units on Scale | Standard Deviation 22.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C17D1 | -6.67 units on Scale | Standard Deviation 26.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C8D22 | -8.80 units on Scale | Standard Deviation 38.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C17D22 | -1.45 units on Scale | Standard Deviation 23.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C18D1 | -4.94 units on Scale | Standard Deviation 23.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C18D1 | -0.62 units on Scale | Standard Deviation 19.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C17D22 | -3.19 units on Scale | Standard Deviation 26.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C9D1 | -15.56 units on Scale | Standard Deviation 34.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C18D22 | 0.00 units on Scale | Standard Deviation 20.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C8D1 | 3.75 units on Scale | Standard Deviation 20.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C19D1 | -1.45 units on Scale | Standard Deviation 18.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C9D22 | -13.33 units on Scale | Standard Deviation 41.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C18D22 | 4.76 units on Scale | Standard Deviation 33.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C19D22 | -5.00 units on Scale | Standard Deviation 20.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C18D22 | 3.17 units on Scale | Standard Deviation 20.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C10D1 | -10.10 units on Scale | Standard Deviation 38.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C19D1 | -1.45 units on Scale | Standard Deviation 32.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C20D1 | -2.90 units on Scale | Standard Deviation 19.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C21D1 | 2.08 units on Scale | Standard Deviation 20.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C20D22 | 0.93 units on Scale | Standard Deviation 17.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C10D22 | -5.85 units on Scale | Standard Deviation 37.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C19D1 | 3.48 units on Scale | Standard Deviation 17.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C21D1 | 0.00 units on Scale | Standard Deviation 15.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C11D1 | -15.34 units on Scale | Standard Deviation 36.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C19D22 | -3.33 units on Scale | Standard Deviation 21.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C21D22 | -2.38 units on Scale | Standard Deviation 14.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C22D1 | 0.00 units on Scale | Standard Deviation 16.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 30 Follow up | 0.46 units on Scale | Standard Deviation 29.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C11D22 | -12.12 units on Scale | Standard Deviation 33.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C20D1 | -4.35 units on Scale | Standard Deviation 25.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C19D22 | -1.00 units on Scale | Standard Deviation 18.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C20D22 | -5.56 units on Scale | Standard Deviation 20.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C12D1 | -10.69 units on Scale | Standard Deviation 33.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C21D1 | -5.00 units on Scale | Standard Deviation 24.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C17D1 | 2.22 units on Scale | Standard Deviation 17.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C22D22 | 4.55 units on Scale | Standard Deviation 19.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C23D1 | -1.04 units on Scale | Standard Deviation 17.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C12D22 | 1.75 units on Scale | Standard Deviation 31.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C23D22 | 1.52 units on Scale | Standard Deviation 15.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C24D1 | 2.38 units on Scale | Standard Deviation 18.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C25D1 | 4.17 units on Scale | Standard Deviation 14.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C25D22 | 0.00 units on Scale | Standard Deviation 16.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C26D1 | 2.56 units on Scale | Standard Deviation 19.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C27D1 | 6.06 units on Scale | Standard Deviation 18.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C28D1 | 4.17 units on Scale | Standard Deviation 18.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 30 Day follow up | -8.56 units on Scale | Standard Deviation 24.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C21D22 | -4.17 units on Scale | Standard Deviation 17.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 90 Day follow up | -11.63 units on Scale | Standard Deviation 21.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C13D1 | -9.72 units on Scale | Standard Deviation 33.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning Baseline | 75.36 units on Scale | Standard Deviation 25.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C8D22 | 1.85 units on Scale | Standard Deviation 18.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C21D22 | -4.76 units on Scale | Standard Deviation 22.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C22D1 | -8.89 units on Scale | Standard Deviation 23.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C13D22 | -5.69 units on Scale | Standard Deviation 39.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C22D22 | -12.12 units on Scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C23D1 | -8.33 units on Scale | Standard Deviation 22.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C1D22 | -3.11 units on Scale | Standard Deviation 24.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia Baseline | 27.50 units on Scale | Standard Deviation 28.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C23D22 | -6.06 units on Scale | Standard Deviation 25.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C24D1 | -11.90 units on Scale | Standard Deviation 24.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C25D1 | -16.67 units on Scale | Standard Deviation 26.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C25D22 | -12.12 units on Scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C26D1 | -15.38 units on Scale | Standard Deviation 25.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C27D1 | -9.09 units on Scale | Standard Deviation 21.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C28D1 | -11.11 units on Scale | Standard Deviation 21.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 30 Day Follow up | 3.24 units on Scale | Standard Deviation 24.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C14D1 | -10.26 units on Scale | Standard Deviation 35.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 90 Day Follow up | 3.88 units on Scale | Standard Deviation 26.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C17D1 | -3.89 units on Scale | Standard Deviation 28.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties Baseline | 19.58 units on Scale | Standard Deviation 28.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C14D22 | -6.25 units on Scale | Standard Deviation 39.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C1D22 | 0.38 units on Scale | Standard Deviation 24.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C20D22 | -1.48 units on Scale | Standard Deviation 24.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C2D1 | -1.45 units on Scale | Standard Deviation 21.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C15D1 | -6.67 units on Scale | Standard Deviation 39.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C2D22 | -0.67 units on Scale | Standard Deviation 20.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C3D1 | 0.35 units on Scale | Standard Deviation 24.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C2D1 | -0.32 units on Scale | Standard Deviation 24.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C15D22 | -5.56 units on Scale | Standard Deviation 42.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C21D1 | 2.33 units on Scale | Standard Deviation 15.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C2D22 | -2.44 units on Scale | Standard Deviation 23.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C16D1 | -14.29 units on Scale | Standard Deviation 27.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C3D1 | 0.53 units on Scale | Standard Deviation 25.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C22D1 | -0.56 units on Scale | Standard Deviation 24.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C3D22 | -5.70 units on Scale | Standard Deviation 25.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C16D22 | -6.90 units on Scale | Standard Deviation 39.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C4D1 | 0.20 units on Scale | Standard Deviation 24.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C21D22 | -3.33 units on Scale | Standard Deviation 18.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C4D22 | -0.95 units on Scale | Standard Deviation 25.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C17D1 | -12.22 units on Scale | Standard Deviation 33.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C5D1 | -1.57 units on Scale | Standard Deviation 29.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C22D1 | 3.11 units on Scale | Standard Deviation 18.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C5D22 | -0.75 units on Scale | Standard Deviation 28.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C17D22 | -4.35 units on Scale | Standard Deviation 32.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C6D1 | 0.54 units on Scale | Standard Deviation 24.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C18D1 | -14.81 units on Scale | Standard Deviation 31.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C6D22 | 1.29 units on Scale | Standard Deviation 24.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C9D1 | 1.78 units on Scale | Standard Deviation 18.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C7D1 | -1.61 units on Scale | Standard Deviation 24.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C18D22 | -7.94 units on Scale | Standard Deviation 27.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C7D22 | -1.03 units on Scale | Standard Deviation 26.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C22D22 | -5.45 units on Scale | Standard Deviation 24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C8D1 | -0.83 units on Scale | Standard Deviation 21.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C19D1 | -11.59 units on Scale | Standard Deviation 23.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C8D22 | 1.85 units on Scale | Standard Deviation 21.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C23D1 | -3.33 units on Scale | Standard Deviation 19.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C9D1 | 2.67 units on Scale | Standard Deviation 21.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C19D22 | -8.33 units on Scale | Standard Deviation 23.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C9D22 | 2.78 units on Scale | Standard Deviation 21.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C22D22 | -10.61 units on Scale | Standard Deviation 29.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C10D1 | 3.03 units on Scale | Standard Deviation 23.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C20D1 | -10.14 units on Scale | Standard Deviation 27.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C10D22 | 2.34 units on Scale | Standard Deviation 21.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C23D22 | 1.82 units on Scale | Standard Deviation 15.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C11D1 | 3.70 units on Scale | Standard Deviation 21.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C20D22 | 1.85 units on Scale | Standard Deviation 33.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C11D22 | -0.76 units on Scale | Standard Deviation 21.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C24D1 | -3.81 units on Scale | Standard Deviation 21.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C12D1 | 4.09 units on Scale | Standard Deviation 17.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C21D1 | -6.67 units on Scale | Standard Deviation 23.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C12D22 | -1.32 units on Scale | Standard Deviation 21.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C25D1 | 5.00 units on Scale | Standard Deviation 11.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C13D1 | 2.43 units on Scale | Standard Deviation 21.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C21D22 | -7.14 units on Scale | Standard Deviation 23.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C13D22 | 1.22 units on Scale | Standard Deviation 23.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C3D1 | -0.88 units on Scale | Standard Deviation 22.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C22D1 | -13.33 units on Scale | Standard Deviation 21.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C25D22 | 2.42 units on Scale | Standard Deviation 15.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C14D1 | 2.99 units on Scale | Standard Deviation 22.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C22D22 | -6.06 units on Scale | Standard Deviation 32.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C14D22 | 0.52 units on Scale | Standard Deviation 20.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C23D1 | -6.25 units on Scale | Standard Deviation 25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C15D1 | 2.38 units on Scale | Standard Deviation 28.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C26D1 | 3.08 units on Scale | Standard Deviation 14.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C3D22 | 0.00 units on Scale | Standard Deviation 21.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C15D22 | 3.89 units on Scale | Standard Deviation 20.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C2322 | -9.09 units on Scale | Standard Deviation 26.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C4D1 | -2.55 units on Scale | Standard Deviation 20.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C24D1 | -11.90 units on Scale | Standard Deviation 24.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C4D22 | -1.90 units on Scale | Standard Deviation 26.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C25D1 | -2.78 units on Scale | Standard Deviation 33.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C16D1 | 3.33 units on Scale | Standard Deviation 22.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C25D22 | -3.03 units on Scale | Standard Deviation 27.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C16D22 | 1.15 units on Scale | Standard Deviation 22.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C26D1 | -10.26 units on Scale | Standard Deviation 28.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C17D1 | 1.67 units on Scale | Standard Deviation 26.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C27D1 | -3.03 units on Scale | Standard Deviation 17.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C17D22 | -3.62 units on Scale | Standard Deviation 22.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C28D1 | 0.00 units on Scale | Standard Deviation 28.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C5D1 | 0.67 units on Scale | Standard Deviation 27.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 30 Day Follow up | 2.31 units on Scale | Standard Deviation 31.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C5D22 | 2.10 units on Scale | Standard Deviation 23.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C27D1 | 3.64 units on Scale | Standard Deviation 15.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C6D1 | -1.63 units on Scale | Standard Deviation 22.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 90 Day Follow up | -5.04 units on Scale | Standard Deviation 35.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C6D22 | -2.27 units on Scale | Standard Deviation 21.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C28D1 | 1.67 units on Scale | Standard Deviation 15.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C7D1 | -1.46 units on Scale | Standard Deviation 24.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C18D1 | 1.85 units on Scale | Standard Deviation 21.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation Baseline | 19.33 units on Scale | Standard Deviation 28.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 30 Day follow up | -9.26 units on Scale | Standard Deviation 24.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C18D22 | 2.38 units on Scale | Standard Deviation 16.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C1D22 | 8.66 units on Scale | Standard Deviation 32.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C19D1 | 3.62 units on Scale | Standard Deviation 16.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C23D1 | -4.17 units on Scale | Standard Deviation 29.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C7D22 | -1.65 units on Scale | Standard Deviation 22.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C19D22 | 0.83 units on Scale | Standard Deviation 11.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C2D1 | -0.48 units on Scale | Standard Deviation 33.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C20D1 | 2.17 units on Scale | Standard Deviation 19.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status Baseline | 64.20 units on Scale | Standard Deviation 20.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C8D1 | 0.42 units on Scale | Standard Deviation 24.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C2D22 | -2.89 units on Scale | Standard Deviation 31.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C8D22 | -1.39 units on Scale | Standard Deviation 24.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning Baseline | 74.77 units on Scale | Standard Deviation 27.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C9D1 | -1.33 units on Scale | Standard Deviation 23.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C3D1 | -5.09 units on Scale | Standard Deviation 31.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C9D22 | -1.11 units on Scale | Standard Deviation 28.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C1D22 | -5.18 units on Scale | Standard Deviation 20.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C3D22 | -2.85 units on Scale | Standard Deviation 28.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C20D22 | 1.85 units on Scale | Standard Deviation 15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C23D22 | -3.79 units on Scale | Standard Deviation 22.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C21D1 | 6.67 units on Scale | Standard Deviation 16.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C4D1 | -2.75 units on Scale | Standard Deviation 32.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C21D22 | 7.14 units on Scale | Standard Deviation 15.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C22D1 | 1.11 units on Scale | Standard Deviation 20.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C2D1 | 1.61 units on Scale | Standard Deviation 20.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C22D22 | -4.55 units on Scale | Standard Deviation 21.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C10D1 | -1.01 units on Scale | Standard Deviation 26.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C4D22 | 1.08 units on Scale | Standard Deviation 31.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C10D22 | -2.92 units on Scale | Standard Deviation 26.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C24D1 | -0.60 units on Scale | Standard Deviation 26.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C11D1 | -3.17 units on Scale | Standard Deviation 28.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C23D1 | 1.04 units on Scale | Standard Deviation 17.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C5D1 | -2.24 units on Scale | Standard Deviation 31.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C23D22 | 4.55 units on Scale | Standard Deviation 19.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C24D1 | 2.38 units on Scale | Standard Deviation 23.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C25D1 | 2.78 units on Scale | Standard Deviation 29.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C2D22 | 0.17 units on Scale | Standard Deviation 18.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C11D22 | -2.27 units on Scale | Standard Deviation 31.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C5D22 | 2.70 units on Scale | Standard Deviation 31.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C12D1 | -1.26 units on Scale | Standard Deviation 30.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C3D1 | 2.85 units on Scale | Standard Deviation 17.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C12D22 | -2.63 units on Scale | Standard Deviation 30.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C6D1 | -2.44 units on Scale | Standard Deviation 28.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C13D1 | -2.78 units on Scale | Standard Deviation 27.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C25D1 | -6.94 units on Scale | Standard Deviation 15.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C13D22 | 0.81 units on Scale | Standard Deviation 30.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C6D22 | -3.24 units on Scale | Standard Deviation 27.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C25D22 | 3.03 units on Scale | Standard Deviation 19.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C26D1 | 2.56 units on Scale | Standard Deviation 21.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C27D1 | 6.06 units on Scale | Standard Deviation 23.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C28D1 | 5.56 units on Scale | Standard Deviation 20.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C14D1 | 0.85 units on Scale | Standard Deviation 22.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C3D22 | -3.13 units on Scale | Standard Deviation 19.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C14D22 | 0.00 units on Scale | Standard Deviation 23.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C7D1 | -2.63 units on Scale | Standard Deviation 29.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C15D1 | -5.71 units on Scale | Standard Deviation 28.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C25D22 | -3.03 units on Scale | Standard Deviation 17.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C15D22 | -5.56 units on Scale | Standard Deviation 26.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C7D22 | -2.47 units on Scale | Standard Deviation 25.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C16D1 | -1.90 units on Scale | Standard Deviation 24.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C4D1 | 0.64 units on Scale | Standard Deviation 20.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C16D22 | -1.15 units on Scale | Standard Deviation 28.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C8D1 | -4.17 units on Scale | Standard Deviation 27.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 30 Day follow up | -12.73 units on Scale | Standard Deviation 30.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C26D1 | 6.41 units on Scale | Standard Deviation 23.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 90 Day follow up | -9.88 units on Scale | Standard Deviation 29.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C8D22 | -6.94 units on Scale | Standard Deviation 29.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue Baseline | 31.13 units on Scale | Standard Deviation 23.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C4D22 | -2.78 units on Scale | Standard Deviation 18.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C1D22 | 8.47 units on Scale | Standard Deviation 23.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C9D1 | -8.44 units on Scale | Standard Deviation 26.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C2D1 | 3.81 units on Scale | Standard Deviation 22.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C5D1 | -0.62 units on Scale | Standard Deviation 20.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C2D22 | 4.00 units on Scale | Standard Deviation 22.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C9D22 | -3.33 units on Scale | Standard Deviation 32.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C3D1 | 2.11 units on Scale | Standard Deviation 23.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C27D1 | 2.27 units on Scale | Standard Deviation 22.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C3D22 | 8.48 units on Scale | Standard Deviation 23.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C17D1 | -1.11 units on Scale | Standard Deviation 25.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C10D1 | -2.02 units on Scale | Standard Deviation 29.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C17D22 | 5.80 units on Scale | Standard Deviation 16.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C5D22 | 0.53 units on Scale | Standard Deviation 21.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C4D1 | 1.70 units on Scale | Standard Deviation 25.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C10D22 | -1.17 units on Scale | Standard Deviation 22.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C18D1 | 1.23 units on Scale | Standard Deviation 17.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C4D22 | 5.96 units on Scale | Standard Deviation 24.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C17D22 | -6.88 units on Scale | Standard Deviation 25.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C5D1 | 4.85 units on Scale | Standard Deviation 26.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C11D1 | -4.23 units on Scale | Standard Deviation 24.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C5D22 | 5.61 units on Scale | Standard Deviation 27.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C17D22 | 2.90 units on Scale | Standard Deviation 19.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C6D1 | 1.90 units on Scale | Standard Deviation 20.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C18D22 | 0.00 units on Scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C18D1 | 0.00 units on Scale | Standard Deviation 13.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C11D22 | -4.55 units on Scale | Standard Deviation 26.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C18D1 | 0.00 units on Scale | Standard Deviation 24.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C6D1 | 1.08 units on Scale | Standard Deviation 25.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C12D1 | -6.29 units on Scale | Standard Deviation 22.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C6D22 | 2.05 units on Scale | Standard Deviation 24.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C5D22 | -6.01 units on Scale | Standard Deviation 32.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C19D1 | 0.00 units on Scale | Standard Deviation 17.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C7D1 | 0.78 units on Scale | Standard Deviation 22.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C12D22 | 1.75 units on Scale | Standard Deviation 29.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C7D22 | 4.53 units on Scale | Standard Deviation 22.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C6D22 | 3.48 units on Scale | Standard Deviation 18.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C13D1 | -3.47 units on Scale | Standard Deviation 26.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C19D22 | 5.00 units on Scale | Standard Deviation 16.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C7D1 | 0.00 units on Scale | Standard Deviation 20.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C20D1 | 0.00 units on Scale | Standard Deviation 17.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C8D1 | -0.14 units on Scale | Standard Deviation 23.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C13D22 | -3.25 units on Scale | Standard Deviation 28.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C8D22 | -0.77 units on Scale | Standard Deviation 22.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C9D22 | 3.33 units on Scale | Standard Deviation 27.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C9D1 | -4.30 units on Scale | Standard Deviation 22.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C14D1 | -8.55 units on Scale | Standard Deviation 25.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C9D22 | -0.74 units on Scale | Standard Deviation 24.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C7D22 | 1.54 units on Scale | Standard Deviation 18.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C14D22 | -3.12 units on Scale | Standard Deviation 30.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C18D22 | 4.76 units on Scale | Standard Deviation 19.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C6D1 | -1.08 units on Scale | Standard Deviation 20.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C12D1 | -3.98 units on Scale | Standard Deviation 19.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C15D1 | -8.57 units on Scale | Standard Deviation 30.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C22D22 | 0.00 units on Scale | Standard Deviation 25.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C20D22 | 3.70 units on Scale | Standard Deviation 19.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C23D1 | -2.08 units on Scale | Standard Deviation 19.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C8D1 | 3.12 units on Scale | Standard Deviation 19.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C21D1 | 1.67 units on Scale | Standard Deviation 22.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C15D22 | -6.67 units on Scale | Standard Deviation 25.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C28D1 | 0.69 units on Scale | Standard Deviation 26.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C21D22 | -7.14 units on Scale | Standard Deviation 19.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C22D1 | -2.22 units on Scale | Standard Deviation 19.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C10D1 | -1.18 units on Scale | Standard Deviation 23.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C16D1 | -5.71 units on Scale | Standard Deviation 24.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C10D22 | -0.39 units on Scale | Standard Deviation 21.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C8D22 | 1.62 units on Scale | Standard Deviation 19.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C16D22 | -3.45 units on Scale | Standard Deviation 27.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C11D1 | -4.23 units on Scale | Standard Deviation 20.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 30 Day follow up | -4.98 units on Scale | Standard Deviation 21.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C11D22 | -3.79 units on Scale | Standard Deviation 19.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C9D1 | 6.11 units on Scale | Standard Deviation 18.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C12D22 | 1.17 units on Scale | Standard Deviation 18.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C6D1 | -1.76 units on Scale | Standard Deviation 29.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C13D1 | -1.16 units on Scale | Standard Deviation 21.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C17D1 | -5.56 units on Scale | Standard Deviation 27.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C13D22 | 1.36 units on Scale | Standard Deviation 23.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C3D22 | 1.32 units on Scale | Standard Deviation 21.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C23D22 | -6.06 units on Scale | Standard Deviation 20.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C24D1 | -4.76 units on Scale | Standard Deviation 22.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C25D1 | -5.56 units on Scale | Standard Deviation 19.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C25D22 | -6.06 units on Scale | Standard Deviation 25.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C26D1 | -5.13 units on Scale | Standard Deviation 22.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C14D1 | 0.00 units on Scale | Standard Deviation 20.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C17D22 | -7.25 units on Scale | Standard Deviation 26.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C14D22 | 0.00 units on Scale | Standard Deviation 21.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C18D1 | -8.64 units on Scale | Standard Deviation 23.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C15D1 | 3.49 units on Scale | Standard Deviation 25.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C9D22 | 3.33 units on Scale | Standard Deviation 19.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C15D22 | 2.96 units on Scale | Standard Deviation 9.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C10D1 | 1.52 units on Scale | Standard Deviation 25.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C27D1 | -3.03 units on Scale | Standard Deviation 23.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C28D1 | -2.78 units on Scale | Standard Deviation 22.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 30 Day Follow up | 4.17 units on Scale | Standard Deviation 26.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C16D1 | -2.22 units on Scale | Standard Deviation 22.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C18D22 | -1.59 units on Scale | Standard Deviation 24.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 90 Day Follow up | 7.75 units on Scale | Standard Deviation 24.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C10D1 | 3.03 units on Scale | Standard Deviation 18.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C16D22 | 1.53 units on Scale | Standard Deviation 27.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C19D1 | -2.90 units on Scale | Standard Deviation 28.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C17D1 | 1.85 units on Scale | Standard Deviation 22.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C6D22 | -2.01 units on Scale | Standard Deviation 22.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C17D22 | 8.70 units on Scale | Standard Deviation 26.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C18D1 | -2.88 units on Scale | Standard Deviation 18.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C19D22 | -5.00 units on Scale | Standard Deviation 22.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C18D22 | -4.23 units on Scale | Standard Deviation 17.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C10D22 | 0.58 units on Scale | Standard Deviation 19.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C19D1 | -0.48 units on Scale | Standard Deviation 23.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C20D1 | -2.90 units on Scale | Standard Deviation 24.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C19D22 | -1.11 units on Scale | Standard Deviation 19.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C6D22 | -4.21 units on Scale | Standard Deviation 29.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C20D1 | 1.45 units on Scale | Standard Deviation 26.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C11D1 | 4.37 units on Scale | Standard Deviation 16.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C20D22 | 4.32 units on Scale | Standard Deviation 29.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C7D1 | -5.56 units on Scale | Standard Deviation 28.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C21D1 | -4.44 units on Scale | Standard Deviation 15.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 90 Day Follow up | 3.49 units on Scale | Standard Deviation 28.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C21D22 | 8.73 units on Scale | Standard Deviation 21.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C22D1 | 5.19 units on Scale | Standard Deviation 20.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C11D22 | 2.65 units on Scale | Standard Deviation 18.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C22D22 | 9.09 units on Scale | Standard Deviation 29.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C23D1 | 11.11 units on Scale | Standard Deviation 22.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C20D22 | -7.41 units on Scale | Standard Deviation 26.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C23D22 | 7.07 units on Scale | Standard Deviation 18.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C24D1 | 6.35 units on Scale | Standard Deviation 22.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C25D1 | 6.48 units on Scale | Standard Deviation 15.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C25D22 | 8.08 units on Scale | Standard Deviation 20.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C26D1 | 3.42 units on Scale | Standard Deviation 17.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C27D1 | 1.01 units on Scale | Standard Deviation 14.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C28D1 | 3.70 units on Scale | Standard Deviation 15.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 30 Day follow up | 8.02 units on Scale | Standard Deviation 26.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C7D22 | -5.35 units on Scale | Standard Deviation 29.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 90 Day follow up | 11.63 units on Scale | Standard Deviation 29.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C7D1 | -1.35 units on Scale | Standard Deviation 21.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting Baseline | 15.37 units on Scale | Standard Deviation 23.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C12D1 | 1.89 units on Scale | Standard Deviation 18.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C1D22 | 9.13 units on Scale | Standard Deviation 23.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C8D1 | -2.92 units on Scale | Standard Deviation 29.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C2D1 | 3.38 units on Scale | Standard Deviation 25.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C21D1 | -3.33 units on Scale | Standard Deviation 26.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C2D22 | 4.33 units on Scale | Standard Deviation 23.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 90 Day follow up | -5.72 units on Scale | Standard Deviation 21.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C3D1 | 0.53 units on Scale | Standard Deviation 27.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C21D22 | 0.00 units on Scale | Standard Deviation 29.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C3D22 | 4.61 units on Scale | Standard Deviation 24.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C22D1 | -6.67 units on Scale | Standard Deviation 25.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C4D1 | 0.00 units on Scale | Standard Deviation 26.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C12D22 | -0.88 units on Scale | Standard Deviation 17.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C4D22 | 2.30 units on Scale | Standard Deviation 25.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C22D22 | -6.06 units on Scale | Standard Deviation 29.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C5D1 | -0.22 units on Scale | Standard Deviation 23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C23D1 | -4.17 units on Scale | Standard Deviation 26.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C5D22 | 2.40 units on Scale | Standard Deviation 21.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C13D1 | 3.47 units on Scale | Standard Deviation 18.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C6D1 | -2.98 units on Scale | Standard Deviation 19.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C23D22 | -3.03 units on Scale | Standard Deviation 17.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C6D22 | -1.13 units on Scale | Standard Deviation 22.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C24D1 | -9.52 units on Scale | Standard Deviation 27.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C7D1 | -2.63 units on Scale | Standard Deviation 19.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C25D1 | 2.78 units on Scale | Standard Deviation 30.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C7D22 | 2.06 units on Scale | Standard Deviation 21.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C25D22 | -3.03 units on Scale | Standard Deviation 31.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C8D1 | -1.46 units on Scale | Standard Deviation 18.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C26D1 | -5.13 units on Scale | Standard Deviation 32.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C8D22 | -1.85 units on Scale | Standard Deviation 22.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C27D1 | 0.00 units on Scale | Standard Deviation 33.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C9D1 | -6.22 units on Scale | Standard Deviation 20.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C28D1 | -5.56 units on Scale | Standard Deviation 31.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C9D22 | -0.56 units on Scale | Standard Deviation 20.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 30 Day Follow up | 0.00 units on Scale | Standard Deviation 32.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C10D1 | -2.27 units on Scale | Standard Deviation 21.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C10D22 | 2.34 units on Scale | Standard Deviation 18.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C10D22 | -1.17 units on Scale | Standard Deviation 21.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C13D22 | -2.85 units on Scale | Standard Deviation 19.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C11D1 | -4.23 units on Scale | Standard Deviation 20.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C8D22 | -1.39 units on Scale | Standard Deviation 28.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C11D22 | 0.38 units on Scale | Standard Deviation 17.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 90 Day Follow up | -5.43 units on Scale | Standard Deviation 33.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C12D1 | -3.77 units on Scale | Standard Deviation 19.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C7D22 | -2.14 units on Scale | Standard Deviation 18.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C12D22 | -1.75 units on Scale | Standard Deviation 19.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C9D1 | 4.89 units on Scale | Standard Deviation 26.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C13D1 | -3.12 units on Scale | Standard Deviation 19.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C14D1 | -0.85 units on Scale | Standard Deviation 23.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C13D22 | -1.63 units on Scale | Standard Deviation 23.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea Baseline | 7.91 units on Scale | Standard Deviation 17.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C14D1 | -5.13 units on Scale | Standard Deviation 22.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C4D1 | -0.20 units on Scale | Standard Deviation 23.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C14D22 | -2.08 units on Scale | Standard Deviation 24.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C9D22 | -0.83 units on Scale | Standard Deviation 30.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C15D1 | -3.33 units on Scale | Standard Deviation 23.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C14D22 | -1.30 units on Scale | Standard Deviation 19.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C15D22 | -3.89 units on Scale | Standard Deviation 22.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C15D1 | -0.71 units on Scale | Standard Deviation 26.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C16D1 | -7.62 units on Scale | Standard Deviation 22.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C1D22 | 4.90 units on Scale | Standard Deviation 23.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C16D22 | -1.72 units on Scale | Standard Deviation 29.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C8D1 | 0.33 units on Scale | Standard Deviation 21.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C17D1 | -10.00 units on Scale | Standard Deviation 21.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C2D1 | 6.28 units on Scale | Standard Deviation 26.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C17D22 | -1.45 units on Scale | Standard Deviation 21.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C18D1 | -7.41 units on Scale | Standard Deviation 20.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C15D22 | -3.89 units on Scale | Standard Deviation 22.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C18D22 | -3.17 units on Scale | Standard Deviation 22.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C2D22 | 4.67 units on Scale | Standard Deviation 24.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C19D1 | -5.07 units on Scale | Standard Deviation 21.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C11D1 | -0.53 units on Scale | Standard Deviation 17.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C19D22 | -5.00 units on Scale | Standard Deviation 22.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C3D1 | 2.11 units on Scale | Standard Deviation 22.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C20D1 | -4.35 units on Scale | Standard Deviation 22.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C16D1 | 1.90 units on Scale | Standard Deviation 20.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C20D22 | -4.63 units on Scale | Standard Deviation 25.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C3D22 | 2.19 units on Scale | Standard Deviation 24.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C21D1 | -1.67 units on Scale | Standard Deviation 16.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning Baseline | 79.71 units on Scale | Standard Deviation 20.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C21D22 | -4.76 units on Scale | Standard Deviation 18.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C22D1 | -2.22 units on Scale | Standard Deviation 20.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C4D1 | -0.20 units on Scale | Standard Deviation 22.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C22D22 | -6.06 units on Scale | Standard Deviation 25.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C23D1 | -5.21 units on Scale | Standard Deviation 19.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C16D22 | -2.59 units on Scale | Standard Deviation 20.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C23D22 | -6.06 units on Scale | Standard Deviation 23.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C24D1 | -8.33 units on Scale | Standard Deviation 21.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C25D1 | -8.33 units on Scale | Standard Deviation 21.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C25D22 | -6.06 units on Scale | Standard Deviation 25.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C26D1 | -10.26 units on Scale | Standard Deviation 21.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C27D1 | -1.52 units on Scale | Standard Deviation 8.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C28D1 | -4.17 units on Scale | Standard Deviation 14.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 30 Day Follow up | 3.24 units on Scale | Standard Deviation 25.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C4D22 | 1.90 units on Scale | Standard Deviation 23.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 90 Day Follow up | 0.39 units on Scale | Standard Deviation 22.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C20D1 | 0.29 units on Scale | Standard Deviation 22.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain Baseline | 25.68 units on Scale | Standard Deviation 25.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C10D22 | -0.58 units on Scale | Standard Deviation 30.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C1D22 | -2.54 units on Scale | Standard Deviation 23.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C10D1 | 0.00 units on Scale | Standard Deviation 29.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C2D1 | -6.36 units on Scale | Standard Deviation 24.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C1D22 | 0.00 units on Scale | Standard Deviation 27.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C2D22 | -7.67 units on Scale | Standard Deviation 24.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C5D1 | 3.58 units on Scale | Standard Deviation 24.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C3D1 | -9.12 units on Scale | Standard Deviation 25.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C11D1 | 1.32 units on Scale | Standard Deviation 32.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C3D22 | -8.44 units on Scale | Standard Deviation 24.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C11D22 | 2.27 units on Scale | Standard Deviation 18.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C4D1 | -9.31 units on Scale | Standard Deviation 24.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C2D1 | -4.03 units on Scale | Standard Deviation 29.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C4D22 | -5.69 units on Scale | Standard Deviation 23.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C5D22 | 0.30 units on Scale | Standard Deviation 20.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C5D1 | -5.82 units on Scale | Standard Deviation 26.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C4D22 | 2.71 units on Scale | Standard Deviation 20.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C5D22 | -5.41 units on Scale | Standard Deviation 26.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C6D1 | -2.17 units on Scale | Standard Deviation 22.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C6D1 | -7.18 units on Scale | Standard Deviation 27.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C2D22 | -5.33 units on Scale | Standard Deviation 29.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C6D22 | -5.34 units on Scale | Standard Deviation 23.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C6D22 | -3.24 units on Scale | Standard Deviation 17.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C7D1 | -5.56 units on Scale | Standard Deviation 24.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C16D22 | 4.60 units on Scale | Standard Deviation 19.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C7D22 | -1.65 units on Scale | Standard Deviation 25.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C7D1 | -3.51 units on Scale | Standard Deviation 20.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C8D1 | -2.92 units on Scale | Standard Deviation 25.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C3D1 | -8.42 units on Scale | Standard Deviation 30.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C8D22 | -8.10 units on Scale | Standard Deviation 23.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C7D22 | 0.41 units on Scale | Standard Deviation 22.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C9D1 | -8.89 units on Scale | Standard Deviation 22.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C8D22 | 1.02 units on Scale | Standard Deviation 18.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C9D22 | -6.11 units on Scale | Standard Deviation 23.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C8D1 | -2.08 units on Scale | Standard Deviation 20.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C10D1 | -6.57 units on Scale | Standard Deviation 24.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C3D22 | -5.26 units on Scale | Standard Deviation 27.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C10D22 | -2.92 units on Scale | Standard Deviation 24.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C11D22 | -3.79 units on Scale | Standard Deviation 28.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C11D1 | -9.26 units on Scale | Standard Deviation 23.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C8D22 | -5.09 units on Scale | Standard Deviation 22.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C11D22 | -7.20 units on Scale | Standard Deviation 22.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C12D1 | 4.40 units on Scale | Standard Deviation 16.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C12D1 | -7.55 units on Scale | Standard Deviation 22.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C9D1 | -2.22 units on Scale | Standard Deviation 26.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C12D22 | -0.88 units on Scale | Standard Deviation 27.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C4D1 | -10.59 units on Scale | Standard Deviation 29.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C13D1 | -5.21 units on Scale | Standard Deviation 25.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C9D22 | -5.00 units on Scale | Standard Deviation 20.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C13D22 | -2.03 units on Scale | Standard Deviation 25.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C9D1 | 2.13 units on Scale | Standard Deviation 20.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C14D1 | -4.27 units on Scale | Standard Deviation 24.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C10D1 | -5.05 units on Scale | Standard Deviation 24.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C14D22 | -5.73 units on Scale | Standard Deviation 18.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C4D22 | -5.42 units on Scale | Standard Deviation 31.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C15D1 | -4.76 units on Scale | Standard Deviation 23.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea Baseline | 13.23 units on Scale | Standard Deviation 22.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C15D22 | -5.00 units on Scale | Standard Deviation 18.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C12D22 | -5.26 units on Scale | Standard Deviation 28.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C16D1 | -3.81 units on Scale | Standard Deviation 24.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C5D1 | -5.59 units on Scale | Standard Deviation 32.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C16D22 | -6.32 units on Scale | Standard Deviation 19.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C13D1 | -1.04 units on Scale | Standard Deviation 29.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C17D1 | 0.56 units on Scale | Standard Deviation 29.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C1D22 | -4.22 units on Scale | Standard Deviation 17.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C17D22 | 2.17 units on Scale | Standard Deviation 31.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C18D1 | -3.09 units on Scale | Standard Deviation 28.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C13D22 | -4.88 units on Scale | Standard Deviation 29.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C18D22 | -1.59 units on Scale | Standard Deviation 17.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C9D22 | 2.78 units on Scale | Standard Deviation 23.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C19D1 | 0.00 units on Scale | Standard Deviation 20.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C14D1 | -2.99 units on Scale | Standard Deviation 26.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C19D22 | 0.00 units on Scale | Standard Deviation 16.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C6D1 | -6.50 units on Scale | Standard Deviation 32.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C20D1 | -2.17 units on Scale | Standard Deviation 26.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C14D22 | -3.65 units on Scale | Standard Deviation 27.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C20D22 | -3.70 units on Scale | Standard Deviation 21.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C12D22 | 2.63 units on Scale | Standard Deviation 16.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C21D1 | -5.83 units on Scale | Standard Deviation 18.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C15D1 | -1.90 units on Scale | Standard Deviation 27.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C21D22 | -2.38 units on Scale | Standard Deviation 17.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C22D1 | -1.11 units on Scale | Standard Deviation 14.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C6D22 | -4.21 units on Scale | Standard Deviation 29.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C22D22 | 0.00 units on Scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C23D1 | 1.04 units on Scale | Standard Deviation 21.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C15D22 | -5.00 units on Scale | Standard Deviation 31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C23D22 | -1.52 units on Scale | Standard Deviation 17.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C24D1 | 3.57 units on Scale | Standard Deviation 26.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C25D1 | 5.56 units on Scale | Standard Deviation 14.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C25D22 | 6.06 units on Scale | Standard Deviation 23.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C26D1 | 1.28 units on Scale | Standard Deviation 14.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C27D1 | 0.00 units on Scale | Standard Deviation 18.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C28D1 | 1.39 units on Scale | Standard Deviation 19.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C5D1 | 2.24 units on Scale | Standard Deviation 20.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C19D1 | 2.90 units on Scale | Standard Deviation 13.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C16D1 | 0.48 units on Scale | Standard Deviation 30.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C19D22 | 3.33 units on Scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C7D1 | -7.02 units on Scale | Standard Deviation 27.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C20D1 | 1.45 units on Scale | Standard Deviation 12.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C16D22 | -6.32 units on Scale | Standard Deviation 31.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C20D22 | 1.85 units on Scale | Standard Deviation 7.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C10D1 | 2.53 units on Scale | Standard Deviation 21.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C21D1 | 0.00 units on Scale | Standard Deviation 0 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C17D1 | -0.56 units on Scale | Standard Deviation 33.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C21D22 | 2.38 units on Scale | Standard Deviation 8.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C22D1 | -2.22 units on Scale | Standard Deviation 8.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C7D22 | -4.94 units on Scale | Standard Deviation 23.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C22D22 | 0.00 units on Scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C23D1 | 6.25 units on Scale | Standard Deviation 21.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C17D22 | -11.59 units on Scale | Standard Deviation 36.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C23D22 | 0.00 units on Scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C24D1 | 0.00 units on Scale | Standard Deviation 13.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C25D1 | -5.56 units on Scale | Standard Deviation 12.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C25D22 | -3.03 units on Scale | Standard Deviation 10.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C26D1 | -2.56 units on Scale | Standard Deviation 9.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C27D1 | 0.00 units on Scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C28D1 | -2.78 units on Scale | Standard Deviation 9.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 30 Day Follow up | 4.63 units on Scale | Standard Deviation 23.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C18D1 | -4.32 units on Scale | Standard Deviation 28.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 90 Day Follow up | 13.57 units on Scale | Standard Deviation 29.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C12D1 | -0.63 units on Scale | Standard Deviation 26.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C2D1 | -0.64 units on Scale | Standard Deviation 26.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C18D22 | -3.17 units on Scale | Standard Deviation 24.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C2D22 | -1.67 units on Scale | Standard Deviation 25.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C8D1 | -6.67 units on Scale | Standard Deviation 26.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C3D1 | 0.96 units on Scale | Standard Deviation 28.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C19D1 | -3.62 units on Scale | Standard Deviation 24.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C3D22 | -3.73 units on Scale | Standard Deviation 25.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C10D22 | 3.27 units on Scale | Standard Deviation 18.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C4D1 | -1.18 units on Scale | Standard Deviation 28.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C19D22 | -8.33 units on Scale | Standard Deviation 18.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C4D22 | -2.98 units on Scale | Standard Deviation 28.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C8D22 | -6.94 units on Scale | Standard Deviation 27.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C5D1 | -4.25 units on Scale | Standard Deviation 29.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C20D1 | -5.80 units on Scale | Standard Deviation 23.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C5D22 | -2.70 units on Scale | Standard Deviation 30.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C13D1 | 2.78 units on Scale | Standard Deviation 15.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C20D22 | -6.48 units on Scale | Standard Deviation 33.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C9D1 | -8.44 units on Scale | Standard Deviation 29.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C21D1 | 2.50 units on Scale | Standard Deviation 21.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C11D1 | 3.60 units on Scale | Standard Deviation 20.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C21D22 | -5.95 units on Scale | Standard Deviation 21.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C22D1 | -2.22 units on Scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C9D22 | -8.89 units on Scale | Standard Deviation 32.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C22D22 | -13.64 units on Scale | Standard Deviation 36.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C23D1 | -6.25 units on Scale | Standard Deviation 28.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C5D22 | 2.10 units on Scale | Standard Deviation 22.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C23D22 | -4.55 units on Scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C24D1 | -7.14 units on Scale | Standard Deviation 26.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C25D1 | -4.17 units on Scale | Standard Deviation 20.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C25D22 | -12.12 units on Scale | Standard Deviation 18.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C26D1 | -11.54 units on Scale | Standard Deviation 19.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C27D1 | -6.06 units on Scale | Standard Deviation 22.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C28D1 | -6.94 units on Scale | Standard Deviation 24.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 30 Day follow up | -13.19 units on Scale | Standard Deviation 29.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C10D1 | -8.59 units on Scale | Standard Deviation 27.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 90 Day follow up | -14.53 units on Scale | Standard Deviation 33.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C11D22 | 3.33 units on Scale | Standard Deviation 18.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning Baseline | 74.64 units on Scale | Standard Deviation 20.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C10D22 | -9.94 units on Scale | Standard Deviation 26.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C1D22 | 0.85 units on Scale | Standard Deviation 19.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C13D22 | 3.25 units on Scale | Standard Deviation 16.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C2D1 | 4.55 units on Scale | Standard Deviation 20.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C11D1 | -8.99 units on Scale | Standard Deviation 27.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C2D22 | 5.78 units on Scale | Standard Deviation 19.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C12D1 | 2.26 units on Scale | Standard Deviation 20.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C3D1 | 6.27 units on Scale | Standard Deviation 20.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C11D22 | -11.36 units on Scale | Standard Deviation 26.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C3D22 | 3.62 units on Scale | Standard Deviation 21.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C1D22 | 1.88 units on Scale | Standard Deviation 22.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C4D1 | 7.40 units on Scale | Standard Deviation 20.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C12D1 | -8.18 units on Scale | Standard Deviation 29.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C4D22 | 2.71 units on Scale | Standard Deviation 19.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C12D22 | 2.63 units on Scale | Standard Deviation 20.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C5D1 | 4.19 units on Scale | Standard Deviation 24.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C12D22 | -3.51 units on Scale | Standard Deviation 26.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C5D22 | 4.35 units on Scale | Standard Deviation 24.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C14D1 | 0.85 units on Scale | Standard Deviation 16.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C6D1 | 6.44 units on Scale | Standard Deviation 24.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C13D1 | -6.25 units on Scale | Standard Deviation 32.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C6D22 | 5.50 units on Scale | Standard Deviation 21.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C13D22 | 1.46 units on Scale | Standard Deviation 21.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C7D1 | 5.70 units on Scale | Standard Deviation 22.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C13D22 | -9.76 units on Scale | Standard Deviation 28.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C7D22 | 3.70 units on Scale | Standard Deviation 20.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C6D1 | 0.81 units on Scale | Standard Deviation 22.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C8D1 | 5.21 units on Scale | Standard Deviation 19.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C14D1 | -9.40 units on Scale | Standard Deviation 25.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C8D22 | 7.29 units on Scale | Standard Deviation 24.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C2D1 | -1.90 units on Scale | Standard Deviation 18.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C9D1 | 8.67 units on Scale | Standard Deviation 23.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C14D22 | -7.29 units on Scale | Standard Deviation 29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C9D22 | 6.11 units on Scale | Standard Deviation 25.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C14D22 | 0.00 units on Scale | Standard Deviation 16.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C10D1 | 7.20 units on Scale | Standard Deviation 23.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C15D1 | -7.62 units on Scale | Standard Deviation 30.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C10D22 | 8.04 units on Scale | Standard Deviation 22.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C2D22 | -0.98 units on Scale | Standard Deviation 17.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C11D1 | 9.13 units on Scale | Standard Deviation 20.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C15D22 | -8.89 units on Scale | Standard Deviation 26.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C11D22 | 8.33 units on Scale | Standard Deviation 17.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 90 Day follow up | -13.57 units on Scale | Standard Deviation 23.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C12D1 | 9.59 units on Scale | Standard Deviation 19.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C16D1 | -9.52 units on Scale | Standard Deviation 28.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C12D22 | 3.95 units on Scale | Standard Deviation 19.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C15D1 | -0.95 units on Scale | Standard Deviation 20.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C13D1 | 7.99 units on Scale | Standard Deviation 23.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C16D22 | -9.20 units on Scale | Standard Deviation 23.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C13D22 | 3.86 units on Scale | Standard Deviation 20.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C3D1 | -0.84 units on Scale | Standard Deviation 19.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C14D1 | 6.20 units on Scale | Standard Deviation 21.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C17D1 | -4.44 units on Scale | Standard Deviation 33.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C14D22 | 3.65 units on Scale | Standard Deviation 21.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C6D22 | 0.65 units on Scale | Standard Deviation 20.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C15D1 | 6.43 units on Scale | Standard Deviation 21.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C17D22 | -4.35 units on Scale | Standard Deviation 30.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C15D22 | 4.17 units on Scale | Standard Deviation 16.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C18D1 | -9.88 units on Scale | Standard Deviation 28.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C16D1 | 9.76 units on Scale | Standard Deviation 21.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C3D22 | -1.36 units on Scale | Standard Deviation 17.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C16D22 | 6.03 units on Scale | Standard Deviation 19.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C18D22 | -1.59 units on Scale | Standard Deviation 28.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C17D1 | 7.50 units on Scale | Standard Deviation 28.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C15D22 | -2.22 units on Scale | Standard Deviation 14.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C17D22 | 7.25 units on Scale | Standard Deviation 23.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C18D1 | 8.33 units on Scale | Standard Deviation 20.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C19D1 | -8.70 units on Scale | Standard Deviation 28.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C18D22 | 5.95 units on Scale | Standard Deviation 18.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C4D1 | 0.12 units on Scale | Standard Deviation 19.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C19D1 | 8.70 units on Scale | Standard Deviation 23.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C19D22 | -8.33 units on Scale | Standard Deviation 28.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C19D22 | 4.17 units on Scale | Standard Deviation 24.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C2D1 | 0.48 units on Scale | Standard Deviation 20.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C20D1 | 10.51 units on Scale | Standard Deviation 17.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C20D1 | -10.14 units on Scale | Standard Deviation 29.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C20D22 | 8.80 units on Scale | Standard Deviation 17.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C4D22 | -2.60 units on Scale | Standard Deviation 19.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C21D1 | 11.25 units on Scale | Standard Deviation 18.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C20D22 | -9.26 units on Scale | Standard Deviation 31.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C21D22 | 6.55 units on Scale | Standard Deviation 16.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C22D1 | 11.67 units on Scale | Standard Deviation 16.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C16D1 | 1.90 units on Scale | Standard Deviation 13.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C22D22 | -2.27 units on Scale | Standard Deviation 27.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C23D1 | 7.81 units on Scale | Standard Deviation 19.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C21D1 | -6.67 units on Scale | Standard Deviation 25.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C23D22 | 4.55 units on Scale | Standard Deviation 17.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C13D1 | 3.06 units on Scale | Standard Deviation 20.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C10D22 | -2.92 units on Scale | Standard Deviation 24.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C21D22 | -9.52 units on Scale | Standard Deviation 24.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C24D1 | 14.88 units on Scale | Standard Deviation 20.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C11D1 | -4.76 units on Scale | Standard Deviation 26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C25D1 | 9.03 units on Scale | Standard Deviation 21.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C25D22 | 1.52 units on Scale | Standard Deviation 22.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C26D1 | 10.90 units on Scale | Standard Deviation 24.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C27D1 | 13.64 units on Scale | Standard Deviation 18.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C22D1 | -6.67 units on Scale | Standard Deviation 25.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C28D1 | 14.58 units on Scale | Standard Deviation 21.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 30 Day follow up | -2.55 units on Scale | Standard Deviation 22.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C5D1 | -3.00 units on Scale | Standard Deviation 22.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C11D22 | -4.55 units on Scale | Standard Deviation 18.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 90 Day follow up | -1.74 units on Scale | Standard Deviation 22.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C22D22 | -3.03 units on Scale | Standard Deviation 27.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C12D1 | 0.00 units on Scale | Standard Deviation 23.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C23D1 | -2.08 units on Scale | Standard Deviation 28.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning Baseline | 87.48 units on Scale | Standard Deviation 17.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C18D22 | -7.14 units on Scale | Standard Deviation 21.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C1D22 | -3.01 units on Scale | Standard Deviation 18.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C23D22 | -6.06 units on Scale | Standard Deviation 29.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C24D1 | -7.14 units on Scale | Standard Deviation 26.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C2D1 | -0.16 units on Scale | Standard Deviation 19.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C25D1 | 0.00 units on Scale | Standard Deviation 24.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C12D22 | -1.75 units on Scale | Standard Deviation 20.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C2D22 | -1.00 units on Scale | Standard Deviation 16.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C25D22 | -3.03 units on Scale | Standard Deviation 31.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C26D1 | -7.69 units on Scale | Standard Deviation 27.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C13D1 | -3.47 units on Scale | Standard Deviation 30.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C27D1 | -9.09 units on Scale | Standard Deviation 30.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C3D1 | -0.61 units on Scale | Standard Deviation 20.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C28D1 | -5.56 units on Scale | Standard Deviation 27.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C3D22 | -3.07 units on Scale | Standard Deviation 18.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 30 Day Follow up | -2.31 units on Scale | Standard Deviation 28.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C4D1 | 0.10 units on Scale | Standard Deviation 19.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C13D22 | -4.07 units on Scale | Standard Deviation 23.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C5D22 | -2.52 units on Scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C4D22 | -5.28 units on Scale | Standard Deviation 21.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 90 Day Follow up | 1.94 units on Scale | Standard Deviation 29.53 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C13D22 | -7.14 units on Scale | Standard Deviation 24.48 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C4D22 | 1.50 units on Scale | Standard Deviation 22.37 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C6D22 | 2.39 units on Scale | Standard Deviation 18.15 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C10D22 | 5.43 units on Scale | Standard Deviation 17.34 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C12D22 | -3.33 units on Scale | Standard Deviation 12.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C14D22 | -1.32 units on Scale | Standard Deviation 16.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 90 Day follow up | -11.49 units on Scale | Standard Deviation 25.95 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning Baseline | 75.52 units on Scale | Standard Deviation 28.02 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C1D22 | -4.13 units on Scale | Standard Deviation 24.1 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C9D22 | 0.91 units on Scale | Standard Deviation 18.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 90 Day Follow up | 4.02 units on Scale | Standard Deviation 31.41 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 30 Follow up | 7.33 units on Scale | Standard Deviation 27.24 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 90 Day Follow up | 6.02 units on Scale | Standard Deviation 29.51 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea Baseline | 13.70 units on Scale | Standard Deviation 23.2 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C1D22 | 1.43 units on Scale | Standard Deviation 22.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C2D1 | 0.59 units on Scale | Standard Deviation 20.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C2D22 | 0.18 units on Scale | Standard Deviation 21.52 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C3D1 | 1.01 units on Scale | Standard Deviation 20.13 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C3D22 | 2.24 units on Scale | Standard Deviation 21.1 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C4D1 | 1.43 units on Scale | Standard Deviation 21.07 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C4D22 | 0.26 units on Scale | Standard Deviation 20.28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C5D1 | -0.46 units on Scale | Standard Deviation 24.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C5D22 | 1.44 units on Scale | Standard Deviation 22.15 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C6D1 | 3.28 units on Scale | Standard Deviation 22.02 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C6D22 | 1.42 units on Scale | Standard Deviation 20.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C7D1 | -1.02 units on Scale | Standard Deviation 19.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C7D22 | -2.25 units on Scale | Standard Deviation 21.6 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C8D1 | -0.40 units on Scale | Standard Deviation 21.77 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C8D22 | -3.59 units on Scale | Standard Deviation 18.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C9D1 | -3.23 units on Scale | Standard Deviation 19.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C9D22 | -3.64 units on Scale | Standard Deviation 21.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C10D1 | 0.00 units on Scale | Standard Deviation 22.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C10D22 | 1.55 units on Scale | Standard Deviation 24.07 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C11D1 | 0.00 units on Scale | Standard Deviation 17.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C11D22 | 2.15 units on Scale | Standard Deviation 28.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C12D1 | 0.00 units on Scale | Standard Deviation 21.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C12D22 | 5.33 units on Scale | Standard Deviation 15.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C18D1 | -1.56 units on Scale | Standard Deviation 13.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C13D1 | 0.95 units on Scale | Standard Deviation 22.12 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C13D22 | -1.59 units on Scale | Standard Deviation 26.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C14D1 | 0.00 units on Scale | Standard Deviation 24.76 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C14D22 | -3.51 units on Scale | Standard Deviation 26.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C15D1 | -1.23 units on Scale | Standard Deviation 26.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C15D22 | -3.92 units on Scale | Standard Deviation 28.58 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C18D22 | -1.67 units on Scale | Standard Deviation 12.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C19D1 | -6.11 units on Scale | Standard Deviation 14.25 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C19D22 | -7.58 units on Scale | Standard Deviation 12.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C20D1 | 1.11 units on Scale | Standard Deviation 12.94 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C20D22 | -0.83 units on Scale | Standard Deviation 15.93 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C21D1 | -1.79 units on Scale | Standard Deviation 15.39 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C16D22 | -2.38 units on Scale | Standard Deviation 14.41 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C17D1 | 0.93 units on Scale | Standard Deviation 13.06 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C22D1 | -6.25 units on Scale | Standard Deviation 14.7 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C23D1 | -0.64 units on Scale | Standard Deviation 15.39 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C5D22 | 0.11 units on Scale | Standard Deviation 19.72 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 30 Day follow up | -4.03 units on Scale | Standard Deviation 20.99 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C6D1 | -1.26 units on Scale | Standard Deviation 18.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C6D22 | -0.92 units on Scale | Standard Deviation 15.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C7D1 | -0.95 units on Scale | Standard Deviation 15.58 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C7D22 | 1.89 units on Scale | Standard Deviation 19.03 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 90 Day follow up | -4.62 units on Scale | Standard Deviation 22.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C8D1 | 0.88 units on Scale | Standard Deviation 15.85 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C16D1 | -1.52 units on Scale | Standard Deviation 26.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning Baseline | 78.79 units on Scale | Standard Deviation 21.13 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C8D22 | -0.31 units on Scale | Standard Deviation 17.66 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C9D1 | 0.43 units on Scale | Standard Deviation 17.24 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C9D22 | 1.94 units on Scale | Standard Deviation 16.61 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C16D22 | 4.76 units on Scale | Standard Deviation 17.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C10D1 | 0.71 units on Scale | Standard Deviation 16.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C10D22 | -2.48 units on Scale | Standard Deviation 19.36 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C11D1 | -3.33 units on Scale | Standard Deviation 16.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C11D22 | -6.02 units on Scale | Standard Deviation 16.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C12D1 | -3.58 units on Scale | Standard Deviation 14.61 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C13D1 | -6.67 units on Scale | Standard Deviation 17.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C1D22 | -1.49 units on Scale | Standard Deviation 15.7 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C2D1 | 1.69 units on Scale | Standard Deviation 17.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C12D22 | -5.60 units on Scale | Standard Deviation 14.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C2D22 | 1.73 units on Scale | Standard Deviation 18.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C3D1 | 2.66 units on Scale | Standard Deviation 18.7 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C3D22 | 1.52 units on Scale | Standard Deviation 15.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C4D1 | 1.47 units on Scale | Standard Deviation 19.25 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C4D22 | -1.51 units on Scale | Standard Deviation 19.61 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C5D1 | 0.55 units on Scale | Standard Deviation 18.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C15D1 | -6.42 units on Scale | Standard Deviation 18.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C15D22 | 0.39 units on Scale | Standard Deviation 14.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C16D1 | -4.55 units on Scale | Standard Deviation 18.79 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C13D22 | -6.98 units on Scale | Standard Deviation 19.6 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C14D1 | -3.56 units on Scale | Standard Deviation 13.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C14D22 | -1.75 units on Scale | Standard Deviation 13.49 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C16D22 | -7.14 units on Scale | Standard Deviation 14.67 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C17D1 | -3.70 units on Scale | Standard Deviation 11.93 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C18D1 | -2.92 units on Scale | Standard Deviation 6.87 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C18D22 | 0.00 units on Scale | Standard Deviation 7.03 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C19D1 | -1.33 units on Scale | Standard Deviation 8.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C17D1 | 0.00 units on Scale | Standard Deviation 16.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C19D22 | -4.24 units on Scale | Standard Deviation 8.58 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C20D1 | -1.78 units on Scale | Standard Deviation 8.9 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C20D22 | -4.67 units on Scale | Standard Deviation 7.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C21D1 | -1.43 units on Scale | Standard Deviation 9.13 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C22D1 | -2.22 units on Scale | Standard Deviation 6.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C23D1 | 1.54 units on Scale | Standard Deviation 9.49 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 30 Day follow up | -6.96 units on Scale | Standard Deviation 21.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status Baseline | 63.47 units on Scale | Standard Deviation 20.63 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C1D22 | 0.48 units on Scale | Standard Deviation 17.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C2D1 | 5.56 units on Scale | Standard Deviation 18.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C3D1 | 5.77 units on Scale | Standard Deviation 19.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C3D22 | 3.13 units on Scale | Standard Deviation 18.03 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C4D1 | 6.65 units on Scale | Standard Deviation 21.04 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C5D1 | 4.83 units on Scale | Standard Deviation 20.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C5D22 | 0.07 units on Scale | Standard Deviation 21.52 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C6D1 | 0.07 units on Scale | Standard Deviation 21.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C7D1 | 4.34 units on Scale | Standard Deviation 17.64 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C7D22 | 3.38 units on Scale | Standard Deviation 20.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C8D1 | 4.82 units on Scale | Standard Deviation 17.9 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C8D22 | 6.92 units on Scale | Standard Deviation 18.67 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C9D1 | 4.57 units on Scale | Standard Deviation 15.14 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C9D22 | 3.18 units on Scale | Standard Deviation 17.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C10D1 | 3.87 units on Scale | Standard Deviation 19.2 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C11D1 | 3.99 units on Scale | Standard Deviation 15.09 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C11D22 | 1.34 units on Scale | Standard Deviation 16.12 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C12D1 | 2.64 units on Scale | Standard Deviation 14 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C13D1 | 0.95 units on Scale | Standard Deviation 13.52 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C13D22 | -0.79 units on Scale | Standard Deviation 13.15 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C14D1 | 0.83 units on Scale | Standard Deviation 20.22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C15D1 | 0.93 units on Scale | Standard Deviation 16.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C15D22 | -3.43 units on Scale | Standard Deviation 18.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C16D1 | 1.89 units on Scale | Standard Deviation 18.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia Baseline | 29.59 units on Scale | Standard Deviation 28.64 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C1D22 | -3.81 units on Scale | Standard Deviation 29.28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C2D1 | -6.22 units on Scale | Standard Deviation 29.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C2D22 | -8.84 units on Scale | Standard Deviation 28.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C3D1 | -10.27 units on Scale | Standard Deviation 30.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C3D22 | -10.07 units on Scale | Standard Deviation 31.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C4D1 | -11.86 units on Scale | Standard Deviation 30.47 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C4D22 | -11.46 units on Scale | Standard Deviation 29.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C5D1 | -8.97 units on Scale | Standard Deviation 34.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C5D22 | -7.47 units on Scale | Standard Deviation 30.16 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C6D1 | -8.47 units on Scale | Standard Deviation 31.36 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C6D22 | -12.77 units on Scale | Standard Deviation 30.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C7D1 | -11.90 units on Scale | Standard Deviation 28.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C7D22 | -13.96 units on Scale | Standard Deviation 25.29 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C8D1 | -8.84 units on Scale | Standard Deviation 29.49 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C8D22 | -14.36 units on Scale | Standard Deviation 24.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C9D1 | -13.98 units on Scale | Standard Deviation 25.99 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C9D22 | -11.52 units on Scale | Standard Deviation 30.24 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C10D1 | -8.33 units on Scale | Standard Deviation 33.78 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C10D22 | -10.85 units on Scale | Standard Deviation 29.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C11D1 | -10.14 units on Scale | Standard Deviation 26.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C11D22 | -10.75 units on Scale | Standard Deviation 29.04 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C12D1 | -12.20 units on Scale | Standard Deviation 30.51 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C12D22 | -8.00 units on Scale | Standard Deviation 25.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C13D1 | -10.48 units on Scale | Standard Deviation 22.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C13D22 | -11.11 units on Scale | Standard Deviation 19.25 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C14D1 | -5.56 units on Scale | Standard Deviation 27.8 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C14D22 | -8.77 units on Scale | Standard Deviation 26.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C15D1 | -6.17 units on Scale | Standard Deviation 24.52 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C15D22 | -3.92 units on Scale | Standard Deviation 26.04 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C16D1 | -1.52 units on Scale | Standard Deviation 24.07 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C16D22 | -7.14 units on Scale | Standard Deviation 29.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C17D1 | -7.41 units on Scale | Standard Deviation 29.27 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C18D1 | 0.00 units on Scale | Standard Deviation 21.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C18D22 | 6.67 units on Scale | Standard Deviation 21.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C19D1 | -2.22 units on Scale | Standard Deviation 29.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C19D22 | 12.12 units on Scale | Standard Deviation 22.47 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C20D1 | -4.44 units on Scale | Standard Deviation 21.33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C20D22 | 10.00 units on Scale | Standard Deviation 27.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C21D1 | 2.38 units on Scale | Standard Deviation 27.62 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C22D1 | 2.78 units on Scale | Standard Deviation 22.29 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C23D1 | -2.56 units on Scale | Standard Deviation 25.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 30 Day Follow up | -2.93 units on Scale | Standard Deviation 33.94 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 90 Day Follow up | -3.21 units on Scale | Standard Deviation 39.51 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss Baseline | 32.17 units on Scale | Standard Deviation 31.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C1D22 | 4.13 units on Scale | Standard Deviation 33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C2D1 | -8.00 units on Scale | Standard Deviation 31.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C2D22 | 0.18 units on Scale | Standard Deviation 35.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C3D1 | -8.75 units on Scale | Standard Deviation 31.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C3D22 | -2.68 units on Scale | Standard Deviation 30.39 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C4D1 | -7.36 units on Scale | Standard Deviation 34.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C4D22 | -4.95 units on Scale | Standard Deviation 31.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C5D1 | -8.28 units on Scale | Standard Deviation 30.31 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C5D22 | -6.03 units on Scale | Standard Deviation 30.33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C6D1 | -5.19 units on Scale | Standard Deviation 31.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C6D22 | -8.51 units on Scale | Standard Deviation 30.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C7D1 | -10.20 units on Scale | Standard Deviation 28.48 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C7D22 | -11.26 units on Scale | Standard Deviation 31.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C8D1 | -8.43 units on Scale | Standard Deviation 28.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C8D22 | -4.10 units on Scale | Standard Deviation 28.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C9D1 | -5.91 units on Scale | Standard Deviation 32.24 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C9D22 | -1.82 units on Scale | Standard Deviation 27.53 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C10D1 | -5.36 units on Scale | Standard Deviation 27.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C10D22 | 0.78 units on Scale | Standard Deviation 33.72 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C11D1 | -2.17 units on Scale | Standard Deviation 28.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C11D22 | -6.45 units on Scale | Standard Deviation 31.53 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C12D1 | -5.69 units on Scale | Standard Deviation 28.77 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C12D22 | -5.33 units on Scale | Standard Deviation 28.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C13D1 | -4.76 units on Scale | Standard Deviation 30.4 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C13D22 | 7.94 units on Scale | Standard Deviation 29.64 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C14D1 | 0.00 units on Scale | Standard Deviation 27.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C14D22 | -7.02 units on Scale | Standard Deviation 21.02 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C15D1 | -6.17 units on Scale | Standard Deviation 27.79 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C15D22 | -7.84 units on Scale | Standard Deviation 25.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C16D1 | -7.58 units on Scale | Standard Deviation 22.84 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C16D22 | -7.14 units on Scale | Standard Deviation 23.31 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C17D1 | -5.56 units on Scale | Standard Deviation 23.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C18D1 | -4.17 units on Scale | Standard Deviation 29.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C18D22 | -10.00 units on Scale | Standard Deviation 27.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C19D1 | -2.22 units on Scale | Standard Deviation 29.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C19D22 | -6.06 units on Scale | Standard Deviation 25.03 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C20D1 | -8.89 units on Scale | Standard Deviation 23.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C20D22 | -10.00 units on Scale | Standard Deviation 27.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C21D1 | -7.14 units on Scale | Standard Deviation 19.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C22D1 | -11.11 units on Scale | Standard Deviation 25.95 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C23D1 | -7.69 units on Scale | Standard Deviation 27.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 30 Day Follow up | 3.30 units on Scale | Standard Deviation 32.6 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 90 Day Follow up | 7.63 units on Scale | Standard Deviation 39.07 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation Baseline | 19.64 units on Scale | Standard Deviation 28.39 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C1D22 | 4.44 units on Scale | Standard Deviation 29.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C2D1 | -2.37 units on Scale | Standard Deviation 32.8 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C2D22 | 0.37 units on Scale | Standard Deviation 31.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C3D1 | -2.53 units on Scale | Standard Deviation 30.4 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C3D22 | -0.89 units on Scale | Standard Deviation 31.7 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C4D1 | -1.02 units on Scale | Standard Deviation 28.79 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C4D22 | 2.08 units on Scale | Standard Deviation 28.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C5D1 | -1.15 units on Scale | Standard Deviation 30.79 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C5D22 | -1.44 units on Scale | Standard Deviation 26.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C6D1 | 0.55 units on Scale | Standard Deviation 28.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C6D22 | -1.77 units on Scale | Standard Deviation 30.67 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C7D1 | -1.36 units on Scale | Standard Deviation 29.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C7D22 | -4.05 units on Scale | Standard Deviation 32.62 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C8D1 | -0.40 units on Scale | Standard Deviation 29.67 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C8D22 | -2.56 units on Scale | Standard Deviation 25.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C9D1 | 0.00 units on Scale | Standard Deviation 28.95 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C9D22 | 2.42 units on Scale | Standard Deviation 33.24 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C10D1 | 4.17 units on Scale | Standard Deviation 30.53 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C10D22 | 7.75 units on Scale | Standard Deviation 31.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C11D1 | 7.25 units on Scale | Standard Deviation 31.36 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C11D22 | 6.45 units on Scale | Standard Deviation 24.97 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C12D1 | 10.57 units on Scale | Standard Deviation 32.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C12D22 | 18.67 units on Scale | Standard Deviation 34.8 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C13D1 | 10.48 units on Scale | Standard Deviation 35.95 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C13D22 | 11.11 units on Scale | Standard Deviation 39.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C14D1 | 11.11 units on Scale | Standard Deviation 36.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C14D22 | 3.51 units on Scale | Standard Deviation 33.14 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C15D1 | 6.17 units on Scale | Standard Deviation 32.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C15D22 | 3.92 units on Scale | Standard Deviation 35.12 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C16D1 | 7.58 units on Scale | Standard Deviation 36.99 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C16D22 | 14.29 units on Scale | Standard Deviation 40.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C5D22 | -2.73 units on Scale | Standard Deviation 27.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C17D1 | 1.85 units on Scale | Standard Deviation 29.09 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C6D1 | -5.46 units on Scale | Standard Deviation 26.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C18D1 | 10.42 units on Scale | Standard Deviation 33.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C18D22 | 6.67 units on Scale | Standard Deviation 37.84 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C19D1 | 15.56 units on Scale | Standard Deviation 37.52 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C19D22 | 18.18 units on Scale | Standard Deviation 37.61 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C6D22 | -2.84 units on Scale | Standard Deviation 25.47 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C7D1 | -2.55 units on Scale | Standard Deviation 22.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C20D1 | 11.11 units on Scale | Standard Deviation 34.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C7D22 | -1.58 units on Scale | Standard Deviation 24.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C20D22 | 3.33 units on Scale | Standard Deviation 29.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C21D1 | 14.29 units on Scale | Standard Deviation 33.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C22D1 | 2.78 units on Scale | Standard Deviation 30.01 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C23D1 | 17.95 units on Scale | Standard Deviation 35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C8D1 | -0.60 units on Scale | Standard Deviation 23.2 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 30 Day Follow up | 2.56 units on Scale | Standard Deviation 34.15 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C8D22 | -1.03 units on Scale | Standard Deviation 21.83 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 90 Day Follow up | 1.20 units on Scale | Standard Deviation 30.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C9D1 | -2.96 units on Scale | Standard Deviation 22.49 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C9D22 | -0.61 units on Scale | Standard Deviation 22.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea Baseline | 10.59 units on Scale | Standard Deviation 19.94 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C1D22 | 2.86 units on Scale | Standard Deviation 24.01 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C2D1 | 2.96 units on Scale | Standard Deviation 22.52 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C2D22 | 0.92 units on Scale | Standard Deviation 22.06 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C3D1 | 1.18 units on Scale | Standard Deviation 24.99 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C3D22 | 1.57 units on Scale | Standard Deviation 24.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C4D1 | 1.02 units on Scale | Standard Deviation 24.12 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C10D1 | -3.27 units on Scale | Standard Deviation 26.1 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C4D22 | -0.78 units on Scale | Standard Deviation 24.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C10D22 | -2.71 units on Scale | Standard Deviation 26.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C11D1 | -0.36 units on Scale | Standard Deviation 21.28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C5D1 | -0.92 units on Scale | Standard Deviation 25.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C5D22 | -4.31 units on Scale | Standard Deviation 22.64 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C6D1 | -1.37 units on Scale | Standard Deviation 24.01 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C6D22 | -1.77 units on Scale | Standard Deviation 23.63 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C7D1 | -2.04 units on Scale | Standard Deviation 24.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C7D22 | -7.66 units on Scale | Standard Deviation 23.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C8D1 | -2.81 units on Scale | Standard Deviation 22.81 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C8D22 | -2.05 units on Scale | Standard Deviation 22.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C9D1 | -2.69 units on Scale | Standard Deviation 18.4 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C9D22 | -3.03 units on Scale | Standard Deviation 22.47 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C11D22 | -9.14 units on Scale | Standard Deviation 20.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C12D1 | -2.85 units on Scale | Standard Deviation 21.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C12D22 | -4.0 units on Scale | Standard Deviation 24.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C13D1 | -2.38 units on Scale | Standard Deviation 24.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C13D22 | 0.00 units on Scale | Standard Deviation 19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C14D1 | -5.56 units on Scale | Standard Deviation 20.22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C14D22 | -2.63 units on Scale | Standard Deviation 20.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C15D1 | -5.56 units on Scale | Standard Deviation 24.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C15D22 | 5.88 units on Scale | Standard Deviation 22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C16D1 | 0.00 units on Scale | Standard Deviation 23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C16D22 | -1.19 units on Scale | Standard Deviation 20.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C17D1 | 0.00 units on Scale | Standard Deviation 16.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C18D1 | -1.04 units on Scale | Standard Deviation 14.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C18D22 | -1.67 units on Scale | Standard Deviation 14.59 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C19D1 | -5.56 units on Scale | Standard Deviation 19.59 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C19D22 | -3.03 units on Scale | Standard Deviation 19.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C20D1 | -4.44 units on Scale | Standard Deviation 20.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C20D22 | -6.67 units on Scale | Standard Deviation 11.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C21D1 | -1.19 units on Scale | Standard Deviation 17.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C22D1 | -2.78 units on Scale | Standard Deviation 18.58 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C23D1 | 1.28 units on Scale | Standard Deviation 12.66 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 30 Day follow up | -10.99 units on Scale | Standard Deviation 30.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 90 Day follow up | -14.26 units on Scale | Standard Deviation 29.58 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning Baseline | 73.45 units on Scale | Standard Deviation 21.16 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C1D22 | 3.33 units on Scale | Standard Deviation 15.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C2D1 | 6.15 units on Scale | Standard Deviation 17.93 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C2D22 | 5.85 units on Scale | Standard Deviation 18.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C3D1 | 9.43 units on Scale | Standard Deviation 18.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C3D22 | 9.06 units on Scale | Standard Deviation 19.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C4D1 | 8.13 units on Scale | Standard Deviation 18.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C4D22 | 6.84 units on Scale | Standard Deviation 20.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C5D1 | 5.80 units on Scale | Standard Deviation 20.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C5D22 | 2.95 units on Scale | Standard Deviation 18.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C6D1 | 4.92 units on Scale | Standard Deviation 17.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C6D22 | 7.54 units on Scale | Standard Deviation 17.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C7D1 | 7.99 units on Scale | Standard Deviation 19.59 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C7D22 | 7.66 units on Scale | Standard Deviation 18.9 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C8D1 | 9.14 units on Scale | Standard Deviation 19.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C8D22 | 6.41 units on Scale | Standard Deviation 20.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C9D1 | 6.99 units on Scale | Standard Deviation 16.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C9D22 | 5.76 units on Scale | Standard Deviation 18.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C10D1 | 6.85 units on Scale | Standard Deviation 18.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C10D22 | 6.20 units on Scale | Standard Deviation 20.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C11D1 | 3.99 units on Scale | Standard Deviation 21.14 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C11D22 | 1.88 units on Scale | Standard Deviation 22.64 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C12D1 | 2.44 units on Scale | Standard Deviation 18.66 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C12D22 | 4.33 units on Scale | Standard Deviation 18.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C13D1 | 1.43 units on Scale | Standard Deviation 24.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C13D22 | -3.17 units on Scale | Standard Deviation 19.63 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C14D1 | 2.22 units on Scale | Standard Deviation 18.94 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C14D22 | -1.75 units on Scale | Standard Deviation 18.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C15D1 | 2.47 units on Scale | Standard Deviation 18.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C15D22 | -2.45 units on Scale | Standard Deviation 20.99 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C16D1 | -3.41 units on Scale | Standard Deviation 21.62 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C16D22 | -4.76 units on Scale | Standard Deviation 20.6 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C17D1 | 3.70 units on Scale | Standard Deviation 19.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C18D1 | 2.60 units on Scale | Standard Deviation 20.12 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C18D22 | -5.00 units on Scale | Standard Deviation 21.59 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C19D1 | -2.22 units on Scale | Standard Deviation 19.02 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C19D22 | -3.79 units on Scale | Standard Deviation 20.87 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C20D1 | 2.78 units on Scale | Standard Deviation 20.33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C20D22 | -6.67 units on Scale | Standard Deviation 19.95 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C21D1 | -2.98 units on Scale | Standard Deviation 24.59 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C22D1 | 2.78 units on Scale | Standard Deviation 21.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C23D1 | 5.13 units on Scale | Standard Deviation 21.93 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C10D1 | -1.79 units on Scale | Standard Deviation 19.51 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C10D22 | -1.55 units on Scale | Standard Deviation 21.77 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C11D1 | 0.72 units on Scale | Standard Deviation 22.76 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 30 Day follow up | -2.47 units on Scale | Standard Deviation 19.9 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C11D22 | -2.15 units on Scale | Standard Deviation 24.24 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 90 Day follow up | -4.02 units on Scale | Standard Deviation 23.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning Baseline | 86.69 units on Scale | Standard Deviation 18.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C1D22 | -0.32 units on Scale | Standard Deviation 14.49 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C12D1 | -3.25 units on Scale | Standard Deviation 19.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C2D1 | 0.30 units on Scale | Standard Deviation 15.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C2D22 | -1.10 units on Scale | Standard Deviation 15.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C12D22 | -4.00 units on Scale | Standard Deviation 20 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C13D1 | 2.86 units on Scale | Standard Deviation 27.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C3D1 | -0.17 units on Scale | Standard Deviation 16.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C3D22 | -0.11 units on Scale | Standard Deviation 13.49 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C4D1 | -1.64 units on Scale | Standard Deviation 15.85 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C4D22 | -1.82 units on Scale | Standard Deviation 16.1 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C13D22 | 4.76 units on Scale | Standard Deviation 19.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C14D1 | 4.44 units on Scale | Standard Deviation 29.99 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C5D1 | -3.56 units on Scale | Standard Deviation 17.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C5D22 | -3.16 units on Scale | Standard Deviation 16.14 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C6D1 | -3.13 units on Scale | Standard Deviation 17.22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C6D22 | -0.71 units on Scale | Standard Deviation 14.85 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C7D1 | -3.57 units on Scale | Standard Deviation 17.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C7D22 | -0.45 units on Scale | Standard Deviation 16.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C8D1 | -2.61 units on Scale | Standard Deviation 16.97 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C8D22 | -5.90 units on Scale | Standard Deviation 20.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C9D1 | -2.15 units on Scale | Standard Deviation 17.72 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C10D1 | -2.68 units on Scale | Standard Deviation 17.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C10D22 | -3.10 units on Scale | Standard Deviation 21.6 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C11D1 | -2.90 units on Scale | Standard Deviation 20.28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C11D22 | -4.30 units on Scale | Standard Deviation 19.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C12D1 | -1.63 units on Scale | Standard Deviation 18.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C12D22 | -6.00 units on Scale | Standard Deviation 15.87 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C13D1 | -5.24 units on Scale | Standard Deviation 28.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C14D22 | 1.75 units on Scale | Standard Deviation 26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C13D22 | -1.59 units on Scale | Standard Deviation 25.77 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C14D1 | -3.89 units on Scale | Standard Deviation 20.85 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C15D1 | -3.70 units on Scale | Standard Deviation 21.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C14D22 | -3.51 units on Scale | Standard Deviation 24.58 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C15D1 | 1.23 units on Scale | Standard Deviation 15.28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C15D22 | 0.00 units on Scale | Standard Deviation 16.67 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C16D1 | 3.03 units on Scale | Standard Deviation 32.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C15D22 | 3.92 units on Scale | Standard Deviation 24.67 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C16D1 | -2.27 units on Scale | Standard Deviation 26.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C16D22 | -1.19 units on Scale | Standard Deviation 17.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C17D1 | -2.78 units on Scale | Standard Deviation 16.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C16D22 | -4.76 units on Scale | Standard Deviation 17.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C17D1 | -3.70 units on Scale | Standard Deviation 19.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C18D1 | 0.00 units on Scale | Standard Deviation 10.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C18D1 | -2.08 units on Scale | Standard Deviation 25.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C18D22 | -3.33 units on Scale | Standard Deviation 10.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C19D1 | -2.22 units on Scale | Standard Deviation 10.67 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C19D22 | 1.52 units on Scale | Standard Deviation 11.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C18D22 | 0.00 units on Scale | Standard Deviation 15.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C20D1 | 1.11 units on Scale | Standard Deviation 11.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C19D1 | 0.00 units on Scale | Standard Deviation 25.2 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C20D22 | 0.00 units on Scale | Standard Deviation 7.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C21D1 | -2.38 units on Scale | Standard Deviation 12.84 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C22D1 | -1.39 units on Scale | Standard Deviation 13.22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C19D22 | 0.00 units on Scale | Standard Deviation 14.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C20D1 | -2.22 units on Scale | Standard Deviation 23.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C20D22 | 3.33 units on Scale | Standard Deviation 10.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C21D1 | 7.14 units on Scale | Standard Deviation 19.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C23D1 | 2.56 units on Scale | Standard Deviation 9.25 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 30 Day follow up | -6.41 units on Scale | Standard Deviation 17.7 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 90 Day follow up | -7.83 units on Scale | Standard Deviation 20.22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning Baseline | 73.26 units on Scale | Standard Deviation 27.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C22D1 | -5.56 units on Scale | Standard Deviation 23.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C23D1 | -5.13 units on Scale | Standard Deviation 22.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 30 Day Follow up | 3.66 units on Scale | Standard Deviation 20.76 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 90 Day Follow up | 9.24 units on Scale | Standard Deviation 30.49 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties Baseline | 18.86 units on Scale | Standard Deviation 27.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C1D22 | -0.48 units on Scale | Standard Deviation 21.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C2D1 | -1.93 units on Scale | Standard Deviation 24.01 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C1D22 | 0.48 units on Scale | Standard Deviation 23.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C2D1 | 3.11 units on Scale | Standard Deviation 25.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C2D22 | -1.84 units on Scale | Standard Deviation 23.76 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C2D22 | 2.76 units on Scale | Standard Deviation 27.47 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C3D1 | 2.44 units on Scale | Standard Deviation 26.78 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C3D22 | 3.80 units on Scale | Standard Deviation 25.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C4D1 | 5.62 units on Scale | Standard Deviation 23.88 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C4D22 | 2.73 units on Scale | Standard Deviation 22.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C5D1 | 1.38 units on Scale | Standard Deviation 29.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C5D22 | 0.86 units on Scale | Standard Deviation 27.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C6D1 | 0.27 units on Scale | Standard Deviation 26.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C6D22 | 3.01 units on Scale | Standard Deviation 29.33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C7D1 | 0.00 units on Scale | Standard Deviation 24.87 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C7D22 | 4.50 units on Scale | Standard Deviation 26.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C8D1 | 3.01 units on Scale | Standard Deviation 22.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C8D22 | 1.03 units on Scale | Standard Deviation 24.09 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C9D1 | 3.23 units on Scale | Standard Deviation 25.22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C9D22 | 3.33 units on Scale | Standard Deviation 26.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C10D1 | -0.60 units on Scale | Standard Deviation 28.6 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C10D22 | -1.55 units on Scale | Standard Deviation 30.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C11D1 | 1.81 units on Scale | Standard Deviation 25.87 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C11D22 | -3.76 units on Scale | Standard Deviation 22.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C12D1 | 0.00 units on Scale | Standard Deviation 26.09 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C12D22 | 4.00 units on Scale | Standard Deviation 22.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C13D1 | 1.43 units on Scale | Standard Deviation 26.62 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C3D1 | -1.85 units on Scale | Standard Deviation 24.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C13D22 | 8.73 units on Scale | Standard Deviation 22.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C14D1 | 0.56 units on Scale | Standard Deviation 25.33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C14D22 | 6.14 units on Scale | Standard Deviation 23.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C15D1 | -6.17 units on Scale | Standard Deviation 24.96 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C3D22 | -1.12 units on Scale | Standard Deviation 22.06 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C4D1 | -3.07 units on Scale | Standard Deviation 22.77 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C15D22 | 0.00 units on Scale | Standard Deviation 22.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C16D1 | 3.79 units on Scale | Standard Deviation 24.09 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C16D22 | 3.57 units on Scale | Standard Deviation 26.29 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C17D1 | 4.63 units on Scale | Standard Deviation 26.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C4D22 | -0.78 units on Scale | Standard Deviation 20.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C5D1 | -0.23 units on Scale | Standard Deviation 26.79 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C5D22 | -1.72 units on Scale | Standard Deviation 26.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C6D1 | 2.73 units on Scale | Standard Deviation 25.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C6D22 | 0.00 units on Scale | Standard Deviation 26.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C7D1 | 0.68 units on Scale | Standard Deviation 23.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C18D1 | -1.04 units on Scale | Standard Deviation 20.61 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C18D22 | -6.67 units on Scale | Standard Deviation 11.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C19D1 | -5.56 units on Scale | Standard Deviation 16.27 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C19D22 | -4.55 units on Scale | Standard Deviation 16.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C7D22 | -2.70 units on Scale | Standard Deviation 28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C8D1 | 0.80 units on Scale | Standard Deviation 26.02 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C8D22 | 1.54 units on Scale | Standard Deviation 27.28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C9D1 | -1.08 units on Scale | Standard Deviation 27.64 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C9D22 | 1.82 units on Scale | Standard Deviation 32.34 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C20D1 | -3.33 units on Scale | Standard Deviation 19.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C20D22 | 5.00 units on Scale | Standard Deviation 13.72 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C21D1 | -11.90 units on Scale | Standard Deviation 15.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C22D1 | -4.17 units on Scale | Standard Deviation 16.09 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C10D1 | 4.76 units on Scale | Standard Deviation 31.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C10D22 | 3.88 units on Scale | Standard Deviation 33.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C23D1 | -2.56 units on Scale | Standard Deviation 16.45 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C11D1 | 0.72 units on Scale | Standard Deviation 31.02 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C11D22 | 6.45 units on Scale | Standard Deviation 23.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C12D1 | 5.69 units on Scale | Standard Deviation 23.45 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C12D22 | 2.67 units on Scale | Standard Deviation 25.31 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C13D1 | 3.81 units on Scale | Standard Deviation 22.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C13D22 | -4.76 units on Scale | Standard Deviation 26.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C14D1 | 5.56 units on Scale | Standard Deviation 26.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C14D22 | -5.26 units on Scale | Standard Deviation 27.81 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C15D1 | 6.17 units on Scale | Standard Deviation 30.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C15D22 | -1.96 units on Scale | Standard Deviation 27.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C16D1 | 1.52 units on Scale | Standard Deviation 26.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C16D22 | 2.38 units on Scale | Standard Deviation 27.62 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 30 Day follow up | -2.56 units on Scale | Standard Deviation 26.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 90 Day follow up | -6.02 units on Scale | Standard Deviation 27.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue Baseline | 32.69 units on Scale | Standard Deviation 23.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C1D22 | 4.50 units on Scale | Standard Deviation 20.34 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C2D1 | -1.48 units on Scale | Standard Deviation 22.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C2D22 | -0.06 units on Scale | Standard Deviation 21.9 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C3D1 | -2.13 units on Scale | Standard Deviation 21.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C17D1 | 1.85 units on Scale | Standard Deviation 24.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C3D22 | -0.37 units on Scale | Standard Deviation 21.47 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C4D1 | -1.30 units on Scale | Standard Deviation 23.34 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C4D22 | -1.48 units on Scale | Standard Deviation 22.8 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C5D1 | 0.38 units on Scale | Standard Deviation 24.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C18D1 | 2.08 units on Scale | Standard Deviation 25.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C18D22 | 3.33 units on Scale | Standard Deviation 24.6 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C5D22 | 1.82 units on Scale | Standard Deviation 25.12 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C6D1 | 2.00 units on Scale | Standard Deviation 22.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C6D22 | -0.35 units on Scale | Standard Deviation 21.83 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C7D1 | -1.81 units on Scale | Standard Deviation 21.15 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C7D22 | -1.35 units on Scale | Standard Deviation 21.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C19D1 | 8.89 units on Scale | Standard Deviation 26.63 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C19D22 | 6.06 units on Scale | Standard Deviation 32.72 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C8D1 | -1.34 units on Scale | Standard Deviation 23.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C8D22 | -1.03 units on Scale | Standard Deviation 23.38 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C9D1 | -3.58 units on Scale | Standard Deviation 21.55 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C9D22 | -3.23 units on Scale | Standard Deviation 23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C18D1 | 2.08 units on Scale | Standard Deviation 19.12 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C20D1 | 4.44 units on Scale | Standard Deviation 24.77 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C12D1 | 0.54 units on Scale | Standard Deviation 20.63 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C20D22 | 6.67 units on Scale | Standard Deviation 34.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C23D1 | 0.00 units on Scale | Standard Deviation 23.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C21D1 | 11.90 units on Scale | Standard Deviation 28.06 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C10D1 | -3.97 units on Scale | Standard Deviation 23.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C22D1 | 2.78 units on Scale | Standard Deviation 26.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C10D22 | 0.26 units on Scale | Standard Deviation 22.55 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C11D1 | -1.21 units on Scale | Standard Deviation 20.45 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C11D22 | -0.36 units on Scale | Standard Deviation 21.94 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C12D22 | 2.67 units on Scale | Standard Deviation 22.52 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C13D1 | 3.17 units on Scale | Standard Deviation 23.43 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C13D22 | 2.65 units on Scale | Standard Deviation 16.06 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C14D1 | 1.48 units on Scale | Standard Deviation 20.37 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C14D22 | -0.58 units on Scale | Standard Deviation 20.11 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C15D1 | 4.94 units on Scale | Standard Deviation 23.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C15D22 | -7.19 units on Scale | Standard Deviation 21.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 30 Day Follow up | 5.13 units on Scale | Standard Deviation 26.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C16D1 | 0.51 units on Scale | Standard Deviation 21.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C16D22 | 2.38 units on Scale | Standard Deviation 23.13 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C17D1 | -0.62 units on Scale | Standard Deviation 23.33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C18D1 | -2.78 units on Scale | Standard Deviation 21.66 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C18D22 | 1.11 units on Scale | Standard Deviation 20.59 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C19D1 | 2.96 units on Scale | Standard Deviation 25.36 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C19D22 | 3.03 units on Scale | Standard Deviation 26.8 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C20D1 | -1.48 units on Scale | Standard Deviation 15.64 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C20D22 | 2.22 units on Scale | Standard Deviation 18.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C21D1 | -0.79 units on Scale | Standard Deviation 19.72 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C22D1 | 2.78 units on Scale | Standard Deviation 17.81 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C23D1 | -1.71 units on Scale | Standard Deviation 19.16 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 30 Day follow up | 6.96 units on Scale | Standard Deviation 25.8 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 90 Day follow up | 13.25 units on Scale | Standard Deviation 25.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting Baseline | 17.18 units on Scale | Standard Deviation 24.33 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C1D22 | 2.70 units on Scale | Standard Deviation 23.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C2D1 | -3.70 units on Scale | Standard Deviation 23.85 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C2D22 | 0.83 units on Scale | Standard Deviation 26.25 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C3D1 | -5.13 units on Scale | Standard Deviation 23.7 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C3D22 | -1.68 units on Scale | Standard Deviation 28.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C4D1 | -4.19 units on Scale | Standard Deviation 23.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C4D22 | -3.39 units on Scale | Standard Deviation 25.48 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C5D1 | -6.78 units on Scale | Standard Deviation 23.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C5D22 | -5.60 units on Scale | Standard Deviation 22.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C6D1 | -3.42 units on Scale | Standard Deviation 24.24 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C6D22 | -5.14 units on Scale | Standard Deviation 24.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C7D1 | -4.25 units on Scale | Standard Deviation 21.31 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C7D22 | -6.53 units on Scale | Standard Deviation 22.21 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C8D1 | -3.61 units on Scale | Standard Deviation 16.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C8D22 | -4.10 units on Scale | Standard Deviation 21.86 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C9D1 | -4.57 units on Scale | Standard Deviation 23.8 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C9D22 | -3.94 units on Scale | Standard Deviation 21.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C10D1 | -3.87 units on Scale | Standard Deviation 19.59 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C10D22 | -2.71 units on Scale | Standard Deviation 25.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C11D1 | -1.81 units on Scale | Standard Deviation 22.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C11D22 | -3.76 units on Scale | Standard Deviation 24.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C12D1 | -1.63 units on Scale | Standard Deviation 25.22 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C12D22 | -3.33 units on Scale | Standard Deviation 24.06 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C13D1 | -3.33 units on Scale | Standard Deviation 23.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C2D22 | 1.98 units on Scale | Standard Deviation 20.79 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C14D1 | -2.78 units on Scale | Standard Deviation 22.35 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C14D22 | -7.02 units on Scale | Standard Deviation 24.42 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C15D1 | -3.09 units on Scale | Standard Deviation 25.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C15D22 | -2.94 units on Scale | Standard Deviation 31.31 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C16D1 | 1.52 units on Scale | Standard Deviation 33.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C16D22 | -7.14 units on Scale | Standard Deviation 30.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C17D1 | -4.63 units on Scale | Standard Deviation 27.3 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C18D1 | -4.17 units on Scale | Standard Deviation 26.87 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C18D22 | -8.33 units on Scale | Standard Deviation 29.66 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C19D1 | -1.11 units on Scale | Standard Deviation 29.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C19D22 | -7.58 units on Scale | Standard Deviation 31.94 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C20D1 | -3.33 units on Scale | Standard Deviation 26.87 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C20D22 | -8.33 units on Scale | Standard Deviation 32.63 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C21D1 | -3.57 units on Scale | Standard Deviation 30.08 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C22D1 | -9.72 units on Scale | Standard Deviation 27.94 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C23D1 | -3.85 units on Scale | Standard Deviation 30.55 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 30 Day Follow up | -1.10 units on Scale | Standard Deviation 27.19 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 90 Day Follow up | -4.42 units on Scale | Standard Deviation 29.34 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain Baseline | 26.61 units on Scale | Standard Deviation 25.13 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C1D22 | -5.48 units on Scale | Standard Deviation 19.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C2D1 | -9.19 units on Scale | Standard Deviation 21.93 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C2D22 | -9.21 units on Scale | Standard Deviation 23.27 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C3D1 | -9.18 units on Scale | Standard Deviation 22.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C3D22 | -7.61 units on Scale | Standard Deviation 22.13 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C4D1 | -9.41 units on Scale | Standard Deviation 21.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C4D22 | -7.94 units on Scale | Standard Deviation 22.91 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C5D1 | -6.55 units on Scale | Standard Deviation 23.27 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C5D22 | -5.60 units on Scale | Standard Deviation 24.27 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C6D1 | -4.64 units on Scale | Standard Deviation 24.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C6D22 | -8.16 units on Scale | Standard Deviation 18.89 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C7D1 | -6.80 units on Scale | Standard Deviation 20.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C7D22 | -6.98 units on Scale | Standard Deviation 20.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C8D1 | -7.83 units on Scale | Standard Deviation 18.28 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C8D22 | -5.90 units on Scale | Standard Deviation 17.04 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C9D1 | -6.99 units on Scale | Standard Deviation 18.74 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C9D22 | -3.94 units on Scale | Standard Deviation 21.75 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C10D1 | -2.38 units on Scale | Standard Deviation 25.71 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C10D22 | -2.71 units on Scale | Standard Deviation 24.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C11D1 | -3.62 units on Scale | Standard Deviation 18.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C11D22 | -3.23 units on Scale | Standard Deviation 15.17 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C12D1 | -1.22 units on Scale | Standard Deviation 19.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C12D22 | -5.33 units on Scale | Standard Deviation 20.25 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C13D1 | -2.86 units on Scale | Standard Deviation 20.41 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C13D22 | -7.14 units on Scale | Standard Deviation 21.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C14D1 | -1.11 units on Scale | Standard Deviation 19.54 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C14D22 | -10.53 units on Scale | Standard Deviation 26.18 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C15D1 | 1.85 units on Scale | Standard Deviation 25.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C15D22 | -4.90 units on Scale | Standard Deviation 28.73 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C16D1 | -4.55 units on Scale | Standard Deviation 22.53 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C16D22 | -3.57 units on Scale | Standard Deviation 11.65 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C17D1 | -4.63 units on Scale | Standard Deviation 15.97 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C18D1 | -6.25 units on Scale | Standard Deviation 10.32 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C18D22 | -5.00 units on Scale | Standard Deviation 15.81 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C19D1 | -1.11 units on Scale | Standard Deviation 13.31 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C19D22 | -4.55 units on Scale | Standard Deviation 10.78 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C20D1 | -3.33 units on Scale | Standard Deviation 15.69 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C20D22 | 1.67 units on Scale | Standard Deviation 16.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C21D1 | -4.76 units on Scale | Standard Deviation 15.23 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C22D1 | -4.17 units on Scale | Standard Deviation 12.56 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C23D1 | -6.41 units on Scale | Standard Deviation 14.5 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C18D22 | -3.33 units on Scale | Standard Deviation 18.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C19D1 | -2.22 units on Scale | Standard Deviation 15.26 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C19D22 | 0.00 units on Scale | Standard Deviation 25.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C20D1 | 2.22 units on Scale | Standard Deviation 23.46 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C20D22 | -6.67 units on Scale | Standard Deviation 14.05 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C21D1 | 4.76 units on Scale | Standard Deviation 25.68 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C22D1 | 0.00 units on Scale | Standard Deviation 20.1 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C23D1 | 0.00 units on Scale | Standard Deviation 19.25 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 30 Day Follow up | 5.49 units on Scale | Standard Deviation 21.81 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 90 Day Follow up | 12.05 units on Scale | Standard Deviation 27.83 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C2D1 | 0.30 units on Scale | Standard Deviation 25.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C2D22 | -1.20 units on Scale | Standard Deviation 28.44 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C3D1 | 2.19 units on Scale | Standard Deviation 26.57 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C3D22 | -0.89 units on Scale | Standard Deviation 25.98 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C4D1 | 1.94 units on Scale | Standard Deviation 26.92 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C4D22 | -2.73 units on Scale | Standard Deviation 24.82 |
| mFOLFOX6+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C5D1 | -2.87 units on Scale | Standard Deviation 27.24 |
Secondary
Change From Baseline in HRQoL Measured by Global Pain (GP)
The GP instrument is a single assessment of overall pain. Participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C7D1 | -0.46 units on a scale | Standard Deviation 2.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C6D1 | -0.63 units on a scale | Standard Deviation 3.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C6D22 | -0.68 units on a scale | Standard Deviation 2.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | Baseline | 2.87 units on a scale | Standard Deviation 2.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C7D22 | -0.31 units on a scale | Standard Deviation 3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C8D1 | -0.69 units on a scale | Standard Deviation 2.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C8D22 | -0.79 units on a scale | Standard Deviation 3.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C9D1 | -0.71 units on a scale | Standard Deviation 3.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C9D22 | -1.02 units on a scale | Standard Deviation 2.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C10D1 | -0.54 units on a scale | Standard Deviation 2.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C10D22 | -0.50 units on a scale | Standard Deviation 3.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C11D1 | -0.38 units on a scale | Standard Deviation 3.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C11D22 | -0.59 units on a scale | Standard Deviation 3.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C12D1 | -0.30 units on a scale | Standard Deviation 3.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C12D22 | -0.14 units on a scale | Standard Deviation 2.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C13D1 | -0.79 units on a scale | Standard Deviation 3.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C13D22 | -0.63 units on a scale | Standard Deviation 3.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C14D1 | -0.21 units on a scale | Standard Deviation 2.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C14D22 | -0.44 units on a scale | Standard Deviation 3.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C15D1 | 0.09 units on a scale | Standard Deviation 3.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C15D22 | -0.38 units on a scale | Standard Deviation 3.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C16D1 | -0.60 units on a scale | Standard Deviation 3.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C16D22 | -0.97 units on a scale | Standard Deviation 3.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C17D1 | -0.03 units on a scale | Standard Deviation 2.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C17D22 | 0.22 units on a scale | Standard Deviation 3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C18D1 | -0.62 units on a scale | Standard Deviation 3.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C18D22 | -1.14 units on a scale | Standard Deviation 2.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C19D1 | -1.04 units on a scale | Standard Deviation 3.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C19D22 | -0.50 units on a scale | Standard Deviation 2.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C20D1 | -0.43 units on a scale | Standard Deviation 3.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C20D22 | -0.17 units on a scale | Standard Deviation 3.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C21D1 | -0.50 units on a scale | Standard Deviation 3.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C21D22 | 0.57 units on a scale | Standard Deviation 2.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C22D1 | 0.07 units on a scale | Standard Deviation 3.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C22D22 | 0.60 units on a scale | Standard Deviation 3.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C23D1 | 1.07 units on a scale | Standard Deviation 4.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C23D22 | 1.27 units on a scale | Standard Deviation 4.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C24D1 | 1.43 units on a scale | Standard Deviation 4.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C25D1 | 2.33 units on a scale | Standard Deviation 3.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C25D22 | 1.45 units on a scale | Standard Deviation 3.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C26D1 | 1.08 units on a scale | Standard Deviation 3.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C27D1 | 1.55 units on a scale | Standard Deviation 3.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C28D1 | 1.42 units on a scale | Standard Deviation 3.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | 30 day follow up | -0.19 units on a scale | Standard Deviation 2.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | 90 Day follow up | -0.27 units on a scale | Standard Deviation 2.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C1D22 | -0.55 units on a scale | Standard Deviation 2.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C2D1 | -0.75 units on a scale | Standard Deviation 2.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C2D22 | -0.67 units on a scale | Standard Deviation 3.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C3D1 | -0.87 units on a scale | Standard Deviation 2.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C3D22 | -0.62 units on a scale | Standard Deviation 3.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C4D1 | -0.86 units on a scale | Standard Deviation 2.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C4D22 | -0.51 units on a scale | Standard Deviation 3.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C5D1 | -0.53 units on a scale | Standard Deviation 2.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C5D22 | -0.54 units on a scale | Standard Deviation 2.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | Baseline | 2.96 units on a scale | Standard Deviation 2.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C12D1 | -0.54 units on a scale | Standard Deviation 2.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C1D22 | -0.74 units on a scale | Standard Deviation 2.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C20D22 | -0.20 units on a scale | Standard Deviation 2.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C2D1 | -0.75 units on a scale | Standard Deviation 2.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C12D22 | -0.88 units on a scale | Standard Deviation 2.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C2D22 | -1.01 units on a scale | Standard Deviation 2.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C18D1 | -0.31 units on a scale | Standard Deviation 2.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C3D1 | -0.90 units on a scale | Standard Deviation 2.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C13D1 | -0.66 units on a scale | Standard Deviation 2.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C3D22 | -0.83 units on a scale | Standard Deviation 2.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | 30 day follow up | 0.39 units on a scale | Standard Deviation 3.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C4D1 | -0.66 units on a scale | Standard Deviation 2.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C13D22 | -1.19 units on a scale | Standard Deviation 3.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C4D22 | -0.78 units on a scale | Standard Deviation 2.55 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C18D22 | -0.40 units on a scale | Standard Deviation 2.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C5D1 | -0.81 units on a scale | Standard Deviation 2.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C14D1 | -0.37 units on a scale | Standard Deviation 2.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C5D22 | -0.84 units on a scale | Standard Deviation 3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C21D1 | -0.79 units on a scale | Standard Deviation 2.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C6D1 | -0.32 units on a scale | Standard Deviation 3.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C14D22 | -0.84 units on a scale | Standard Deviation 3.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C6D22 | -0.98 units on a scale | Standard Deviation 2.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C19D1 | -0.73 units on a scale | Standard Deviation 2.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C7D1 | -0.86 units on a scale | Standard Deviation 2.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C15D1 | 0.22 units on a scale | Standard Deviation 3.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C7D22 | -1.01 units on a scale | Standard Deviation 2.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | 90 Day follow up | 0.31 units on a scale | Standard Deviation 3.12 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C8D1 | -0.67 units on a scale | Standard Deviation 3.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C15D22 | -0.71 units on a scale | Standard Deviation 3.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C8D22 | -1.09 units on a scale | Standard Deviation 2.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C19D22 | -0.45 units on a scale | Standard Deviation 2.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C9D1 | -1.18 units on a scale | Standard Deviation 2.04 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C16D1 | -0.45 units on a scale | Standard Deviation 3.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C9D22 | -1.13 units on a scale | Standard Deviation 2.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C23D1 | -0.54 units on a scale | Standard Deviation 2.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C10D1 | -0.75 units on a scale | Standard Deviation 2.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C16D22 | -0.71 units on a scale | Standard Deviation 2.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C10D22 | -0.74 units on a scale | Standard Deviation 3.09 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C20D1 | 0.60 units on a scale | Standard Deviation 3.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C11D1 | -0.96 units on a scale | Standard Deviation 2.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C17D1 | -0.53 units on a scale | Standard Deviation 2.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C11D22 | -0.77 units on a scale | Standard Deviation 1.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C22D1 | -0.42 units on a scale | Standard Deviation 2.78 |
Secondary
Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire
EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C5D1 | 0.13 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C1D22 | -0.03 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C9D22 | -0.02 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C2D1 | -0.09 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C5D22 | 0.17 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C2D22 | -0.09 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C21D1 | 0.15 units on a scale | Standard Deviation 0.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C3D1 | -0.14 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C6D1 | 0.14 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C3D22 | -0.10 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C10D1 | -0.03 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C4D1 | -0.22 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C6D22 | 0.15 units on a scale | Standard Deviation 1.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C4D22 | -0.10 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care Baseline | 1.23 units on a scale | Standard Deviation 0.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C5D1 | -0.15 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C7D1 | 0.15 units on a scale | Standard Deviation 1.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C5D22 | -0.11 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C10D22 | -0.04 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C6D1 | -0.20 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C7D22 | 0.15 units on a scale | Standard Deviation 1.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C6D22 | -0.08 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C20D1 | 0.13 units on a scale | Standard Deviation 0.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C7D1 | -0.12 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C8D1 | 0.18 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C7D22 | -0.06 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C11D1 | 0.00 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C8D1 | -0.18 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C8D22 | 0.03 units on a scale | Standard Deviation 1.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C8D22 | -0.10 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C1DD22 | 0.11 units on a scale | Standard Deviation 0.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C9D1 | -0.17 units on a scale | Standard Deviation 1.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C9D1 | 0.07 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C9D22 | -0.08 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C11D22 | -0.04 units on a scale | Standard Deviation 0.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C10D1 | -0.17 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C9D22 | 0.13 units on a scale | Standard Deviation 0.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C10D22 | -0.16 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C21D22 | 0.14 units on a scale | Standard Deviation 0.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C11D1 | -0.21 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C10D1 | -0.02 units on a scale | Standard Deviation 1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C11D22 | -0.20 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C12D1 | -0.04 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C12D1 | -0.09 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C10D22 | -0.02 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C12D22 | -0.11 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C2D1 | 0.08 units on a scale | Standard Deviation 0.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C13D1 | -0.10 units on a scale | Standard Deviation 1.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C11D1 | -0.05 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C13D22 | -0.10 units on a scale | Standard Deviation 1.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C12D22 | -0.05 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C14D1 | -0.03 units on a scale | Standard Deviation 1.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C11D22 | 0.09 units on a scale | Standard Deviation 0.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C14D22 | -0.19 units on a scale | Standard Deviation 1.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C22D1 | 0.20 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C15D1 | -0.26 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C12D1 | -0.08 units on a scale | Standard Deviation 1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C15D22 | -0.17 units on a scale | Standard Deviation 1.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C13DD1 | -0.06 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C16D1 | -0.29 units on a scale | Standard Deviation 1.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C12D22 | 0.00 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C16D22 | -0.41 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C2D22 | 0.09 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C17D1 | -0.10 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C13D1 | 0.04 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C17D22 | -0.26 units on a scale | Standard Deviation 1.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C18D1 | -0.48 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C13D22 | -0.02 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C18D22 | -0.33 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C13D22 | 0.15 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C19D1 | -0.30 units on a scale | Standard Deviation 0.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C19D22 | 0.20 units on a scale | Standard Deviation 0.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C19D22 | -0.25 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C14D1 | 0.03 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C20D1 | -0.26 units on a scale | Standard Deviation 0.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C14D1 | -0.08 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C20D22 | -0.39 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C14D22 | 0.06 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C21D1 | -0.35 units on a scale | Standard Deviation 0.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C3D1 | 0.06 units on a scale | Standard Deviation 0.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C21D22 | -0.36 units on a scale | Standard Deviation 0.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C22D1 | -0.27 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C15D1 | 0.09 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility Baseline | 1.40 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C14D22 | 0.03 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C1D22 | 0.15 units on a scale | Standard Deviation 0.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C15D22 | 0.13 units on a scale | Standard Deviation 1.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C2D1 | 0.09 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C22D22 | 0.55 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C2D22 | 0.03 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C16D1 | 0.20 units on a scale | Standard Deviation 1.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C3D1 | 0.09 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C15D1 | -0.03 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C3D22 | 0.21 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C16D22 | -0.10 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C4D1 | 0.16 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C3D22 | 0.06 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C4D22 | 0.16 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C17D1 | 0.23 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C5D1 | 0.15 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C15D22 | -0.03 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C5D22 | 0.27 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C17D22 | 0.26 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C6D1 | 0.20 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C18D1 | -0.07 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C6D22 | 0.17 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C23D1 | 0.31 units on a scale | Standard Deviation 0.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C7D1 | 0.17 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C18D22 | 0.00 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C7D22 | 0.26 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C16D1 | 0.00 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C8D1 | 0.17 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C19D1 | 0.13 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C8D22 | 0.10 units on a scale | Standard Deviation 0.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C4D1 | 0.08 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C9D1 | 0.13 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C19D22 | 0.20 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C9D22 | 0.11 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C16D22 | -0.10 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C10D1 | 0.12 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C20D1 | 0.04 units on a scale | Standard Deviation 0.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C10D22 | 0.00 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C20D22 | 0.17 units on a scale | Standard Deviation 0.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C11D1 | 0.16 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C20D22 | 0.11 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C11D22 | 0.11 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C17D1 | 0.03 units on a scale | Standard Deviation 1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C12D1 | 0.08 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C21D1 | 0.10 units on a scale | Standard Deviation 0.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C12D22 | 0.21 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C4D22 | 0.05 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C13D1 | 0.02 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C21D22 | 0.14 units on a scale | Standard Deviation 0.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C13D22 | 0.20 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C22D1 | 0.13 units on a scale | Standard Deviation 0.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C14D1 | 0.05 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C17D22 | 0.13 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C14D22 | 0.16 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C22D22 | 0.36 units on a scale | Standard Deviation 0.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C15D1 | 0.23 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C23D1 | 0.50 units on a scale | Standard Deviation 0.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C15D22 | 0.30 units on a scale | Standard Deviation 0.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C18D1 | 0.00 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C16D1 | 0.20 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C23D22 | 0.18 units on a scale | Standard Deviation 0.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C16D22 | 0.03 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C24D1 | 0.36 units on a scale | Standard Deviation 0.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C17D1 | 0.23 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C25D1 | 0.17 units on a scale | Standard Deviation 0.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C17D22 | 0.17 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C18D1 | 0.15 units on a scale | Standard Deviation 1.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C25D22 | 0.18 units on a scale | Standard Deviation 0.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C18D22 | 0.05 units on a scale | Standard Deviation 0.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C26D1 | 0.15 units on a scale | Standard Deviation 0.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C7D1 | 1.32 units on a scale | Standard Deviation 20.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C27D1 | 0.27 units on a scale | Standard Deviation 0.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C23D1 | -0.06 units on a scale | Standard Deviation 1.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C28D1 | 0.17 units on a scale | Standard Deviation 0.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C23D22 | -0.18 units on a scale | Standard Deviation 1.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C24D1 | 0.00 units on a scale | Standard Deviation 1.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C25D1 | -0.17 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C25D22 | -0.27 units on a scale | Standard Deviation 0.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C26D1 | -0.23 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C27D1 | -0.27 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C28D1 | -0.33 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 30 Day follow up | 0.04 units on a scale | Standard Deviation 1.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 30 Day follow up | 0.29 units on a scale | Standard Deviation 1.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 90 Day follow up | 0.01 units on a scale | Standard Deviation 1.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C23D22 | 0.09 units on a scale | Standard Deviation 0.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale Baseline | 68.91 units on a scale | Standard Deviation 19.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 90 Day follow up | 0.41 units on a scale | Standard Deviation 1.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C1D22 | -3.44 units on a scale | Standard Deviation 18.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C18D22 | -0.10 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C2D1 | 0.05 units on a scale | Standard Deviation 18.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort Baseline | 1.93 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C2D22 | 0.63 units on a scale | Standard Deviation 18.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C5D1 | 0.10 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C3D1 | 1.16 units on a scale | Standard Deviation 18.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C22D22 | 0.00 units on a scale | Standard Deviation 1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C3D22 | -1.69 units on a scale | Standard Deviation 18.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C1D22 | 0.08 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C4D1 | 0.35 units on a scale | Standard Deviation 17.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C19D1 | 0.04 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C4D22 | -1.11 units on a scale | Standard Deviation 19.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C2D1 | -0.14 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C5D1 | -0.54 units on a scale | Standard Deviation 19.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C24D1 | 0.14 units on a scale | Standard Deviation 0.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C5D22 | 0.37 units on a scale | Standard Deviation 22.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C2D22 | -0.14 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C6D1 | 1.28 units on a scale | Standard Deviation 19.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C19D22 | 0.20 units on a scale | Standard Deviation 1.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C6D22 | 4.33 units on a scale | Standard Deviation 18.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C7D22 | 3.51 units on a scale | Standard Deviation 17.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C3D1 | -0.23 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C8D1 | 3.77 units on a scale | Standard Deviation 21.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C5D22 | 0.16 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C8D22 | 2.71 units on a scale | Standard Deviation 19.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C3D22 | -0.11 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C9D1 | 5.05 units on a scale | Standard Deviation 19.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C20D1 | 0.09 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C9D22 | 2.44 units on a scale | Standard Deviation 21.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C4D1 | -0.16 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C10D1 | 2.52 units on a scale | Standard Deviation 18.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C25D1 | 0.25 units on a scale | Standard Deviation 0.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | C10D22 | 3.23 units on a scale | Standard Deviation 17.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C4D22 | -0.14 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C11D1 | 5.10 units on a scale | Standard Deviation 17.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C20D22 | 0.06 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C11D22 | 3.96 units on a scale | Standard Deviation 15.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C5D1 | -0.19 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C12D1 | 1.06 units on a scale | Standard Deviation 18.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C6D1 | 0.07 units on a scale | Standard Deviation 0.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C12D22 | -1.55 units on a scale | Standard Deviation 17.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C5D22 | -0.02 units on a scale | Standard Deviation 1.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C13D1 | 3.27 units on a scale | Standard Deviation 17.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C21D1 | 0.10 units on a scale | Standard Deviation 0.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C13D22 | -0.29 units on a scale | Standard Deviation 18.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C6D1 | -0.18 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C14D1 | -0.15 units on a scale | Standard Deviation 16.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C25D22 | 0.27 units on a scale | Standard Deviation 0.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C14D22 | -0.25 units on a scale | Standard Deviation 18.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C6D22 | -0.08 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C15D1 | -0.09 units on a scale | Standard Deviation 16.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C21D22 | 0.29 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C15D22 | -2.63 units on a scale | Standard Deviation 23.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C7D1 | -0.15 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C16D1 | 2.43 units on a scale | Standard Deviation 16.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C22D1 | 0.20 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C16D22 | 2.00 units on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C7D22 | -0.12 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C17D1 | 2.50 units on a scale | Standard Deviation 16.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C6D22 | 0.07 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C17D22 | -2.61 units on a scale | Standard Deviation 17.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C18D1 | 2.85 units on a scale | Standard Deviation 18.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C8D1 | -0.12 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C18D22 | 0.86 units on a scale | Standard Deviation 18.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C22D22 | 0.18 units on a scale | Standard Deviation 0.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C19D1 | 5.39 units on a scale | Standard Deviation 16.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C8D22 | -0.14 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C19D22 | -0.25 units on a scale | Standard Deviation 19.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C23D1 | 0.31 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C20D1 | 1.57 units on a scale | Standard Deviation 21.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C9D1 | -0.21 units on a scale | Standard Deviation 1.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C20D22 | 0.78 units on a scale | Standard Deviation 16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C26D1 | 0.23 units on a scale | Standard Deviation 0.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C21D1 | 2.80 units on a scale | Standard Deviation 15.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C9D22 | -0.05 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C21D22 | -4.64 units on a scale | Standard Deviation 12.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C22D1 | 1.33 units on a scale | Standard Deviation 17.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C23D22 | 0.27 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C22D22 | -6.00 units on a scale | Standard Deviation 19.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C23D1 | -2.25 units on a scale | Standard Deviation 18.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C10D1 | -0.20 units on a scale | Standard Deviation 0.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C23D22 | -3.09 units on a scale | Standard Deviation 16.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C24D1 | -3.43 units on a scale | Standard Deviation 18.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C25D1 | -4.08 units on a scale | Standard Deviation 15.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C25D22 | -4.64 units on a scale | Standard Deviation 14.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C26D1 | 1.69 units on a scale | Standard Deviation 16.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C27D1 | 1.45 units on a scale | Standard Deviation 17.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C28D1 | -0.42 units on a scale | Standard Deviation 17.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 30 Day follow up | -1.33 units on a scale | Standard Deviation 18.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C24D1 | 0.21 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 90 Day follow up | -3.79 units on a scale | Standard Deviation 20.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C10D22 | -0.14 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C25D1 | 0.00 units on a scale | Standard Deviation 0.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C11D1 | -0.22 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C25D22 | 0.09 units on a scale | Standard Deviation 0.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C11D22 | -0.11 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C26D1 | -0.08 units on a scale | Standard Deviation 0.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C12D1 | -0.19 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C27D1 | -0.18 units on a scale | Standard Deviation 0.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C12D22 | -0.18 units on a scale | Standard Deviation 0.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C28D1 | -0.08 units on a scale | Standard Deviation 0.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C13D1 | -0.13 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care 30 Day follow up | 0.21 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C13D22 | 0.07 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C7D1 | 0.11 units on a scale | Standard Deviation 0.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C14D1 | -0.05 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care 90 Day follow up | 0.35 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C14D22 | -0.09 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C27D1 | 0.00 units on a scale | Standard Deviation 0 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C15D1 | -0.14 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities Baseline | 1.68 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C15D22 | -0.17 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C7D22 | 0.01 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C16D1 | -0.17 units on a scale | Standard Deviation 0.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C1D22 | 0.24 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C16D22 | -0.28 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C28D1 | 0.17 units on a scale | Standard Deviation 0.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C17D1 | -0.23 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C2D1 | 0.08 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C17D22 | -0.13 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C18D1 | -0.26 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C8D1 | 0.09 units on a scale | Standard Deviation 0.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C18D22 | -0.43 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C2D22 | 0.05 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C19D1 | -0.30 units on a scale | Standard Deviation 0.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 30 Day follow up | 0.38 units on a scale | Standard Deviation 1.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C19D22 | -0.10 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C3D1 | 0.05 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C20D1 | -0.22 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C8D22 | -0.01 units on a scale | Standard Deviation 0.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C20D22 | -0.28 units on a scale | Standard Deviation 0.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C3D22 | 0.23 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C21D1 | -0.25 units on a scale | Standard Deviation 0.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C19D1 | 0.09 units on a scale | Standard Deviation 0.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C21D22 | 0.21 units on a scale | Standard Deviation 0.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C22D1 | -0.20 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C4D1 | 0.06 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C22D22 | 0.00 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C23D1 | -0.13 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C9D1 | 0.08 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C23D22 | -0.09 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C24D1 | -0.07 units on a scale | Standard Deviation 1.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C25D1 | -0.17 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C25D22 | -0.09 units on a scale | Standard Deviation 0.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C26D1 | -0.08 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C27D1 | -0.27 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C28D1 | -0.25 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 30 Day follow up | -0.06 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C4D22 | 0.11 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 90 day follow up | 0.02 units on a scale | Standard Deviation 1.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 90 Day follow up | 0.51 units on a scale | Standard Deviation 1.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression Baseline | 1.76 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 90 Day follow up | -4.84 units on a scale | Standard Deviation 19.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C19D1 | 0.27 units on a scale | Standard Deviation 0.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C19D22 | 0.27 units on a scale | Standard Deviation 0.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C20D1 | 0.13 units on a scale | Standard Deviation 0.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C20D22 | 0.10 units on a scale | Standard Deviation 0.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C21D1 | 0.07 units on a scale | Standard Deviation 0.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C22D1 | 0.00 units on a scale | Standard Deviation 0.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C23D1 | 0.00 units on a scale | Standard Deviation 0.41 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 30 Day follow up | 0.47 units on a scale | Standard Deviation 0.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 90 Day follow up | 0.53 units on a scale | Standard Deviation 0.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care Baseline | 1.21 units on a scale | Standard Deviation 0.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C1DD22 | 0.07 units on a scale | Standard Deviation 0.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C2D1 | -0.04 units on a scale | Standard Deviation 0.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C2D22 | -0.01 units on a scale | Standard Deviation 0.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C3D1 | 0.06 units on a scale | Standard Deviation 0.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C3D22 | -0.01 units on a scale | Standard Deviation 0.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C4D1 | 0.03 units on a scale | Standard Deviation 0.54 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C4D22 | 0.03 units on a scale | Standard Deviation 0.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C5D1 | 0.05 units on a scale | Standard Deviation 0.5 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C5D22 | 0.09 units on a scale | Standard Deviation 0.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C6D1 | 0.10 units on a scale | Standard Deviation 0.54 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C6D22 | 0.05 units on a scale | Standard Deviation 0.55 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C7D1 | 0.11 units on a scale | Standard Deviation 0.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C7D22 | 0.04 units on a scale | Standard Deviation 0.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C8D1 | 0.10 units on a scale | Standard Deviation 0.55 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C8D22 | 0.08 units on a scale | Standard Deviation 0.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C9D1 | 0.02 units on a scale | Standard Deviation 0.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C9D22 | 0.04 units on a scale | Standard Deviation 0.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C10D1 | 0.11 units on a scale | Standard Deviation 0.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C10D22 | 0.09 units on a scale | Standard Deviation 0.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C11D1 | 0.11 units on a scale | Standard Deviation 0.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C11D22 | 0.10 units on a scale | Standard Deviation 0.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C12D1 | 0.20 units on a scale | Standard Deviation 0.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C12D22 | 0.15 units on a scale | Standard Deviation 0.37 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C13DD1 | 0.14 units on a scale | Standard Deviation 0.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C13D22 | 0.14 units on a scale | Standard Deviation 0.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C14D1 | 0.10 units on a scale | Standard Deviation 0.31 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C14D22 | 0.16 units on a scale | Standard Deviation 0.37 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C15D1 | 0.19 units on a scale | Standard Deviation 0.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C15D22 | 0.12 units on a scale | Standard Deviation 0.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C16D1 | 0.09 units on a scale | Standard Deviation 0.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C16D22 | 0.07 units on a scale | Standard Deviation 0.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C17D1 | 0.00 units on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C18D1 | 0.06 units on a scale | Standard Deviation 0.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C18D22 | 0.10 units on a scale | Standard Deviation 0.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C19D1 | 0.20 units on a scale | Standard Deviation 0.41 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C19D22 | 0.09 units on a scale | Standard Deviation 0.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C20D1 | 0.13 units on a scale | Standard Deviation 0.35 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C20D22 | 0.00 units on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C21D1 | 0.14 units on a scale | Standard Deviation 0.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C22D1 | 0.00 units on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care C23D1 | 0.08 units on a scale | Standard Deviation 0.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care 30 Day follow up | 0.30 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-care 90 Day follow up | 0.39 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities Baseline | 1.56 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C1D22 | 0.14 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C2D1 | -0.01 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C2D22 | -0.01 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C3D1 | 0.01 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C3D22 | 0.05 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C4D1 | 0.04 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C4D22 | 0.16 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C5D1 | 0.15 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C5D22 | 0.18 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C6D1 | 0.25 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C6D22 | 0.15 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C7D1 | 0.12 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C7D22 | 0.05 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C8D1 | 0.18 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C8D22 | 0.09 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C9D1 | 0.03 units on a scale | Standard Deviation 0.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C9D22 | 0.07 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C10D1 | 0.07 units on a scale | Standard Deviation 0.95 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C10D22 | 0.09 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C11D1 | 0.04 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C11D22 | 0.23 units on a scale | Standard Deviation 0.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C12D1 | 0.12 units on a scale | Standard Deviation 0.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C12D22 | 0.23 units on a scale | Standard Deviation 0.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C13D1 | 0.14 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C13D22 | 0.10 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C14D1 | 0.27 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C14D22 | 0.00 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C15D1 | 0.07 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C15D22 | -0.12 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C16D1 | 0.05 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C16D22 | 0.14 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C17D1 | 0.00 units on a scale | Standard Deviation 0.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C18D1 | 0.00 units on a scale | Standard Deviation 0.37 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C18D22 | 0.10 units on a scale | Standard Deviation 0.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C19D1 | 0.13 units on a scale | Standard Deviation 0.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C19D22 | 0.00 units on a scale | Standard Deviation 0.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C20D1 | 0.07 units on a scale | Standard Deviation 0.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C20D22 | -0.10 units on a scale | Standard Deviation 0.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C21D1 | 0.07 units on a scale | Standard Deviation 0.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C22D1 | 0.08 units on a scale | Standard Deviation 0.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C23D1 | 0.00 units on a scale | Standard Deviation 0.41 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 30 Day follow up | 0.40 units on a scale | Standard Deviation 1.02 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 90 Day follow up | 0.59 units on a scale | Standard Deviation 1.06 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort Baseline | 1.98 units on a scale | Standard Deviation 0.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C1D22 | -0.15 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C2D1 | -0.36 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C2D22 | -0.24 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C3D1 | -0.31 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C3D22 | -0.31 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C4D1 | -0.28 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C4D22 | -0.28 units on a scale | Standard Deviation 0.85 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C5D1 | -0.22 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C5D22 | -0.19 units on a scale | Standard Deviation 0.95 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C6D1 | -0.19 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C6D22 | -0.26 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C7D1 | -0.21 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C7D22 | -0.30 units on a scale | Standard Deviation 0.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C8D1 | -0.18 units on a scale | Standard Deviation 0.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C8D22 | -0.34 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C9D1 | -0.29 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C9D22 | -0.31 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C10D1 | -0.30 units on a scale | Standard Deviation 1.03 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C10D22 | -0.35 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C11D1 | -0.17 units on a scale | Standard Deviation 0.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C11D22 | -0.32 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C12D1 | -0.15 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C12D22 | -0.27 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C13D1 | -0.20 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C13D22 | -0.19 units on a scale | Standard Deviation 1.12 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C14D1 | -0.33 units on a scale | Standard Deviation 0.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C14D22 | -0.47 units on a scale | Standard Deviation 1.02 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C15D1 | -0.07 units on a scale | Standard Deviation 0.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C15D22 | -0.35 units on a scale | Standard Deviation 1.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C16D1 | -0.14 units on a scale | Standard Deviation 1.04 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C16D22 | -0.29 units on a scale | Standard Deviation 0.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C17D1 | -0.33 units on a scale | Standard Deviation 0.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C18D1 | 0.00 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C18D22 | -0.20 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C19D1 | -0.07 units on a scale | Standard Deviation 0.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C19D22 | -0.18 units on a scale | Standard Deviation 0.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C20D1 | 0.00 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C20D22 | 0.10 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C21D1 | -0.14 units on a scale | Standard Deviation 0.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C22D1 | -0.17 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C23D1 | -0.23 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 30 Day follow up | 0.17 units on a scale | Standard Deviation 0.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 90 day follow up | 0.07 units on a scale | Standard Deviation 1.06 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression Baseline | 1.80 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C1D22 | -0.09 units on a scale | Standard Deviation 0.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C2D1 | -0.22 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C2D22 | -0.12 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C3D1 | -0.24 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C3D22 | -0.24 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C4D1 | -0.23 units on a scale | Standard Deviation 0.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C4D22 | -0.17 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C5D1 | -0.16 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C5D22 | -0.05 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C6D1 | -0.18 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C6D22 | -0.14 units on a scale | Standard Deviation 0.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C7D1 | -0.28 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C7D22 | -0.19 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C8D1 | -0.11 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C8D22 | -0.22 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C9D1 | -0.19 units on a scale | Standard Deviation 0.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C9D22 | -0.15 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C10D1 | -0.27 units on a scale | Standard Deviation 0.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C10D22 | -0.19 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C11D1 | -0.15 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C11D22 | -0.03 units on a scale | Standard Deviation 1.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C12D1 | -0.07 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C12D22 | 0.08 units on a scale | Standard Deviation 0.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C13D1 | 0.00 units on a scale | Standard Deviation 1.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C13D22 | 0.19 units on a scale | Standard Deviation 0.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C14D1 | 0.00 units on a scale | Standard Deviation 1.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C14D22 | -0.05 units on a scale | Standard Deviation 1.13 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C15D1 | -0.15 units on a scale | Standard Deviation 0.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C15D22 | -0.12 units on a scale | Standard Deviation 0.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C16D1 | -0.14 units on a scale | Standard Deviation 0.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C16D22 | -0.14 units on a scale | Standard Deviation 0.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C17D1 | -0.33 units on a scale | Standard Deviation 0.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C18D1 | -0.06 units on a scale | Standard Deviation 0.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C18D22 | -0.40 units on a scale | Standard Deviation 0.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C19D1 | -0.13 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C19D22 | -0.18 units on a scale | Standard Deviation 1.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C20D1 | -0.20 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C20D22 | -0.20 units on a scale | Standard Deviation 0.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C21D1 | -0.21 units on a scale | Standard Deviation 0.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C22D1 | -0.33 units on a scale | Standard Deviation 0.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility Baseline | 1.40 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C1D22 | -0.01 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C2D1 | -0.05 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C2D22 | -0.05 units on a scale | Standard Deviation 0.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C3D1 | -0.02 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C3D22 | -0.04 units on a scale | Standard Deviation 0.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C4D1 | 0.01 units on a scale | Standard Deviation 0.76 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C4D22 | 0.13 units on a scale | Standard Deviation 0.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C5D1 | 0.18 units on a scale | Standard Deviation 0.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C5D22 | 0.16 units on a scale | Standard Deviation 0.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C6D1 | 0.20 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C6D22 | 0.23 units on a scale | Standard Deviation 0.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C7D1 | 0.10 units on a scale | Standard Deviation 0.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C7D22 | 0.24 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C8D1 | 0.20 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C8D22 | 0.12 units on a scale | Standard Deviation 0.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C9D1 | 0.10 units on a scale | Standard Deviation 0.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C9D22 | 0.09 units on a scale | Standard Deviation 0.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C10D1 | 0.11 units on a scale | Standard Deviation 0.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C10D22 | 0.09 units on a scale | Standard Deviation 0.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C11D1 | 0.17 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C11D22 | 0.23 units on a scale | Standard Deviation 0.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C12D1 | 0.32 units on a scale | Standard Deviation 0.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C12D22 | 0.31 units on a scale | Standard Deviation 0.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C13D1 | 0.20 units on a scale | Standard Deviation 0.68 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C13D22 | 0.24 units on a scale | Standard Deviation 0.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C14D1 | 0.23 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C14D22 | 0.16 units on a scale | Standard Deviation 0.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C15D1 | 0.15 units on a scale | Standard Deviation 0.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C15D22 | 0.06 units on a scale | Standard Deviation 0.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C16D1 | 0.14 units on a scale | Standard Deviation 0.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C16D22 | 0.29 units on a scale | Standard Deviation 0.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C17D1 | 0.17 units on a scale | Standard Deviation 0.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C18D1 | 0.19 units on a scale | Standard Deviation 0.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C6D22 | 5.21 units on a scale | Standard Deviation 16.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C7D1 | 6.15 units on a scale | Standard Deviation 15.2 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C23D1 | -0.15 units on a scale | Standard Deviation 0.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 30 Day follow up | 0.12 units on a scale | Standard Deviation 0.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 90 Day follow up | 0.00 units on a scale | Standard Deviation 0.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale Baseline | 67.95 units on a scale | Standard Deviation 19.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C1D22 | -0.21 units on a scale | Standard Deviation 15.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C2D1 | 4.10 units on a scale | Standard Deviation 17.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C2D22 | 2.25 units on a scale | Standard Deviation 19.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C3D1 | 5.57 units on a scale | Standard Deviation 18.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C3D22 | 2.73 units on a scale | Standard Deviation 19.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C4D1 | 5.89 units on a scale | Standard Deviation 17.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C4D22 | 3.39 units on a scale | Standard Deviation 17.41 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C5D1 | 5.14 units on a scale | Standard Deviation 17.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C5D22 | 2.29 units on a scale | Standard Deviation 18 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C6D1 | 2.48 units on a scale | Standard Deviation 20.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C7D22 | 5.14 units on a scale | Standard Deviation 14.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C8D1 | 6.60 units on a scale | Standard Deviation 14.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C8D22 | 7.65 units on a scale | Standard Deviation 14.13 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C9D1 | 5.24 units on a scale | Standard Deviation 13.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C9D22 | 6.42 units on a scale | Standard Deviation 15.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C10D1 | 5.86 units on a scale | Standard Deviation 18.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | C10D22 | 6.72 units on a scale | Standard Deviation 15.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C11D1 | 7.33 units on a scale | Standard Deviation 14.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C11D22 | 5.58 units on a scale | Standard Deviation 15.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C12D1 | 3.95 units on a scale | Standard Deviation 17.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C12D22 | 3.69 units on a scale | Standard Deviation 16.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C13D1 | 3.34 units on a scale | Standard Deviation 17.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C13D22 | 1.67 units on a scale | Standard Deviation 17.02 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C14D1 | 5.83 units on a scale | Standard Deviation 13.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C14D22 | 3.53 units on a scale | Standard Deviation 14.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C15D1 | 7.11 units on a scale | Standard Deviation 14.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C15D22 | 2.29 units on a scale | Standard Deviation 17.85 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C16D1 | 3.86 units on a scale | Standard Deviation 15.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C16D22 | 0.36 units on a scale | Standard Deviation 12.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C17D1 | 1.72 units on a scale | Standard Deviation 14.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C18D1 | 2.69 units on a scale | Standard Deviation 12.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C18D22 | 2.90 units on a scale | Standard Deviation 12.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C19D1 | 3.33 units on a scale | Standard Deviation 14.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C19D22 | 3.73 units on a scale | Standard Deviation 10.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C20D1 | 3.67 units on a scale | Standard Deviation 13.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C20D22 | 7.00 units on a scale | Standard Deviation 14.24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C21D1 | 4.00 units on a scale | Standard Deviation 15.06 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C22D1 | 4.25 units on a scale | Standard Deviation 16.19 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C23D1 | 5.31 units on a scale | Standard Deviation 17.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 30 Day follow up | -2.07 units on a scale | Standard Deviation 17.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C18D22 | 0.20 units on a scale | Standard Deviation 0.42 |
Secondary
Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire
The EORTC-QLQ-OG25 consists of a 25-item instrument that evaluates gastric and GEJ cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. This module consists of 6 scales: dysphagia (3 items), eating restrictions (4 items), reflux (2 items), odynophagia (2 items), pain and discomfort (2 items) and anxiety (2 items), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. All questions have four response alternatives (1:not at all; 2:a little, 3:quite a bit, 4:very much). Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 For symptom scales/items, higher scores indicate worse symptoms.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C13D22 | -4.17 unit on a scale | Standard Deviation 19.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C6D22 | -0.65 unit on a scale | Standard Deviation 19.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C5D1 | -4.95 unit on a scale | Standard Deviation 22.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C7D1 | 0.29 unit on a scale | Standard Deviation 20.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C14D1 | -2.56 unit on a scale | Standard Deviation 23.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C7D22 | -1.65 unit on a scale | Standard Deviation 18.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C5D22 | -2.88 unit on a scale | Standard Deviation 21.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C8D1 | 0.83 unit on a scale | Standard Deviation 21.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C17D1 | -2.22 unit on a scale | Standard Deviation 15.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C8D22 | 2.35 unit on a scale | Standard Deviation 18.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C6D1 | -5.87 unit on a scale | Standard Deviation 23.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C9D1 | -2.22 unit on a scale | Standard Deviation 17.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C14D22 | -5.73 unit on a scale | Standard Deviation 15.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C9D22 | 2.22 unit on a scale | Standard Deviation 22.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C6D22 | -4.53 unit on a scale | Standard Deviation 20.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C10D1 | -1.01 unit on a scale | Standard Deviation 18.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C24D1 | -3.17 unit on a scale | Standard Deviation 19.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C10D22 | 0.58 unit on a scale | Standard Deviation 17.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C7D1 | -4.13 unit on a scale | Standard Deviation 19.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C11D1 | 0.00 unit on a scale | Standard Deviation 17.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C17D22 | -4.35 unit on a scale | Standard Deviation 18.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C11D22 | -1.52 unit on a scale | Standard Deviation 16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C7D22 | -5.14 unit on a scale | Standard Deviation 21.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C12D1 | -0.63 unit on a scale | Standard Deviation 16.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C15D1 | -1.43 unit on a scale | Standard Deviation 15.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C12D22 | 0.90 unit on a scale | Standard Deviation 12.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C8D1 | -5.63 unit on a scale | Standard Deviation 21.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C13D1 | 2.08 unit on a scale | Standard Deviation 17.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C14D1 | -6.84 unit on a scale | Standard Deviation 22.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C13D22 | 4.17 unit on a scale | Standard Deviation 15.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C8D22 | -6.34 unit on a scale | Standard Deviation 22.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C14D1 | 2.56 unit on a scale | Standard Deviation 16.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C18D1 | -5.76 unit on a scale | Standard Deviation 15.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C14D22 | -3.12 unit on a scale | Standard Deviation 13.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C9D1 | -6.00 unit on a scale | Standard Deviation 23.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C15D1 | 2.86 unit on a scale | Standard Deviation 23.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C14D22 | -7.29 unit on a scale | Standard Deviation 21.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C15D22 | 0.00 unit on a scale | Standard Deviation 15.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C9D22 | -2.22 unit on a scale | Standard Deviation 18.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C16D1 | 1.90 unit on a scale | Standard Deviation 16.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C6D1 | -5.37 unit on a scale | Standard Deviation 20.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C16D22 | 4.60 unit on a scale | Standard Deviation 19.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C10D1 | -4.80 unit on a scale | Standard Deviation 23.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C17D1 | 3.33 unit on a scale | Standard Deviation 16.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C15D1 | -1.90 unit on a scale | Standard Deviation 20.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C17D22 | -1.45 unit on a scale | Standard Deviation 15.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C18D1 | 0.00 unit on a scale | Standard Deviation 16.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C10D22 | -6.43 unit on a scale | Standard Deviation 20.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C18D22 | 1.67 unit on a scale | Standard Deviation 13.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C18D22 | -6.11 unit on a scale | Standard Deviation 14.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C19D1 | -1.45 unit on a scale | Standard Deviation 12.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C11D1 | -7.41 unit on a scale | Standard Deviation 21.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C19D22 | 3.33 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C15D22 | -1.72 unit on a scale | Standard Deviation 16.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C20D1 | 0.00 unit on a scale | Standard Deviation 14.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C11D22 | -6.82 unit on a scale | Standard Deviation 17.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C20D22 | 1.85 unit on a scale | Standard Deviation 13.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C1D22 | 4.40 unit on a scale | Standard Deviation 22.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C21D1 | -3.33 unit on a scale | Standard Deviation 10.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C12D1 | -4.40 unit on a scale | Standard Deviation 19.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C21D22 | 2.38 unit on a scale | Standard Deviation 8.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C22D1 | -4.44 unit on a scale | Standard Deviation 11.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C16D1 | -3.81 unit on a scale | Standard Deviation 13.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C22D22 | 0.00 unit on a scale | Standard Deviation 15.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C23D1 | -2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C12D22 | -5.86 unit on a scale | Standard Deviation 21.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C23D22 | -6.06 unit on a scale | Standard Deviation 13.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C24D1 | -4.76 unit on a scale | Standard Deviation 12.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C25D1 | -8.33 unit on a scale | Standard Deviation 15.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C25D22 | -3.03 unit on a scale | Standard Deviation 10.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C26D1 | -7.69 unit on a scale | Standard Deviation 14.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C27D1 | -6.06 unit on a scale | Standard Deviation 13.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C28D1 | -8.33 unit on a scale | Standard Deviation 15.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing 30 day follow up | -0.93 unit on a scale | Standard Deviation 27.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C19D1 | -3.38 unit on a scale | Standard Deviation 14.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing 90 Day follow up | 2.33 unit on a scale | Standard Deviation 22.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C13D1 | -4.17 unit on a scale | Standard Deviation 20.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking Baseline | 5.45 unit on a scale | Standard Deviation 14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C15D22 | -5.17 unit on a scale | Standard Deviation 18.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C1D22 | 3.03 unit on a scale | Standard Deviation 19.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C13D22 | -2.08 unit on a scale | Standard Deviation 18.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C2D1 | 0.81 unit on a scale | Standard Deviation 16.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C6D22 | -5.07 unit on a scale | Standard Deviation 20.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C2D22 | 0.89 unit on a scale | Standard Deviation 16.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C14D1 | -1.71 unit on a scale | Standard Deviation 21.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C3D1 | -0.18 unit on a scale | Standard Deviation 15.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C19D22 | -3.89 unit on a scale | Standard Deviation 10.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C3D22 | 0.66 unit on a scale | Standard Deviation 16.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C14D22 | -5.73 unit on a scale | Standard Deviation 21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C4D1 | 0.59 unit on a scale | Standard Deviation 16.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C16D22 | -4.02 unit on a scale | Standard Deviation 15.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C4D22 | 2.19 unit on a scale | Standard Deviation 19.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C15D1 | -0.95 unit on a scale | Standard Deviation 14.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C5D1 | -0.68 unit on a scale | Standard Deviation 15.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C25D1 | -4.63 unit on a scale | Standard Deviation 10 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C5D22 | 1.21 unit on a scale | Standard Deviation 16.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C15D22 | -4.60 unit on a scale | Standard Deviation 19.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C6D1 | -0.27 unit on a scale | Standard Deviation 15.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C17D1 | -4.44 unit on a scale | Standard Deviation 16.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C6D22 | -1.62 unit on a scale | Standard Deviation 16.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C16D1 | -3.33 unit on a scale | Standard Deviation 17.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C7D1 | -1.47 unit on a scale | Standard Deviation 17.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C16D1 | -6.19 unit on a scale | Standard Deviation 18.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C7D22 | -1.65 unit on a scale | Standard Deviation 15.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C16D22 | -8.62 unit on a scale | Standard Deviation 21.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C8D1 | 1.25 unit on a scale | Standard Deviation 20.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C20D1 | -4.35 unit on a scale | Standard Deviation 11.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C8D22 | -1.41 unit on a scale | Standard Deviation 15.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C17D1 | -1.11 unit on a scale | Standard Deviation 21.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C9D1 | -2.67 unit on a scale | Standard Deviation 11.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C17D22 | 1.45 unit on a scale | Standard Deviation 25.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C9D22 | -0.56 unit on a scale | Standard Deviation 15.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C17D22 | -1.45 unit on a scale | Standard Deviation 21.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C10D1 | -1.01 unit on a scale | Standard Deviation 13.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C18D1 | -4.32 unit on a scale | Standard Deviation 20.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C10D22 | 0.58 unit on a scale | Standard Deviation 13.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C18D1 | -5.56 unit on a scale | Standard Deviation 16.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C11D1 | 0.53 unit on a scale | Standard Deviation 14.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C18D22 | 0.83 unit on a scale | Standard Deviation 22.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C11D22 | -3.03 unit on a scale | Standard Deviation 14.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C7D1 | -6.88 unit on a scale | Standard Deviation 19.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C12D1 | -0.63 unit on a scale | Standard Deviation 13.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C19D1 | -0.72 unit on a scale | Standard Deviation 15.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C12D22 | -2.70 unit on a scale | Standard Deviation 12.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C20D22 | -6.17 unit on a scale | Standard Deviation 14.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C13D1 | -0.69 unit on a scale | Standard Deviation 14.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C19D22 | -1.67 unit on a scale | Standard Deviation 14.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C13D22 | -0.83 unit on a scale | Standard Deviation 14.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C18D22 | -2.50 unit on a scale | Standard Deviation 13.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C14D1 | -0.85 unit on a scale | Standard Deviation 14.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C20D1 | 0.00 unit on a scale | Standard Deviation 15.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C14D22 | -2.08 unit on a scale | Standard Deviation 11.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C25D22 | 0.00 unit on a scale | Standard Deviation 12.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C20D22 | -2.78 unit on a scale | Standard Deviation 15.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C19D22 | -3.33 unit on a scale | Standard Deviation 18.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C19D1 | -5.80 unit on a scale | Standard Deviation 13.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C20D1 | -5.80 unit on a scale | Standard Deviation 25.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C21D1 | 0.00 unit on a scale | Standard Deviation 9.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C20D22 | -5.56 unit on a scale | Standard Deviation 23.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C21D1 | -3.89 unit on a scale | Standard Deviation 10.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C21D1 | -10.00 unit on a scale | Standard Deviation 24.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C21D22 | 0.00 unit on a scale | Standard Deviation 11.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C15D1 | 0.00 unit on a scale | Standard Deviation 14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C22D1 | 0.00 unit on a scale | Standard Deviation 19.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C15D22 | 0.00 unit on a scale | Standard Deviation 12.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C19D22 | -5.00 unit on a scale | Standard Deviation 13.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C16D1 | -1.90 unit on a scale | Standard Deviation 13.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C22D22 | -6.67 unit on a scale | Standard Deviation 19.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C16D22 | -3.45 unit on a scale | Standard Deviation 13.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C23D1 | -5.56 unit on a scale | Standard Deviation 15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C21D22 | -4.76 unit on a scale | Standard Deviation 22.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C7D22 | -6.04 unit on a scale | Standard Deviation 20.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C22D1 | -11.11 unit on a scale | Standard Deviation 24.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C23D22 | -6.06 unit on a scale | Standard Deviation 18.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C22D22 | -10.00 unit on a scale | Standard Deviation 22.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C23D1 | -13.33 unit on a scale | Standard Deviation 27.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C24D1 | -4.76 unit on a scale | Standard Deviation 16.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C23D22 | -12.12 unit on a scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C24D1 | -14.29 unit on a scale | Standard Deviation 25.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C25D1 | -11.11 unit on a scale | Standard Deviation 21.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C25D22 | -12.12 unit on a scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C26D1 | -17.95 unit on a scale | Standard Deviation 25.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C1D22 | 10.80 unit on a scale | Standard Deviation 29.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C27D1 | -21.21 unit on a scale | Standard Deviation 26.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C28D1 | -19.44 unit on a scale | Standard Deviation 26.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth 30 day follow up | 5.09 unit on a scale | Standard Deviation 28.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C25D1 | -5.56 unit on a scale | Standard Deviation 19.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth 90 Day follow up | 1.94 unit on a scale | Standard Deviation 30.83 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C25D22 | -4.55 unit on a scale | Standard Deviation 15.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste Baseline | 12.06 unit on a scale | Standard Deviation 23.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C26D1 | -1.28 unit on a scale | Standard Deviation 17.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C27D1 | 0.00 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C2D1 | 12.62 unit on a scale | Standard Deviation 29.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C28D1 | 0.00 unit on a scale | Standard Deviation 12.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C17D1 | 1.11 unit on a scale | Standard Deviation 13.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux 30 day follow up | -1.85 unit on a scale | Standard Deviation 26.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C17D22 | -4.35 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C18D1 | -2.47 unit on a scale | Standard Deviation 8.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C16D22 | -2.30 unit on a scale | Standard Deviation 26.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C18D22 | 0.00 unit on a scale | Standard Deviation 10.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux 90 day follow up | -0.78 unit on a scale | Standard Deviation 24.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C19D1 | -1.45 unit on a scale | Standard Deviation 6.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C21D22 | -4.76 unit on a scale | Standard Deviation 18.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C19D22 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia Baseline | 22.18 unit on a scale | Standard Deviation 25.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C20D1 | 4.35 unit on a scale | Standard Deviation 23.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C17D1 | -5.56 unit on a scale | Standard Deviation 16.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C2D22 | 15.78 unit on a scale | Standard Deviation 33.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C1D22 | -2.37 unit on a scale | Standard Deviation 24.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C3D1 | 14.56 unit on a scale | Standard Deviation 34.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C22D1 | -3.70 unit on a scale | Standard Deviation 12.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C3D22 | 21.93 unit on a scale | Standard Deviation 31.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C2D1 | -4.77 unit on a scale | Standard Deviation 24.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C4D1 | 17.75 unit on a scale | Standard Deviation 35.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C17D22 | -2.17 unit on a scale | Standard Deviation 17.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C4D22 | 20.49 unit on a scale | Standard Deviation 32.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C2D22 | -6.22 unit on a scale | Standard Deviation 24.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C5D1 | 19.59 unit on a scale | Standard Deviation 31.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C20D1 | -0.72 unit on a scale | Standard Deviation 25.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C5D22 | 20.00 unit on a scale | Standard Deviation 28.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C3D1 | -9.39 unit on a scale | Standard Deviation 24.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C6D1 | 12.02 unit on a scale | Standard Deviation 27.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C18D1 | -6.17 unit on a scale | Standard Deviation 17.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C6D22 | 9.71 unit on a scale | Standard Deviation 29.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C3D22 | -6.36 unit on a scale | Standard Deviation 22.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C7D1 | 8.55 unit on a scale | Standard Deviation 24.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia Baseline | 18.50 unit on a scale | Standard Deviation 24.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C7D22 | 10.70 unit on a scale | Standard Deviation 26.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C4D1 | -9.66 unit on a scale | Standard Deviation 24.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C8D1 | 6.25 unit on a scale | Standard Deviation 22.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C18D22 | -5.00 unit on a scale | Standard Deviation 15.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C8D22 | 3.76 unit on a scale | Standard Deviation 22.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C4D22 | -3.69 unit on a scale | Standard Deviation 25.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C9D1 | 3.56 unit on a scale | Standard Deviation 20.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C22D22 | -2.22 unit on a scale | Standard Deviation 26.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C9D22 | 12.78 unit on a scale | Standard Deviation 28.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C5D1 | -4.73 unit on a scale | Standard Deviation 23.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C10D1 | 7.07 unit on a scale | Standard Deviation 23.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C19D1 | -5.80 unit on a scale | Standard Deviation 13.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C10D22 | 7.02 unit on a scale | Standard Deviation 22.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C5D22 | -4.85 unit on a scale | Standard Deviation 26.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C11D1 | 6.35 unit on a scale | Standard Deviation 26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C23D1 | -4.44 unit on a scale | Standard Deviation 18.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C11D22 | 4.55 unit on a scale | Standard Deviation 18.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C6D1 | -7.92 unit on a scale | Standard Deviation 20.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C12D1 | 6.29 unit on a scale | Standard Deviation 26.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C2D1 | -3.32 unit on a scale | Standard Deviation 27.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C12D22 | 11.71 unit on a scale | Standard Deviation 25.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C6D22 | -8.41 unit on a scale | Standard Deviation 22.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C13D1 | 7.64 unit on a scale | Standard Deviation 20.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C20D22 | -6.48 unit on a scale | Standard Deviation 14.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C13D22 | 10.00 unit on a scale | Standard Deviation 27.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C7D1 | -9.44 unit on a scale | Standard Deviation 21.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C14D1 | 4.27 unit on a scale | Standard Deviation 24.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C19D22 | -3.33 unit on a scale | Standard Deviation 15.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C14D22 | 9.37 unit on a scale | Standard Deviation 22.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C7D22 | -8.23 unit on a scale | Standard Deviation 22.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C15D1 | 3.81 unit on a scale | Standard Deviation 26.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C8D1 | -3.89 unit on a scale | Standard Deviation 18.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C15D22 | 11.49 unit on a scale | Standard Deviation 28.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C8D1 | -5.21 unit on a scale | Standard Deviation 20.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C16D1 | 7.62 unit on a scale | Standard Deviation 21.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C21D1 | -3.33 unit on a scale | Standard Deviation 8.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C16D22 | 6.90 unit on a scale | Standard Deviation 24.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C2D22 | -11.67 unit on a scale | Standard Deviation 24.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C17D1 | 4.44 unit on a scale | Standard Deviation 24.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C3D22 | -9.65 unit on a scale | Standard Deviation 26.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C17D22 | 11.59 unit on a scale | Standard Deviation 29.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C18D1 | 1.23 unit on a scale | Standard Deviation 19.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C2D22 | -5.00 unit on a scale | Standard Deviation 26.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C18D22 | 3.33 unit on a scale | Standard Deviation 18.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C3D1 | -12.63 unit on a scale | Standard Deviation 26.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C19D1 | 2.90 unit on a scale | Standard Deviation 17.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C21D22 | -1.19 unit on a scale | Standard Deviation 10.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C19D22 | 5.00 unit on a scale | Standard Deviation 22.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C26D1 | -1.71 unit on a scale | Standard Deviation 14.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C20D1 | 1.45 unit on a scale | Standard Deviation 15.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C22D1 | -2.22 unit on a scale | Standard Deviation 10.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C20D22 | 3.70 unit on a scale | Standard Deviation 15.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C4D1 | -14.60 unit on a scale | Standard Deviation 24.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C21D1 | 6.67 unit on a scale | Standard Deviation 17.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C3D1 | -8.77 unit on a scale | Standard Deviation 27.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with Taste C21D22 | -2.38 unit on a scale | Standard Deviation 20.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C22D1 | 2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C4D22 | -11.34 unit on a scale | Standard Deviation 26.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C22D22 | 0.00 unit on a scale | Standard Deviation 15.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C23D1 | 2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C22D22 | 0.00 unit on a scale | Standard Deviation 13.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C23D22 | 6.06 unit on a scale | Standard Deviation 13.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C24D1 | 2.38 unit on a scale | Standard Deviation 15.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C25D1 | 0.00 unit on a scale | Standard Deviation 20.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C25D22 | 3.03 unit on a scale | Standard Deviation 17.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C26D1 | 2.56 unit on a scale | Standard Deviation 16.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C27D1 | 0.00 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C28D1 | 2.78 unit on a scale | Standard Deviation 22.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste 30 day follow up | 12.96 unit on a scale | Standard Deviation 27.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C5D1 | -12.16 unit on a scale | Standard Deviation 28.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste 90 day follow up | 14.73 unit on a scale | Standard Deviation 28.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C23D1 | -4.44 unit on a scale | Standard Deviation 9.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image Baseline | 22.57 unit on a scale | Standard Deviation 29.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C5D22 | -10.30 unit on a scale | Standard Deviation 29.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C1D22 | 3.60 unit on a scale | Standard Deviation 25.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C8D22 | -5.63 unit on a scale | Standard Deviation 17.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C2D1 | 3.56 unit on a scale | Standard Deviation 26.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C6D1 | -13.39 unit on a scale | Standard Deviation 31.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C2D22 | 5.11 unit on a scale | Standard Deviation 26.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C23D22 | 0.00 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C3D1 | 4.21 unit on a scale | Standard Deviation 25.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C6D22 | -11.65 unit on a scale | Standard Deviation 26.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C3D22 | 7.46 unit on a scale | Standard Deviation 25.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C24D1 | 1.19 unit on a scale | Standard Deviation 21.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C4D1 | 1.58 unit on a scale | Standard Deviation 24.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C7D1 | -12.68 unit on a scale | Standard Deviation 28.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C4D22 | 9.29 unit on a scale | Standard Deviation 27.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C20D1 | -2.17 unit on a scale | Standard Deviation 21.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C5D1 | 5.63 unit on a scale | Standard Deviation 28.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C7D22 | -13.79 unit on a scale | Standard Deviation 27.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C5D22 | 5.76 unit on a scale | Standard Deviation 30.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C3D22 | -0.38 unit on a scale | Standard Deviation 27.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C6D1 | 4.64 unit on a scale | Standard Deviation 31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C8D1 | -11.46 unit on a scale | Standard Deviation 28.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C6D22 | 1.62 unit on a scale | Standard Deviation 27.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C20D22 | -4.63 unit on a scale | Standard Deviation 17.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C7D1 | -0.29 unit on a scale | Standard Deviation 29.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C8D22 | -13.62 unit on a scale | Standard Deviation 26.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C7D22 | 3.70 unit on a scale | Standard Deviation 30.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C1D22 | 2.90 unit on a scale | Standard Deviation 21.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C8D1 | -1.25 unit on a scale | Standard Deviation 28.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C9D1 | -18.22 unit on a scale | Standard Deviation 25.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C8D22 | -0.47 unit on a scale | Standard Deviation 31.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C21D1 | -0.83 unit on a scale | Standard Deviation 15.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C9D1 | -4.44 unit on a scale | Standard Deviation 30.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C9D22 | -16.94 unit on a scale | Standard Deviation 25.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C9D22 | -1.11 unit on a scale | Standard Deviation 32.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C4D1 | -6.41 unit on a scale | Standard Deviation 29.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C10D1 | -1.01 unit on a scale | Standard Deviation 32.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C10D1 | -16.67 unit on a scale | Standard Deviation 25.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C10D22 | -0.58 unit on a scale | Standard Deviation 31.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C21D22 | -3.57 unit on a scale | Standard Deviation 12.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C11D1 | -2.65 unit on a scale | Standard Deviation 31.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C10D22 | -18.71 unit on a scale | Standard Deviation 27.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C11D22 | -7.58 unit on a scale | Standard Deviation 27.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C22D1 | -5.00 unit on a scale | Standard Deviation 12.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C12D1 | -0.63 unit on a scale | Standard Deviation 28.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C11D1 | -18.25 unit on a scale | Standard Deviation 30.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C12D22 | 0.00 unit on a scale | Standard Deviation 33.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C25D1 | -1.39 unit on a scale | Standard Deviation 4.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C13D1 | -2.08 unit on a scale | Standard Deviation 31.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C11D22 | -20.83 unit on a scale | Standard Deviation 27.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C13D22 | -5.00 unit on a scale | Standard Deviation 28.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C25D22 | 4.55 unit on a scale | Standard Deviation 7.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C14D1 | -4.27 unit on a scale | Standard Deviation 30.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C12D1 | -17.30 unit on a scale | Standard Deviation 30.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C14D22 | -1.04 unit on a scale | Standard Deviation 31.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C26D1 | -1.28 unit on a scale | Standard Deviation 10.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C15D1 | -3.81 unit on a scale | Standard Deviation 27.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C12D22 | -13.06 unit on a scale | Standard Deviation 28.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C15D22 | 29.08 unit on a scale | Standard Deviation 8.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C9D1 | -6.67 unit on a scale | Standard Deviation 17.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C16D1 | -5.71 unit on a scale | Standard Deviation 28.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C13D1 | -15.63 unit on a scale | Standard Deviation 29.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C16D22 | -8.05 unit on a scale | Standard Deviation 26.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C27D1 | -4.55 unit on a scale | Standard Deviation 10.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C17D1 | 0.00 unit on a scale | Standard Deviation 36.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C13D22 | -9.58 unit on a scale | Standard Deviation 25.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C17D22 | -2.90 unit on a scale | Standard Deviation 30.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C18D1 | -7.41 unit on a scale | Standard Deviation 21.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C28D1 | 1.39 unit on a scale | Standard Deviation 4.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C18D22 | -5.00 unit on a scale | Standard Deviation 27.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C14D1 | -13.68 unit on a scale | Standard Deviation 25.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C19D1 | -1.45 unit on a scale | Standard Deviation 25.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia 30 day follow up | -3.01 unit on a scale | Standard Deviation 25.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C19D22 | -5.00 unit on a scale | Standard Deviation 24.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C14D22 | -18.75 unit on a scale | Standard Deviation 28.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C20D1 | -2.90 unit on a scale | Standard Deviation 28.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C4D22 | -1.09 unit on a scale | Standard Deviation 28.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C20D22 | -3.70 unit on a scale | Standard Deviation 27.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C15D1 | -13.33 unit on a scale | Standard Deviation 27.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C21D1 | -6.67 unit on a scale | Standard Deviation 17.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C22D22 | -2.50 unit on a scale | Standard Deviation 18.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C21D22 | -4.76 unit on a scale | Standard Deviation 22.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble Talking C20D22 | -1.85 unit on a scale | Standard Deviation 7.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C15D22 | -14.37 unit on a scale | Standard Deviation 27.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C21D1 | -1.67 unit on a scale | Standard Deviation 7.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C23D1 | -6.11 unit on a scale | Standard Deviation 11.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C21D22 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C22D1 | -2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C16D1 | -17.14 unit on a scale | Standard Deviation 31.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C22D22 | -3.33 unit on a scale | Standard Deviation 10.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C2D1 | -3.83 unit on a scale | Standard Deviation 23.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C23D1 | 0.00 unit on a scale | Standard Deviation 12.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C23D22 | -3.03 unit on a scale | Standard Deviation 10.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C24D1 | -4.76 unit on a scale | Standard Deviation 12.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C22D1 | 0.00 unit on a scale | Standard Deviation 28.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C16D22 | -14.94 unit on a scale | Standard Deviation 26.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C22D22 | -6.67 unit on a scale | Standard Deviation 30.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C23D1 | -6.67 unit on a scale | Standard Deviation 22.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C23D22 | -4.55 unit on a scale | Standard Deviation 14.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C23D22 | -6.06 unit on a scale | Standard Deviation 20.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C24D1 | -4.76 unit on a scale | Standard Deviation 22.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C25D1 | -8.33 unit on a scale | Standard Deviation 28.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C25D22 | -9.09 unit on a scale | Standard Deviation 30.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C26D1 | -5.13 unit on a scale | Standard Deviation 26.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C27D1 | -12.12 unit on a scale | Standard Deviation 16.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C28D1 | -11.11 unit on a scale | Standard Deviation 16.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image 30 day follow up | 9.72 unit on a scale | Standard Deviation 28.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C17D1 | -12.78 unit on a scale | Standard Deviation 33.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image 90 Day follow up | 6.98 unit on a scale | Standard Deviation 32.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia 90 day follow up | -5.62 unit on a scale | Standard Deviation 27.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva Baseline | 7.65 unit on a scale | Standard Deviation 17.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C17D22 | -11.59 unit on a scale | Standard Deviation 22.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C1D22 | 0.95 unit on a scale | Standard Deviation 21.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C18D1 | -14.81 unit on a scale | Standard Deviation 27.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C2D1 | 1.46 unit on a scale | Standard Deviation 21.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C5D1 | -4.84 unit on a scale | Standard Deviation 27.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C2D22 | 1.56 unit on a scale | Standard Deviation 19.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C18D22 | -15.83 unit on a scale | Standard Deviation 24.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C3D1 | -0.18 unit on a scale | Standard Deviation 20.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort Baseline | 27.04 unit on a scale | Standard Deviation 26.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C3D22 | 3.73 unit on a scale | Standard Deviation 25.02 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C19D1 | -19.57 unit on a scale | Standard Deviation 30.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C4D1 | -0.59 unit on a scale | Standard Deviation 21.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C9D22 | -5.93 unit on a scale | Standard Deviation 18.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C4D22 | 1.64 unit on a scale | Standard Deviation 23.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C19D22 | -10.00 unit on a scale | Standard Deviation 30.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C5D1 | 3.60 unit on a scale | Standard Deviation 24.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C1D22 | -4.55 unit on a scale | Standard Deviation 21.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C5D22 | 2.12 unit on a scale | Standard Deviation 21.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C20D1 | -21.01 unit on a scale | Standard Deviation 28.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C6D1 | -0.82 unit on a scale | Standard Deviation 18.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C5D22 | -3.86 unit on a scale | Standard Deviation 29.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C6D22 | -1.29 unit on a scale | Standard Deviation 18.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C20D22 | -16.67 unit on a scale | Standard Deviation 25.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C7D1 | -1.77 unit on a scale | Standard Deviation 19.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C24D1 | 0.00 unit on a scale | Standard Deviation 19.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C7D22 | -0.41 unit on a scale | Standard Deviation 20.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C21D1 | -19.17 unit on a scale | Standard Deviation 29.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C8D1 | 0.00 unit on a scale | Standard Deviation 19.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C25D1 | -4.86 unit on a scale | Standard Deviation 13.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C8D22 | -0.47 unit on a scale | Standard Deviation 17.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C21D22 | -14.29 unit on a scale | Standard Deviation 21.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C9D1 | -0.44 unit on a scale | Standard Deviation 17.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C22D1 | -18.89 unit on a scale | Standard Deviation 33.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C9D22 | 0.56 unit on a scale | Standard Deviation 19.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C25D22 | -0.76 unit on a scale | Standard Deviation 13.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C10D1 | -1.52 unit on a scale | Standard Deviation 21.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C22D22 | -3.33 unit on a scale | Standard Deviation 42.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C10D22 | -1.17 unit on a scale | Standard Deviation 20.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C23D1 | -22.22 unit on a scale | Standard Deviation 38.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C11D1 | 0.00 unit on a scale | Standard Deviation 19.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C2D1 | -4.94 unit on a scale | Standard Deviation 26.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C11D22 | -4.55 unit on a scale | Standard Deviation 21.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C23D22 | -16.67 unit on a scale | Standard Deviation 29.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C12D1 | 0.00 unit on a scale | Standard Deviation 14.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C24D1 | -20.24 unit on a scale | Standard Deviation 35.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C12D22 | -3.60 unit on a scale | Standard Deviation 21.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C25D1 | -19.44 unit on a scale | Standard Deviation 38.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C13D1 | -1.39 unit on a scale | Standard Deviation 22.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C25D22 | -12.12 unit on a scale | Standard Deviation 38.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C13D22 | 0.00 unit on a scale | Standard Deviation 23.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C26D1 | -21.79 unit on a scale | Standard Deviation 36.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C14D1 | 1.71 unit on a scale | Standard Deviation 17.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C27D1 | -30.30 unit on a scale | Standard Deviation 30.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C14D22 | -2.08 unit on a scale | Standard Deviation 14.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C28D1 | -20.83 unit on a scale | Standard Deviation 33.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C15D1 | -0.95 unit on a scale | Standard Deviation 15.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety 30 day follow up | -3.47 unit on a scale | Standard Deviation 30.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C15D22 | -2.30 unit on a scale | Standard Deviation 12.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C27D1 | 1.01 unit on a scale | Standard Deviation 12.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C16D1 | 0.95 unit on a scale | Standard Deviation 15.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety 90 day follow up | -2.52 unit on a scale | Standard Deviation 31.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C16D22 | -1.15 unit on a scale | Standard Deviation 14.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C2D22 | -8.00 unit on a scale | Standard Deviation 25.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C17D1 | 1.11 unit on a scale | Standard Deviation 16.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others Baseline | 14.66 unit on a scale | Standard Deviation 25.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C17D22 | 0.00 unit on a scale | Standard Deviation 17.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C18D1 | -1.23 unit on a scale | Standard Deviation 17.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C26D1 | -4.49 unit on a scale | Standard Deviation 11.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C18D22 | -1.67 unit on a scale | Standard Deviation 13.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C1D22 | -1.14 unit on a scale | Standard Deviation 25.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C19D1 | -1.45 unit on a scale | Standard Deviation 12.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C6D1 | -7.79 unit on a scale | Standard Deviation 26.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C19D22 | 0.00 unit on a scale | Standard Deviation 10.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C2D1 | -1.46 unit on a scale | Standard Deviation 25.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C20D1 | 0.00 unit on a scale | Standard Deviation 10.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C3D1 | -9.56 unit on a scale | Standard Deviation 24.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C20D22 | 0.00 unit on a scale | Standard Deviation 11.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C2D22 | -2.00 unit on a scale | Standard Deviation 28.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C21D1 | 1.67 unit on a scale | Standard Deviation 13.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C10D1 | -5.56 unit on a scale | Standard Deviation 18.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C21D22 | 0.00 unit on a scale | Standard Deviation 13.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C22D1 | -4.44 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C3D1 | -5.79 unit on a scale | Standard Deviation 25.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C22D22 | -6.67 unit on a scale | Standard Deviation 21.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C23D1 | -4.44 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C27D1 | -6.06 unit on a scale | Standard Deviation 10.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C23D22 | -9.09 unit on a scale | Standard Deviation 15.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C24D1 | -2.38 unit on a scale | Standard Deviation 15.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C25D1 | -8.33 unit on a scale | Standard Deviation 15.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C25D22 | -3.03 unit on a scale | Standard Deviation 17.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C26D1 | -2.56 unit on a scale | Standard Deviation 21.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C27D1 | -3.03 unit on a scale | Standard Deviation 17.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C28D1 | -2.78 unit on a scale | Standard Deviation 17.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva 30 Day follow up | 6.94 unit on a scale | Standard Deviation 24.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C3D22 | -2.19 unit on a scale | Standard Deviation 26.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva 90 Day follow up | 2.33 unit on a scale | Standard Deviation 24.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C3D22 | -6.14 unit on a scale | Standard Deviation 23.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing Baseline | 7.00 unit on a scale | Standard Deviation 18.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C4D1 | -4.93 unit on a scale | Standard Deviation 27.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C1D22 | 1.52 unit on a scale | Standard Deviation 17.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C6D22 | -8.25 unit on a scale | Standard Deviation 27.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C2D1 | -0.49 unit on a scale | Standard Deviation 17.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C4D22 | -0.82 unit on a scale | Standard Deviation 25.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C2D22 | -2.67 unit on a scale | Standard Deviation 19.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C4D1 | -9.76 unit on a scale | Standard Deviation 24.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C3D1 | -1.23 unit on a scale | Standard Deviation 18.9 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C5D1 | -3.83 unit on a scale | Standard Deviation 25.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C3D22 | 2.19 unit on a scale | Standard Deviation 19.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C2D22 | -4.00 unit on a scale | Standard Deviation 22.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C4D1 | -0.99 unit on a scale | Standard Deviation 17.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C5D22 | -2.42 unit on a scale | Standard Deviation 26.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C4D22 | 1.09 unit on a scale | Standard Deviation 18.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C4D22 | -6.56 unit on a scale | Standard Deviation 21.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C5D1 | 0.45 unit on a scale | Standard Deviation 18.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C6D1 | -5.74 unit on a scale | Standard Deviation 22.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C5D22 | 0.91 unit on a scale | Standard Deviation 18.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C7D1 | -9.14 unit on a scale | Standard Deviation 26.63 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C6D1 | -1.37 unit on a scale | Standard Deviation 17.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C6D22 | -2.27 unit on a scale | Standard Deviation 21.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C6D22 | -1.62 unit on a scale | Standard Deviation 16.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C5D1 | -5.29 unit on a scale | Standard Deviation 22.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C7D1 | -2.95 unit on a scale | Standard Deviation 17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C7D1 | -2.36 unit on a scale | Standard Deviation 26.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C7D22 | 0.41 unit on a scale | Standard Deviation 17.07 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C10D22 | -8.38 unit on a scale | Standard Deviation 17.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C8D1 | -0.83 unit on a scale | Standard Deviation 18.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C25D1 | -5.56 unit on a scale | Standard Deviation 12.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C25D22 | 3.03 unit on a scale | Standard Deviation 23.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C26D1 | -2.56 unit on a scale | Standard Deviation 9.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C27D1 | -3.03 unit on a scale | Standard Deviation 10.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C28D1 | -2.78 unit on a scale | Standard Deviation 9.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking 30 day follow up | 1.85 unit on a scale | Standard Deviation 21.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C7D22 | -2.88 unit on a scale | Standard Deviation 20.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking 90 Day follow up | 1.16 unit on a scale | Standard Deviation 18.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C5D22 | -7.42 unit on a scale | Standard Deviation 26.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss Baseline | 29.70 unit on a scale | Standard Deviation 32.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C8D1 | -1.25 unit on a scale | Standard Deviation 23.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C1D22 | 0.95 unit on a scale | Standard Deviation 28.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C7D22 | -8.13 unit on a scale | Standard Deviation 28.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C2D1 | -0.65 unit on a scale | Standard Deviation 31.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C8D22 | -3.29 unit on a scale | Standard Deviation 21.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C2D22 | 0.00 unit on a scale | Standard Deviation 30.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C6D1 | -7.51 unit on a scale | Standard Deviation 23.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C3D1 | -2.46 unit on a scale | Standard Deviation 31.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C9D1 | -6.67 unit on a scale | Standard Deviation 19.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C3D22 | -1.75 unit on a scale | Standard Deviation 31.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C28D1 | 0.00 unit on a scale | Standard Deviation 12.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C4D1 | -5.72 unit on a scale | Standard Deviation 29.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C9D22 | -2.22 unit on a scale | Standard Deviation 22.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C4D22 | -2.19 unit on a scale | Standard Deviation 32.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C6D22 | -9.87 unit on a scale | Standard Deviation 26.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C5D1 | -3.15 unit on a scale | Standard Deviation 35.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C7D1 | -11.80 unit on a scale | Standard Deviation 31.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C10D1 | -6.06 unit on a scale | Standard Deviation 26.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C5D22 | -5.76 unit on a scale | Standard Deviation 33.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C8D1 | -8.02 unit on a scale | Standard Deviation 21.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C6D1 | -6.01 unit on a scale | Standard Deviation 31.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C10D22 | -3.51 unit on a scale | Standard Deviation 21.53 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C6D22 | -9.39 unit on a scale | Standard Deviation 34.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C7D1 | -8.41 unit on a scale | Standard Deviation 23.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C11D1 | -6.35 unit on a scale | Standard Deviation 23.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C7D22 | -8.64 unit on a scale | Standard Deviation 34.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C11D1 | -6.53 unit on a scale | Standard Deviation 20.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C8D1 | -10.83 unit on a scale | Standard Deviation 31.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C11D22 | -8.33 unit on a scale | Standard Deviation 22.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C8D22 | -11.27 unit on a scale | Standard Deviation 33.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C7D22 | -9.67 unit on a scale | Standard Deviation 21.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C9D1 | -15.56 unit on a scale | Standard Deviation 32.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C12D1 | -5.03 unit on a scale | Standard Deviation 20.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C9D22 | -9.44 unit on a scale | Standard Deviation 34.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C8D22 | -8.92 unit on a scale | Standard Deviation 23.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C10D1 | -10.61 unit on a scale | Standard Deviation 33.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C12D22 | -9.91 unit on a scale | Standard Deviation 27.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C10D22 | -11.11 unit on a scale | Standard Deviation 30.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C8D1 | -5.42 unit on a scale | Standard Deviation 24.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C11D1 | -12.17 unit on a scale | Standard Deviation 34.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C13D1 | -4.17 unit on a scale | Standard Deviation 27.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C11D22 | -17.42 unit on a scale | Standard Deviation 29.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C3D1 | -8.30 unit on a scale | Standard Deviation 23.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C12D1 | -10.06 unit on a scale | Standard Deviation 33.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C13D22 | -3.33 unit on a scale | Standard Deviation 21.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C12D22 | -11.71 unit on a scale | Standard Deviation 27.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C8D22 | -10.09 unit on a scale | Standard Deviation 23.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C13D1 | -10.42 unit on a scale | Standard Deviation 29.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C14D1 | -4.27 unit on a scale | Standard Deviation 20.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C13D22 | -10.00 unit on a scale | Standard Deviation 26.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C9D1 | -10.89 unit on a scale | Standard Deviation 24.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C14D1 | -11.97 unit on a scale | Standard Deviation 25.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C14D22 | -2.08 unit on a scale | Standard Deviation 22.3 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C14D22 | -8.33 unit on a scale | Standard Deviation 28.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C9D1 | -10.00 unit on a scale | Standard Deviation 22.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C15D1 | -6.67 unit on a scale | Standard Deviation 26.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C15D1 | -0.95 unit on a scale | Standard Deviation 18.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C15D22 | -8.05 unit on a scale | Standard Deviation 26.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C11D22 | -8.59 unit on a scale | Standard Deviation 19.59 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C16D1 | -13.33 unit on a scale | Standard Deviation 23.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C15D22 | 1.15 unit on a scale | Standard Deviation 25.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C16D22 | -8.05 unit on a scale | Standard Deviation 30.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C9D22 | -6.94 unit on a scale | Standard Deviation 22.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C17D1 | -10.00 unit on a scale | Standard Deviation 26.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C16D1 | -2.86 unit on a scale | Standard Deviation 18.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C17D22 | -8.70 unit on a scale | Standard Deviation 25.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C18D1 | -14.81 unit on a scale | Standard Deviation 23.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C9D22 | -5.97 unit on a scale | Standard Deviation 26.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C18D22 | -15.00 unit on a scale | Standard Deviation 25.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C16D22 | -2.30 unit on a scale | Standard Deviation 17.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C19D1 | -17.39 unit on a scale | Standard Deviation 22.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C10D1 | -10.35 unit on a scale | Standard Deviation 22.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C19D22 | -11.67 unit on a scale | Standard Deviation 29.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C17D1 | -2.22 unit on a scale | Standard Deviation 21.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C20D1 | -15.94 unit on a scale | Standard Deviation 24.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia 30 day follow-up | 0.93 unit on a scale | Standard Deviation 21.65 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C20D22 | -14.81 unit on a scale | Standard Deviation 26.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C17D22 | -1.45 unit on a scale | Standard Deviation 23.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C21D1 | -16.67 unit on a scale | Standard Deviation 25.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C18D1 | -3.70 unit on a scale | Standard Deviation 16.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C21D22 | -16.67 unit on a scale | Standard Deviation 28.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C22D1 | -15.56 unit on a scale | Standard Deviation 27.79 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C10D22 | -6.14 unit on a scale | Standard Deviation 22.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C22D22 | -20.00 unit on a scale | Standard Deviation 28.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C23D1 | -15.56 unit on a scale | Standard Deviation 24.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C18D22 | -3.33 unit on a scale | Standard Deviation 18.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C23D22 | -9.09 unit on a scale | Standard Deviation 30.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C24D1 | -16.67 unit on a scale | Standard Deviation 28.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C25D1 | -11.11 unit on a scale | Standard Deviation 25.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C25D22 | -12.12 unit on a scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C26D1 | -17.95 unit on a scale | Standard Deviation 22.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C27D1 | -24.24 unit on a scale | Standard Deviation 15.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C28D1 | -16.67 unit on a scale | Standard Deviation 22.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss 30 day follow up | 3.24 unit on a scale | Standard Deviation 34.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C10D1 | -7.45 unit on a scale | Standard Deviation 25.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight Loss 90 Day follow up | -2.71 unit on a scale | Standard Deviation 37.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C19D1 | -5.80 unit on a scale | Standard Deviation 16.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss Baseline | 15.62 unit on a scale | Standard Deviation 26.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C11D1 | -8.47 unit on a scale | Standard Deviation 19.37 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C1D22 | 11.11 unit on a scale | Standard Deviation 25.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C19D22 | -6.67 unit on a scale | Standard Deviation 17.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C2D1 | 0.88 unit on a scale | Standard Deviation 27.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C12D1 | -4.19 unit on a scale | Standard Deviation 16.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C2D22 | 4.04 unit on a scale | Standard Deviation 32.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C20D1 | -4.35 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C3D1 | 8.82 unit on a scale | Standard Deviation 26.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C11D22 | -7.95 unit on a scale | Standard Deviation 19.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C3D22 | 10.34 unit on a scale | Standard Deviation 25.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C20D22 | -3.70 unit on a scale | Standard Deviation 19.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C4D1 | 9.68 unit on a scale | Standard Deviation 23.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C8D22 | -8.69 unit on a scale | Standard Deviation 22.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C4D22 | 11.54 unit on a scale | Standard Deviation 22.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in Front of Other C21D1 | -3.33 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C5D1 | 6.17 unit on a scale | Standard Deviation 24.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C12D1 | -4.40 unit on a scale | Standard Deviation 20.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C5D22 | 10.53 unit on a scale | Standard Deviation 27.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C21D22 | -4.76 unit on a scale | Standard Deviation 17.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C6D1 | 8.70 unit on a scale | Standard Deviation 25.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C22D1 | -2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C6D22 | 4.17 unit on a scale | Standard Deviation 23.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C12D22 | -6.61 unit on a scale | Standard Deviation 19.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C7D1 | 2.22 unit on a scale | Standard Deviation 23.46 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C22D22 | 0.00 unit on a scale | Standard Deviation 15.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C7D22 | 1.96 unit on a scale | Standard Deviation 18.52 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C23D1 | -4.44 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C8D1 | 5.56 unit on a scale | Standard Deviation 17.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C12D22 | -4.95 unit on a scale | Standard Deviation 19.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C8D22 | 9.09 unit on a scale | Standard Deviation 15.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C23D22 | -3.03 unit on a scale | Standard Deviation 10.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C9D1 | 0.00 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C24D1 | -4.76 unit on a scale | Standard Deviation 17.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C9D22 | 13.33 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C25D1 | -8.33 unit on a scale | Standard Deviation 15.08 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C10D1 | 11.11 unit on a scale | Standard Deviation 28.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C25D22 | -3.03 unit on a scale | Standard Deviation 17.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C10D22 | 12.50 unit on a scale | Standard Deviation 17.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C26D1 | -7.69 unit on a scale | Standard Deviation 19.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C11D1 | 15.15 unit on a scale | Standard Deviation 17.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C27D1 | -6.06 unit on a scale | Standard Deviation 20.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C11D22 | 12.50 unit on a scale | Standard Deviation 17.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C28D1 | -5.56 unit on a scale | Standard Deviation 19.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C12D1 | 13.33 unit on a scale | Standard Deviation 23.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others 30 day follow up | 3.24 unit on a scale | Standard Deviation 24.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C12D22 | 12.50 unit on a scale | Standard Deviation 35.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C9D1 | -8.67 unit on a scale | Standard Deviation 20.2 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C13D1 | 7.41 unit on a scale | Standard Deviation 14.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C13D22 | 13.33 unit on a scale | Standard Deviation 18.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others 90 day follow up | 1.94 unit on a scale | Standard Deviation 25.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C14D1 | 9.52 unit on a scale | Standard Deviation 16.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C13D1 | -4.86 unit on a scale | Standard Deviation 21.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C14D22 | 33.33 unit on a scale | Standard Deviation 40.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C15D1 | 23.81 unit on a scale | Standard Deviation 37.09 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C15D22 | 16.67 unit on a scale | Standard Deviation 19.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C16D1 | 13.33 unit on a scale | Standard Deviation 18.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C16D22 | 16.67 unit on a scale | Standard Deviation 19.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C17D1 | 8.33 unit on a scale | Standard Deviation 31.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C17D22 | 0.00 unit on a scale | Standard Deviation 27.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C18D1 | 0.00 unit on a scale | Standard Deviation 27.22 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C19D22 | 41.67 unit on a scale | Standard Deviation 31.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss 30 day follow up | -11.11 unit on a scale | Standard Deviation 45.54 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth Baseline | 21.92 unit on a scale | Standard Deviation 26.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss 90 day follow up | 21.43 unit on a scale | Standard Deviation 33.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C3D22 | -4.02 unit on a scale | Standard Deviation 23.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C1D22 | 5.68 unit on a scale | Standard Deviation 27.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C13D22 | -4.58 unit on a scale | Standard Deviation 22.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C2D1 | 1.78 unit on a scale | Standard Deviation 31.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C9D22 | -5.56 unit on a scale | Standard Deviation 20.74 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C2D22 | 3.56 unit on a scale | Standard Deviation 26.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C14D1 | -2.99 unit on a scale | Standard Deviation 22.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C3D1 | 1.05 unit on a scale | Standard Deviation 31.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C13D1 | -6.25 unit on a scale | Standard Deviation 18.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C3D22 | 4.39 unit on a scale | Standard Deviation 30.85 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C14D22 | -9.38 unit on a scale | Standard Deviation 17.42 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C4D1 | -0.39 unit on a scale | Standard Deviation 30.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C10D1 | -6.31 unit on a scale | Standard Deviation 18.89 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C4D22 | 1.09 unit on a scale | Standard Deviation 29.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C15D1 | -1.90 unit on a scale | Standard Deviation 24.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C5D1 | 3.15 unit on a scale | Standard Deviation 32.14 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C13D1 | -3.82 unit on a scale | Standard Deviation 16.93 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C5D22 | -1.91 unit on a scale | Standard Deviation 26.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C15D22 | -6.32 unit on a scale | Standard Deviation 24.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C6D1 | -0.87 unit on a scale | Standard Deviation 25.92 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C10D22 | -4.09 unit on a scale | Standard Deviation 18.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C6D22 | -3.56 unit on a scale | Standard Deviation 27.97 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C16D1 | -7.14 unit on a scale | Standard Deviation 25.34 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C7D1 | -2.06 unit on a scale | Standard Deviation 25.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C13D22 | -4.72 unit on a scale | Standard Deviation 16.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C7D22 | -0.82 unit on a scale | Standard Deviation 29.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C16D22 | -8.62 unit on a scale | Standard Deviation 22.55 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C8D1 | -0.83 unit on a scale | Standard Deviation 28.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C11D1 | -5.56 unit on a scale | Standard Deviation 17.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C8D22 | -0.94 unit on a scale | Standard Deviation 28.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C17D1 | -3.89 unit on a scale | Standard Deviation 22.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C9D1 | -0.44 unit on a scale | Standard Deviation 27.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C4D1 | -6.64 unit on a scale | Standard Deviation 23.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C9D22 | 2.22 unit on a scale | Standard Deviation 29.98 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C17D22 | -4.35 unit on a scale | Standard Deviation 21.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C10D1 | -0.51 unit on a scale | Standard Deviation 30.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C18D1 | -8.02 unit on a scale | Standard Deviation 22.35 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C10D22 | -0.58 unit on a scale | Standard Deviation 25.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C11D22 | -3.41 unit on a scale | Standard Deviation 14.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C11D1 | 1.59 unit on a scale | Standard Deviation 27.06 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C18D22 | -8.33 unit on a scale | Standard Deviation 22.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C11D22 | 2.27 unit on a scale | Standard Deviation 24.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C14D1 | -4.27 unit on a scale | Standard Deviation 12.39 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C12D1 | 2.52 unit on a scale | Standard Deviation 29.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C19D1 | -13.77 unit on a scale | Standard Deviation 18.57 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C12D22 | 0.90 unit on a scale | Standard Deviation 25.44 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C12D1 | -4.40 unit on a scale | Standard Deviation 20.45 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C13D1 | 2.08 unit on a scale | Standard Deviation 26.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C19D22 | -7.50 unit on a scale | Standard Deviation 21.95 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C13D22 | 4.17 unit on a scale | Standard Deviation 25.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia 90 day follow-up | -2.20 unit on a scale | Standard Deviation 25.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C14D1 | 0.00 unit on a scale | Standard Deviation 26.49 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C20D1 | -11.59 unit on a scale | Standard Deviation 17.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C14D22 | 0.00 unit on a scale | Standard Deviation 26.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C12D22 | -2.25 unit on a scale | Standard Deviation 17.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C15D1 | 0.00 unit on a scale | Standard Deviation 29.15 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C20D22 | -11.11 unit on a scale | Standard Deviation 18.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C15D22 | 0.00 unit on a scale | Standard Deviation 26.73 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C14D22 | -4.17 unit on a scale | Standard Deviation 13.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C16D1 | -1.90 unit on a scale | Standard Deviation 27.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C21D1 | -8.33 unit on a scale | Standard Deviation 19.12 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C16D22 | 2.30 unit on a scale | Standard Deviation 26.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C4D22 | -2.82 unit on a scale | Standard Deviation 22.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C17D1 | 5.56 unit on a scale | Standard Deviation 30.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C21D22 | -9.52 unit on a scale | Standard Deviation 21.4 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C17D22 | 1.45 unit on a scale | Standard Deviation 27.48 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C18D1 | -3.70 unit on a scale | Standard Deviation 23.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C22D1 | -13.33 unit on a scale | Standard Deviation 19.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C18D22 | -1.67 unit on a scale | Standard Deviation 22.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C13D22 | -4.17 unit on a scale | Standard Deviation 18.78 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C19D1 | -2.90 unit on a scale | Standard Deviation 26.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C8D22 | -1.88 unit on a scale | Standard Deviation 16.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C22D22 | -13.33 unit on a scale | Standard Deviation 21.94 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C9D1 | -2.22 unit on a scale | Standard Deviation 14.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C23D1 | -14.44 unit on a scale | Standard Deviation 18.76 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C9D22 | -0.56 unit on a scale | Standard Deviation 17.88 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C15D1 | -2.22 unit on a scale | Standard Deviation 12.58 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C10D1 | -0.51 unit on a scale | Standard Deviation 17.04 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C23D22 | -10.61 unit on a scale | Standard Deviation 18.67 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C10D22 | -1.17 unit on a scale | Standard Deviation 16.62 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C24D1 | -13.10 unit on a scale | Standard Deviation 19.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C11D1 | 0.53 unit on a scale | Standard Deviation 15.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C25D1 | -11.11 unit on a scale | Standard Deviation 19.25 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C11D22 | -1.52 unit on a scale | Standard Deviation 18.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C25D22 | -10.61 unit on a scale | Standard Deviation 20.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C12D1 | 0.00 unit on a scale | Standard Deviation 16.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C26D1 | -14.10 unit on a scale | Standard Deviation 20.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C12D22 | -1.80 unit on a scale | Standard Deviation 17.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C27D1 | -10.61 unit on a scale | Standard Deviation 15.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C13D1 | -0.69 unit on a scale | Standard Deviation 16.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C28D1 | -6.94 unit on a scale | Standard Deviation 16.6 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C13D22 | 0.83 unit on a scale | Standard Deviation 19.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort 30 day follow up | -6.02 unit on a scale | Standard Deviation 29.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C14D1 | -2.56 unit on a scale | Standard Deviation 16.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C15D22 | -4.98 unit on a scale | Standard Deviation 14.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C14D22 | -6.25 unit on a scale | Standard Deviation 15.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort 90 day follow up | -6.59 unit on a scale | Standard Deviation 30.17 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C15D1 | -0.95 unit on a scale | Standard Deviation 12.75 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C10D22 | -7.60 unit on a scale | Standard Deviation 25.11 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C15D22 | -4.60 unit on a scale | Standard Deviation 11.7 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety Baseline | 51.30 unit on a scale | Standard Deviation 28.99 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C16D1 | -1.90 unit on a scale | Standard Deviation 13.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C23D22 | -7.07 unit on a scale | Standard Deviation 16.68 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C16D22 | -2.30 unit on a scale | Standard Deviation 12.38 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C1D22 | -8.33 unit on a scale | Standard Deviation 24.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C17D1 | -2.22 unit on a scale | Standard Deviation 17.36 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C28D1 | -4.17 unit on a scale | Standard Deviation 14.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C17D22 | -1.45 unit on a scale | Standard Deviation 21.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C18D1 | -2.47 unit on a scale | Standard Deviation 18.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions 30 day follow up | 2.31 unit on a scale | Standard Deviation 25.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C18D22 | 1.67 unit on a scale | Standard Deviation 13.13 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C11D1 | -10.05 unit on a scale | Standard Deviation 24.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C19D1 | 0.00 unit on a scale | Standard Deviation 17.41 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions 90 day follow up | -5.62 unit on a scale | Standard Deviation 30.8 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C19D22 | 0.00 unit on a scale | Standard Deviation 10.81 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C5D1 | -6.31 unit on a scale | Standard Deviation 22.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C20D1 | 0.00 unit on a scale | Standard Deviation 10.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux Baseline | 17.64 unit on a scale | Standard Deviation 24.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C20D22 | 0.00 unit on a scale | Standard Deviation 11.43 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C11D22 | -8.33 unit on a scale | Standard Deviation 23.23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C21D1 | -1.67 unit on a scale | Standard Deviation 17.01 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C2D1 | -10.19 unit on a scale | Standard Deviation 26.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C21D22 | -4.76 unit on a scale | Standard Deviation 17.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C22D1 | -2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C16D1 | -4.44 unit on a scale | Standard Deviation 15.29 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C22D22 | -10.00 unit on a scale | Standard Deviation 22.5 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C23D1 | -4.44 unit on a scale | Standard Deviation 21.33 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C1D22 | -1.70 unit on a scale | Standard Deviation 21.61 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C23D22 | -9.09 unit on a scale | Standard Deviation 21.56 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C24D1 | -4.76 unit on a scale | Standard Deviation 22.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C25D1 | -8.33 unit on a scale | Standard Deviation 20.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C25D22 | -6.06 unit on a scale | Standard Deviation 25.03 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C26D1 | -5.13 unit on a scale | Standard Deviation 22.96 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C27D1 | 0.00 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C28D1 | 0.00 unit on a scale | Standard Deviation 14.21 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing 30 Day follow up | 1.39 unit on a scale | Standard Deviation 20.51 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C12D1 | -7.39 unit on a scale | Standard Deviation 21.1 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing 90 Day follow up | 2.71 unit on a scale | Standard Deviation 19.28 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C2D1 | -2.99 unit on a scale | Standard Deviation 24.32 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing Baseline | 12.06 unit on a scale | Standard Deviation 19.69 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions Baseline | 30.54 unit on a scale | Standard Deviation 29.05 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C1D22 | 4.17 unit on a scale | Standard Deviation 23.27 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C2D22 | -4.56 unit on a scale | Standard Deviation 23 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C2D1 | 2.75 unit on a scale | Standard Deviation 23.47 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C12D22 | -4.95 unit on a scale | Standard Deviation 20.64 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C2D22 | 2.22 unit on a scale | Standard Deviation 20.31 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C3D1 | -5.61 unit on a scale | Standard Deviation 23.71 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C3D1 | 4.74 unit on a scale | Standard Deviation 26.24 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C16D22 | -2.30 unit on a scale | Standard Deviation 15.82 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C3D22 | 3.29 unit on a scale | Standard Deviation 24.19 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C3D22 | -4.39 unit on a scale | Standard Deviation 21.16 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C4D1 | 1.97 unit on a scale | Standard Deviation 23.77 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C13D1 | -7.47 unit on a scale | Standard Deviation 20.72 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C4D22 | 1.37 unit on a scale | Standard Deviation 18.87 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C4D1 | -5.52 unit on a scale | Standard Deviation 22.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C5D1 | 1.80 unit on a scale | Standard Deviation 20.86 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C5D22 | -4.85 unit on a scale | Standard Deviation 21.84 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C5D22 | 1.21 unit on a scale | Standard Deviation 20.66 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C4D22 | -2.46 unit on a scale | Standard Deviation 21.18 |
| mFOLFOX6 + Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C6D1 | -0.82 unit on a scale | Standard Deviation 22.05 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss 90 day follow up | 16.67 unit on a scale | Standard Deviation 25.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C23D1 | -4.27 unit on a scale | Standard Deviation 14.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia 30 day follow-up | -5.93 unit on a scale | Standard Deviation 28.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia 90 day follow-up | -5.42 unit on a scale | Standard Deviation 34.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions Baseline | 33.01 unit on a scale | Standard Deviation 30.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C1D22 | -1.32 unit on a scale | Standard Deviation 23.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C1D22 | -1.66 unit on a scale | Standard Deviation 22.31 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia Baseline | 20.02 unit on a scale | Standard Deviation 26.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C2D1 | -7.92 unit on a scale | Standard Deviation 25.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C2D22 | -8.46 unit on a scale | Standard Deviation 23.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C3D1 | -8.45 unit on a scale | Standard Deviation 24.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C3D22 | -9.16 unit on a scale | Standard Deviation 26.55 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C4D1 | -8.70 unit on a scale | Standard Deviation 23.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C4D22 | -7.26 unit on a scale | Standard Deviation 24.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C5D1 | -8.02 unit on a scale | Standard Deviation 24.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C5D22 | -7.25 unit on a scale | Standard Deviation 22.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C6D1 | -5.42 unit on a scale | Standard Deviation 20.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C6D22 | -7.61 unit on a scale | Standard Deviation 21.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C7D1 | -6.35 unit on a scale | Standard Deviation 20.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C7D22 | -8.07 unit on a scale | Standard Deviation 20.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C8D1 | -5.62 unit on a scale | Standard Deviation 16.02 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C8D22 | -5.64 unit on a scale | Standard Deviation 20.42 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C9D1 | -6.81 unit on a scale | Standard Deviation 18.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C9D22 | -3.03 unit on a scale | Standard Deviation 19.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C10D1 | -4.76 unit on a scale | Standard Deviation 19.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C10D22 | -3.10 unit on a scale | Standard Deviation 20.19 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C11D1 | -0.24 unit on a scale | Standard Deviation 23.13 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C11D22 | -1.08 unit on a scale | Standard Deviation 10.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C12D22 | -5.33 unit on a scale | Standard Deviation 14.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C13D1 | -4.76 unit on a scale | Standard Deviation 17.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C13D22 | -6.88 unit on a scale | Standard Deviation 24.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C14D1 | -5.56 unit on a scale | Standard Deviation 20.37 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C14D22 | -7.02 unit on a scale | Standard Deviation 25.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C15D1 | -5.76 unit on a scale | Standard Deviation 19.58 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C15D22 | -6.54 unit on a scale | Standard Deviation 27.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C16D1 | -4.55 unit on a scale | Standard Deviation 26.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C16D22 | -8.73 unit on a scale | Standard Deviation 28.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C17D1 | -6.79 unit on a scale | Standard Deviation 24.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C18D1 | -7.64 unit on a scale | Standard Deviation 23.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C18D22 | -6.67 unit on a scale | Standard Deviation 16.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C19D1 | -2.22 unit on a scale | Standard Deviation 16.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C19D22 | -4.04 unit on a scale | Standard Deviation 16.68 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C20D1 | -3.70 unit on a scale | Standard Deviation 12.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C20D22 | -5.56 unit on a scale | Standard Deviation 15.04 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C21D1 | -4.76 unit on a scale | Standard Deviation 12.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C22D1 | -5.56 unit on a scale | Standard Deviation 13.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C2D1 | -9.94 unit on a scale | Standard Deviation 29.44 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C2D22 | -7.92 unit on a scale | Standard Deviation 30.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C3D1 | -13.52 unit on a scale | Standard Deviation 28.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C3D22 | -10.98 unit on a scale | Standard Deviation 29.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C4D1 | -13.15 unit on a scale | Standard Deviation 28.12 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C4D22 | -10.96 unit on a scale | Standard Deviation 28.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C5D1 | -13.43 unit on a scale | Standard Deviation 30.02 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C5D22 | -11.09 unit on a scale | Standard Deviation 28.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C6D1 | -9.92 unit on a scale | Standard Deviation 27.41 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C6D22 | -14.67 unit on a scale | Standard Deviation 26.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C7D1 | -12.16 unit on a scale | Standard Deviation 24.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C7D22 | -14.16 unit on a scale | Standard Deviation 25.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C8D1 | -10.60 unit on a scale | Standard Deviation 23.68 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C8D22 | -10.13 unit on a scale | Standard Deviation 26.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C9D1 | -12.63 unit on a scale | Standard Deviation 24.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C9D22 | -7.73 unit on a scale | Standard Deviation 25.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C8D1 | -6.58 unit on a scale | Standard Deviation 16.39 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C8D22 | -7.44 unit on a scale | Standard Deviation 19.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C9D1 | -8.06 unit on a scale | Standard Deviation 20.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C9D22 | -2.42 unit on a scale | Standard Deviation 19.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C10D1 | -4.17 unit on a scale | Standard Deviation 17.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C10D22 | -3.49 unit on a scale | Standard Deviation 18.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C11D1 | -2.54 unit on a scale | Standard Deviation 16.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C11D22 | 0.54 unit on a scale | Standard Deviation 11.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C12D1 | -1.22 unit on a scale | Standard Deviation 15.09 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C12D22 | -2.00 unit on a scale | Standard Deviation 17.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C13D1 | -3.33 unit on a scale | Standard Deviation 13.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C13D22 | 0.79 unit on a scale | Standard Deviation 15.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C10D1 | -9.97 unit on a scale | Standard Deviation 25.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C10D22 | -5.81 unit on a scale | Standard Deviation 29.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C11D1 | -6.16 unit on a scale | Standard Deviation 28.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C11D22 | -5.38 unit on a scale | Standard Deviation 20.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C12D1 | -7.32 unit on a scale | Standard Deviation 24.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C12D22 | -10.67 unit on a scale | Standard Deviation 20.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C13D1 | -9.52 unit on a scale | Standard Deviation 25.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C14D1 | -0.00 unit on a scale | Standard Deviation 13.13 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C13D22 | -7.94 unit on a scale | Standard Deviation 30.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C14D22 | -1.75 unit on a scale | Standard Deviation 15.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C14D1 | -8.61 unit on a scale | Standard Deviation 28.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C14D22 | -8.33 unit on a scale | Standard Deviation 28.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C15D1 | 2.47 unit on a scale | Standard Deviation 18.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C15D22 | -1.96 unit on a scale | Standard Deviation 18.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C15D1 | -6.17 unit on a scale | Standard Deviation 30.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C15D22 | -12.75 unit on a scale | Standard Deviation 35.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C16D1 | 1.52 unit on a scale | Standard Deviation 18.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C16D22 | 1.19 unit on a scale | Standard Deviation 21.15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C17D1 | -0.93 unit on a scale | Standard Deviation 12.09 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C16D1 | -5.68 unit on a scale | Standard Deviation 36.95 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C18D1 | -1.04 unit on a scale | Standard Deviation 14.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C18D22 | -5.00 unit on a scale | Standard Deviation 13.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C19D1 | -2.22 unit on a scale | Standard Deviation 12.39 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C19D22 | -3.03 unit on a scale | Standard Deviation 17.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C16D22 | -10.12 unit on a scale | Standard Deviation 37.15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C17D1 | -13.89 unit on a scale | Standard Deviation 30.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C18D1 | -12.50 unit on a scale | Standard Deviation 31.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C18D22 | -15.00 unit on a scale | Standard Deviation 23.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C19D1 | -8.89 unit on a scale | Standard Deviation 26.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C20D1 | -5.56 unit on a scale | Standard Deviation 16.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C20D22 | 0.00 unit on a scale | Standard Deviation 15.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C21D1 | -3.57 unit on a scale | Standard Deviation 13.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C19D22 | -7.58 unit on a scale | Standard Deviation 20.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C22D1 | -2.78 unit on a scale | Standard Deviation 9.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C23D1 | -5.13 unit on a scale | Standard Deviation 8.01 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C20D1 | -10.00 unit on a scale | Standard Deviation 21.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C20D22 | -10.00 unit on a scale | Standard Deviation 19.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C21D1 | -11.31 unit on a scale | Standard Deviation 20.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C22D1 | -9.72 unit on a scale | Standard Deviation 25.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia 30 day follow up | -4.44 unit on a scale | Standard Deviation 24.2 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions C23D1 | -8.97 unit on a scale | Standard Deviation 24.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia 90 day follow up | -3.46 unit on a scale | Standard Deviation 29.01 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort Baseline | 26.39 unit on a scale | Standard Deviation 27.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C1D22 | -3.45 unit on a scale | Standard Deviation 23.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C2D1 | -8.37 unit on a scale | Standard Deviation 28.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C2D22 | -8.89 unit on a scale | Standard Deviation 26.04 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C3D1 | -8.50 unit on a scale | Standard Deviation 23.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C3D22 | -8.67 unit on a scale | Standard Deviation 24.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C4D1 | -8.70 unit on a scale | Standard Deviation 23.13 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C4D22 | -8.79 unit on a scale | Standard Deviation 23.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C5D1 | -8.68 unit on a scale | Standard Deviation 24.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C5D22 | -8.99 unit on a scale | Standard Deviation 22.44 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C6D1 | -5.79 unit on a scale | Standard Deviation 23.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C6D22 | -12.68 unit on a scale | Standard Deviation 24.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C7D1 | -8.50 unit on a scale | Standard Deviation 21.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C7D22 | -8.68 unit on a scale | Standard Deviation 20.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C8D1 | -7.82 unit on a scale | Standard Deviation 23.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C8D22 | -9.23 unit on a scale | Standard Deviation 23.39 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C9D1 | -7.53 unit on a scale | Standard Deviation 22.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C9D22 | -7.27 unit on a scale | Standard Deviation 21.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C10D1 | -7.14 unit on a scale | Standard Deviation 19.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C10D22 | -3.49 unit on a scale | Standard Deviation 21.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C11D1 | -0.72 unit on a scale | Standard Deviation 20.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C11D22 | -2.15 unit on a scale | Standard Deviation 17.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C12D1 | -1.63 unit on a scale | Standard Deviation 21.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C12D22 | -1.33 unit on a scale | Standard Deviation 19.2 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C13D1 | -2.38 unit on a scale | Standard Deviation 21.44 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C13D22 | 0.79 unit on a scale | Standard Deviation 23.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C14D1 | -1.67 unit on a scale | Standard Deviation 21.15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C14D22 | -5.26 unit on a scale | Standard Deviation 20.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C15D1 | -1.23 unit on a scale | Standard Deviation 24.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C15D22 | -2.94 unit on a scale | Standard Deviation 25.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C16D1 | -3.03 unit on a scale | Standard Deviation 20.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C16D22 | -3.57 unit on a scale | Standard Deviation 23.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C17D1 | 1.85 unit on a scale | Standard Deviation 18.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C18D1 | -4.17 unit on a scale | Standard Deviation 20.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C18D22 | -6.67 unit on a scale | Standard Deviation 11.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C19D1 | -6.67 unit on a scale | Standard Deviation 23.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C19D22 | -4.55 unit on a scale | Standard Deviation 21.2 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C20D1 | -7.78 unit on a scale | Standard Deviation 20.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C20D22 | -5.00 unit on a scale | Standard Deviation 15.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C21D1 | -10.71 unit on a scale | Standard Deviation 19.18 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C22D1 | -4.17 unit on a scale | Standard Deviation 16.09 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort C23D1 | -7.69 unit on a scale | Standard Deviation 21.1 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort 30 day follow up | -1.85 unit on a scale | Standard Deviation 27.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Pain and Discomfort 90 day follow up | -1.83 unit on a scale | Standard Deviation 32.5 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety Baseline | 52.92 unit on a scale | Standard Deviation 30.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions 30 day follow up | -5.46 unit on a scale | Standard Deviation 33.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating restrictions 90 day follow up | -5.08 unit on a scale | Standard Deviation 38.53 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C1D22 | -6.09 unit on a scale | Standard Deviation 25.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux Baseline | 16.60 unit on a scale | Standard Deviation 24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C1D22 | -1.28 unit on a scale | Standard Deviation 21.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C2D1 | -5.31 unit on a scale | Standard Deviation 26.2 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C2D22 | -5.00 unit on a scale | Standard Deviation 23.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C3D1 | -6.46 unit on a scale | Standard Deviation 23.1 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C3D22 | -5.86 unit on a scale | Standard Deviation 21.19 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C4D1 | -5.28 unit on a scale | Standard Deviation 20.95 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C4D22 | -5.64 unit on a scale | Standard Deviation 20.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C5D1 | -3.24 unit on a scale | Standard Deviation 22.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C5D22 | -2.75 unit on a scale | Standard Deviation 22.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C6D1 | -1.38 unit on a scale | Standard Deviation 20.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C6D22 | -1.81 unit on a scale | Standard Deviation 20.44 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C7D1 | 1.36 unit on a scale | Standard Deviation 18.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C7D22 | -1.14 unit on a scale | Standard Deviation 16.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C8D1 | 0.41 unit on a scale | Standard Deviation 14.19 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C8D22 | 1.03 unit on a scale | Standard Deviation 18.13 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C9D1 | -0.81 unit on a scale | Standard Deviation 16.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C9D22 | 1.82 unit on a scale | Standard Deviation 14.58 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C10D1 | 0.30 unit on a scale | Standard Deviation 17.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C10D22 | 5.04 unit on a scale | Standard Deviation 19.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C11D1 | 7.97 unit on a scale | Standard Deviation 24.02 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C11D22 | 7.53 unit on a scale | Standard Deviation 21.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C12D1 | 8.13 unit on a scale | Standard Deviation 24.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C12D22 | 2.67 unit on a scale | Standard Deviation 19.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C13D1 | 4.76 unit on a scale | Standard Deviation 21.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C13D22 | 5.56 unit on a scale | Standard Deviation 13.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C14D1 | -0.56 unit on a scale | Standard Deviation 15.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C14D22 | 7.02 unit on a scale | Standard Deviation 13.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C15D1 | 2.47 unit on a scale | Standard Deviation 21.03 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C15D22 | 2.94 unit on a scale | Standard Deviation 15.85 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C16D1 | 6.06 unit on a scale | Standard Deviation 22.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C16D22 | 7.14 unit on a scale | Standard Deviation 28.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C17D1 | 1.85 unit on a scale | Standard Deviation 20.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C18D1 | -3.13 unit on a scale | Standard Deviation 17.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C18D22 | 0.00 unit on a scale | Standard Deviation 23.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C19D1 | -1.11 unit on a scale | Standard Deviation 20.38 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C19D22 | 3.03 unit on a scale | Standard Deviation 14.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C20D1 | -3.33 unit on a scale | Standard Deviation 14.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C20D22 | 1.67 unit on a scale | Standard Deviation 14.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C21D1 | -1.19 unit on a scale | Standard Deviation 12.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C22D1 | -6.94 unit on a scale | Standard Deviation 16.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux C23D1 | 0.00 unit on a scale | Standard Deviation 19.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux 30 day follow up | -2.96 unit on a scale | Standard Deviation 26.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Reflux 90 day follow up | 1.02 unit on a scale | Standard Deviation 26.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia Baseline | 22.44 unit on a scale | Standard Deviation 26.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C1D22 | -5.69 unit on a scale | Standard Deviation 22.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C2D1 | -9.19 unit on a scale | Standard Deviation 24.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C2D22 | -9.35 unit on a scale | Standard Deviation 25.05 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C3D1 | -11.39 unit on a scale | Standard Deviation 24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C3D22 | -12.50 unit on a scale | Standard Deviation 23.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C4D1 | -11.18 unit on a scale | Standard Deviation 23.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C4D22 | -9.19 unit on a scale | Standard Deviation 22.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C5D1 | -11.23 unit on a scale | Standard Deviation 23.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C5D22 | -11.01 unit on a scale | Standard Deviation 23.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C6D1 | -8.13 unit on a scale | Standard Deviation 20.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C6D22 | -12.32 unit on a scale | Standard Deviation 21.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C7D1 | -7.99 unit on a scale | Standard Deviation 19.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Odynophagia C7D22 | -7.31 unit on a scale | Standard Deviation 18.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C2D1 | -11.29 unit on a scale | Standard Deviation 29.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C2D22 | -11.85 unit on a scale | Standard Deviation 30.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C3D1 | -13.44 unit on a scale | Standard Deviation 28.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C3D22 | -14.30 unit on a scale | Standard Deviation 27.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C8D1 | 0.00 unit on a scale | Standard Deviation 14.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C4D1 | -12.63 unit on a scale | Standard Deviation 26.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C4D22 | -12.99 unit on a scale | Standard Deviation 26.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C5D1 | -7.75 unit on a scale | Standard Deviation 28.42 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C5D22 | -8.12 unit on a scale | Standard Deviation 25.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C6D1 | -9.09 unit on a scale | Standard Deviation 28.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C6D22 | -14.67 unit on a scale | Standard Deviation 25.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C7D1 | -17.18 unit on a scale | Standard Deviation 25.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C7D22 | -15.98 unit on a scale | Standard Deviation 27.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C8D1 | -14.20 unit on a scale | Standard Deviation 25.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C8D22 | -16.92 unit on a scale | Standard Deviation 28.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C9D1 | -15.86 unit on a scale | Standard Deviation 27.06 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C9D22 | -20.30 unit on a scale | Standard Deviation 26.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C10D1 | -18.15 unit on a scale | Standard Deviation 31.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C10D22 | -13.95 unit on a scale | Standard Deviation 29.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C11D1 | -9.06 unit on a scale | Standard Deviation 24.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C11D22 | -14.52 unit on a scale | Standard Deviation 29.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C12D1 | -10.57 unit on a scale | Standard Deviation 22.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C12D22 | -19.33 unit on a scale | Standard Deviation 29.53 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C13D1 | -15.24 unit on a scale | Standard Deviation 25.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C13D22 | -10.32 unit on a scale | Standard Deviation 26.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C14D1 | -15.00 unit on a scale | Standard Deviation 24.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C14D22 | -10.53 unit on a scale | Standard Deviation 23.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C15D1 | -16.67 unit on a scale | Standard Deviation 30.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C15D22 | -17.65 unit on a scale | Standard Deviation 33.06 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C16D1 | -15.91 unit on a scale | Standard Deviation 29.76 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C16D22 | -20.24 unit on a scale | Standard Deviation 31.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C17D1 | -20.37 unit on a scale | Standard Deviation 29.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C18D1 | -15.63 unit on a scale | Standard Deviation 25.44 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C18D22 | -16.67 unit on a scale | Standard Deviation 30.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C19D1 | -21.11 unit on a scale | Standard Deviation 32.41 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C19D22 | -16.67 unit on a scale | Standard Deviation 29.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C20D1 | -21.11 unit on a scale | Standard Deviation 26.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C20D22 | -18.33 unit on a scale | Standard Deviation 22.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C21D1 | -15.48 unit on a scale | Standard Deviation 33.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C22D1 | -16.67 unit on a scale | Standard Deviation 26.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety C23D1 | -23.08 unit on a scale | Standard Deviation 29.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety 30 day follow up | -6.30 unit on a scale | Standard Deviation 33.39 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Anxiety 90 day follow up | -2.44 unit on a scale | Standard Deviation 33.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others Baseline | 15.95 unit on a scale | Standard Deviation 26.85 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C1D22 | -0.64 unit on a scale | Standard Deviation 23.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C2D1 | -4.04 unit on a scale | Standard Deviation 23.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C2D22 | -3.52 unit on a scale | Standard Deviation 25.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C3D1 | -5.27 unit on a scale | Standard Deviation 27.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C3D22 | -6.08 unit on a scale | Standard Deviation 26.38 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C4D1 | -7.45 unit on a scale | Standard Deviation 23.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C4D22 | -4.99 unit on a scale | Standard Deviation 26.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C5D1 | -4.63 unit on a scale | Standard Deviation 25.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C5D22 | -4.06 unit on a scale | Standard Deviation 22.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C6D1 | -1.93 unit on a scale | Standard Deviation 24.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C6D22 | -4.71 unit on a scale | Standard Deviation 23.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C7D1 | -4.76 unit on a scale | Standard Deviation 23.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C7D22 | -3.65 unit on a scale | Standard Deviation 22.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C8D1 | -4.94 unit on a scale | Standard Deviation 18.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C8D22 | -3.59 unit on a scale | Standard Deviation 20.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C9D1 | -4.84 unit on a scale | Standard Deviation 23.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C9D22 | -0.61 unit on a scale | Standard Deviation 27.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C10D1 | -2.98 unit on a scale | Standard Deviation 22.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C10D22 | -2.33 unit on a scale | Standard Deviation 21.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C11D1 | -1.45 unit on a scale | Standard Deviation 22.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C11D22 | -2.15 unit on a scale | Standard Deviation 17.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C12D1 | -2.44 unit on a scale | Standard Deviation 18.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C12D22 | -5.33 unit on a scale | Standard Deviation 18.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C13D1 | -3.81 unit on a scale | Standard Deviation 17.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C13D22 | -0.00 unit on a scale | Standard Deviation 25.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C14D1 | -2.22 unit on a scale | Standard Deviation 21.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C14D22 | -3.51 unit on a scale | Standard Deviation 18.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C15D1 | -2.47 unit on a scale | Standard Deviation 15.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C15D22 | -1.96 unit on a scale | Standard Deviation 21.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C16D1 | -1.52 unit on a scale | Standard Deviation 21.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C16D22 | -4.76 unit on a scale | Standard Deviation 17.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C17D1 | -3.70 unit on a scale | Standard Deviation 15.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C18D1 | -4.17 unit on a scale | Standard Deviation 16.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C18D22 | -10.00 unit on a scale | Standard Deviation 16.1 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C19D1 | -4.44 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C19D22 | -6.06 unit on a scale | Standard Deviation 13.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C20D1 | -4.44 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C20D22 | -6.67 unit on a scale | Standard Deviation 21.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in Front of Other C21D1 | -7.14 unit on a scale | Standard Deviation 19.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C22D1 | -5.56 unit on a scale | Standard Deviation 19.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others C23D1 | -2.56 unit on a scale | Standard Deviation 21.35 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others 30 day follow up | 0.37 unit on a scale | Standard Deviation 33.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Eating in front of others 90 day follow up | 0.81 unit on a scale | Standard Deviation 34.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth Baseline | 22.70 unit on a scale | Standard Deviation 26.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C1D22 | 4.33 unit on a scale | Standard Deviation 27.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C2D1 | 0.45 unit on a scale | Standard Deviation 28.03 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C2D22 | 1.11 unit on a scale | Standard Deviation 29.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C3D1 | -1.53 unit on a scale | Standard Deviation 29.68 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C3D22 | 1.13 unit on a scale | Standard Deviation 29.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C4D1 | -0.62 unit on a scale | Standard Deviation 29.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C4D22 | 1.57 unit on a scale | Standard Deviation 29.05 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C5D1 | 1.16 unit on a scale | Standard Deviation 27.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C5D22 | -0.58 unit on a scale | Standard Deviation 25.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C6D1 | 0.28 unit on a scale | Standard Deviation 29.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C6D22 | -3.99 unit on a scale | Standard Deviation 25.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C7D1 | -2.38 unit on a scale | Standard Deviation 29.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C7D22 | -3.65 unit on a scale | Standard Deviation 31.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C8D1 | -3.29 unit on a scale | Standard Deviation 29.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C8D22 | 0.51 unit on a scale | Standard Deviation 30.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C9D1 | -0.54 unit on a scale | Standard Deviation 30.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C9D22 | -1.21 unit on a scale | Standard Deviation 31.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C10D1 | -2.38 unit on a scale | Standard Deviation 28.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C10D22 | -0.78 unit on a scale | Standard Deviation 31.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C11D1 | -2.17 unit on a scale | Standard Deviation 27.58 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C11D22 | -1.08 unit on a scale | Standard Deviation 21.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C12D1 | -0.81 unit on a scale | Standard Deviation 29.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C12D22 | 2.67 unit on a scale | Standard Deviation 27.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C13D1 | -1.90 unit on a scale | Standard Deviation 29.09 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C13D22 | -1.59 unit on a scale | Standard Deviation 34.12 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C14D1 | -4.44 unit on a scale | Standard Deviation 29.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C14D22 | -5.26 unit on a scale | Standard Deviation 31.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C15D1 | -9.88 unit on a scale | Standard Deviation 28.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C15D22 | -13.73 unit on a scale | Standard Deviation 33.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C16D1 | -12.12 unit on a scale | Standard Deviation 30.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C16D22 | -7.14 unit on a scale | Standard Deviation 41.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C17D1 | -9.26 unit on a scale | Standard Deviation 31.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C18D1 | -8.33 unit on a scale | Standard Deviation 35.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C18D22 | -6.67 unit on a scale | Standard Deviation 30.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C8D22 | -0.51 unit on a scale | Standard Deviation 15.01 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C9D1 | -1.61 unit on a scale | Standard Deviation 16.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C9D22 | -0.61 unit on a scale | Standard Deviation 17.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C10D1 | -2.38 unit on a scale | Standard Deviation 17.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C10D22 | -2.33 unit on a scale | Standard Deviation 18.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C11D1 | -1.45 unit on a scale | Standard Deviation 19.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C11D22 | 2.15 unit on a scale | Standard Deviation 14.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C12D1 | -0.81 unit on a scale | Standard Deviation 13.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C12D22 | -1.33 unit on a scale | Standard Deviation 15.15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C13D1 | 0.95 unit on a scale | Standard Deviation 22.12 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C13D22 | 1.59 unit on a scale | Standard Deviation 16.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C14D1 | 0.00 unit on a scale | Standard Deviation 15.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C14D22 | -1.75 unit on a scale | Standard Deviation 13.49 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C15D1 | -2.47 unit on a scale | Standard Deviation 12.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C15D22 | -3.92 unit on a scale | Standard Deviation 11.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C16D1 | 0.00 unit on a scale | Standard Deviation 10.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C16D22 | -2.38 unit on a scale | Standard Deviation 8.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C17D1 | -3.70 unit on a scale | Standard Deviation 10.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C18D1 | 0.00 unit on a scale | Standard Deviation 12.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C18D22 | 0.00 unit on a scale | Standard Deviation 22.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C19D1 | -2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C19D22 | -3.03 unit on a scale | Standard Deviation 17.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C20D1 | -4.44 unit on a scale | Standard Deviation 11.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C20D22 | -3.33 unit on a scale | Standard Deviation 18.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C21D1 | -4.76 unit on a scale | Standard Deviation 12.1 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C22D1 | -2.78 unit on a scale | Standard Deviation 17.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C23D1 | 2.56 unit on a scale | Standard Deviation 16.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing 30 Day follow up | 0.00 unit on a scale | Standard Deviation 17.31 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing 90 Day follow up | 1.63 unit on a scale | Standard Deviation 22.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing Baseline | 16.73 unit on a scale | Standard Deviation 22.85 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C1D22 | -3.04 unit on a scale | Standard Deviation 21.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C2D1 | -4.19 unit on a scale | Standard Deviation 24.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C2D22 | -3.70 unit on a scale | Standard Deviation 27.04 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C3D1 | -5.78 unit on a scale | Standard Deviation 24.12 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C3D22 | -4.28 unit on a scale | Standard Deviation 23.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C4D1 | -7.04 unit on a scale | Standard Deviation 23.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C4D22 | -4.20 unit on a scale | Standard Deviation 23.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C5D1 | -5.32 unit on a scale | Standard Deviation 22.18 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C5D22 | -3.48 unit on a scale | Standard Deviation 23.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C6D1 | -3.03 unit on a scale | Standard Deviation 22.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C6D22 | -5.80 unit on a scale | Standard Deviation 22.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C7D1 | -4.42 unit on a scale | Standard Deviation 19.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C7D22 | -7.31 unit on a scale | Standard Deviation 20.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C8D1 | -3.29 unit on a scale | Standard Deviation 20.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C8D22 | -5.64 unit on a scale | Standard Deviation 21.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C9D1 | -1.61 unit on a scale | Standard Deviation 22.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C9D22 | -1.82 unit on a scale | Standard Deviation 22.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C10D1 | -4.17 unit on a scale | Standard Deviation 22.97 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C10D22 | -3.88 unit on a scale | Standard Deviation 25.42 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C11D1 | -1.45 unit on a scale | Standard Deviation 26.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C11D22 | 0.00 unit on a scale | Standard Deviation 22.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C12D1 | -4.88 unit on a scale | Standard Deviation 24.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C12D22 | -6.67 unit on a scale | Standard Deviation 23.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C13D1 | -8.57 unit on a scale | Standard Deviation 21.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C13D22 | -4.76 unit on a scale | Standard Deviation 28.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C14D1 | -2.22 unit on a scale | Standard Deviation 26.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C14D22 | -7.02 unit on a scale | Standard Deviation 26.24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C15D1 | -1.23 unit on a scale | Standard Deviation 25.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C15D22 | -7.84 unit on a scale | Standard Deviation 25.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C16D1 | -9.09 unit on a scale | Standard Deviation 21.04 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C16D22 | -9.52 unit on a scale | Standard Deviation 27.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C17D1 | -3.70 unit on a scale | Standard Deviation 25.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C18D1 | -6.25 unit on a scale | Standard Deviation 27.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C18D22 | -10.00 unit on a scale | Standard Deviation 22.5 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C19D1 | -4.44 unit on a scale | Standard Deviation 21.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C19D22 | -6.06 unit on a scale | Standard Deviation 25.03 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C20D1 | -4.44 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C20D22 | -6.67 unit on a scale | Standard Deviation 21.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C21D1 | 0.00 unit on a scale | Standard Deviation 26.15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C22D1 | -2.78 unit on a scale | Standard Deviation 26.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing C23D1 | 0.00 unit on a scale | Standard Deviation 23.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing 30 day follow up | -5.93 unit on a scale | Standard Deviation 26.24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with coughing 90 Day follow up | -2.85 unit on a scale | Standard Deviation 21.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking Baseline | 5.97 unit on a scale | Standard Deviation 15.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C1D22 | 1.60 unit on a scale | Standard Deviation 14.56 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C2D1 | -0.75 unit on a scale | Standard Deviation 15.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C2D22 | 0.93 unit on a scale | Standard Deviation 15.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C3D1 | -0.34 unit on a scale | Standard Deviation 15.09 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C3D22 | 0.23 unit on a scale | Standard Deviation 15.31 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C4D1 | -0.21 unit on a scale | Standard Deviation 14.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C4D22 | -0.52 unit on a scale | Standard Deviation 17.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C5D1 | 1.16 unit on a scale | Standard Deviation 17.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C5D22 | 1.45 unit on a scale | Standard Deviation 19.94 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C6D1 | 1.10 unit on a scale | Standard Deviation 16.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C6D22 | 1.09 unit on a scale | Standard Deviation 16.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C7D1 | 0.34 unit on a scale | Standard Deviation 14.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C7D22 | 0.46 unit on a scale | Standard Deviation 15.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C8D1 | 5.35 unit on a scale | Standard Deviation 17.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C8D22 | 3.59 unit on a scale | Standard Deviation 18.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C9D1 | 3.23 unit on a scale | Standard Deviation 17.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C9D22 | 1.82 unit on a scale | Standard Deviation 13.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C10D1 | 2.38 unit on a scale | Standard Deviation 12.48 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C10D22 | 4.65 unit on a scale | Standard Deviation 18.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C11D1 | 4.35 unit on a scale | Standard Deviation 19.38 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C11D22 | 4.30 unit on a scale | Standard Deviation 22.35 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C12D1 | 2.44 unit on a scale | Standard Deviation 17.3 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C12D22 | 8.00 unit on a scale | Standard Deviation 24.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C13D1 | 4.76 unit on a scale | Standard Deviation 21.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C13D22 | 6.35 unit on a scale | Standard Deviation 22.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C14D1 | 3.33 unit on a scale | Standard Deviation 13.42 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C14D22 | 1.75 unit on a scale | Standard Deviation 7.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C19D1 | -2.22 unit on a scale | Standard Deviation 23.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C19D22 | 0.00 unit on a scale | Standard Deviation 29.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C20D1 | -4.44 unit on a scale | Standard Deviation 24.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C20D22 | -6.67 unit on a scale | Standard Deviation 30.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C21D1 | -2.38 unit on a scale | Standard Deviation 27.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C15D1 | 1.23 unit on a scale | Standard Deviation 11.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C15D22 | -1.96 unit on a scale | Standard Deviation 8.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C16D1 | 1.52 unit on a scale | Standard Deviation 12.5 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C16D22 | 0.00 unit on a scale | Standard Deviation 13.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C21D22 | -11.11 unit on a scale | Standard Deviation 21.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C22D1 | -2.56 unit on a scale | Standard Deviation 28.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth C23D1 | -2.56 unit on a scale | Standard Deviation 28.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth 30 day follow up | 5.19 unit on a scale | Standard Deviation 36.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dry Mouth 90 Day follow up | 4.47 unit on a scale | Standard Deviation 33.85 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste Baseline | 11.54 unit on a scale | Standard Deviation 22.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C1D22 | 8.17 unit on a scale | Standard Deviation 27.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C2D1 | 4.19 unit on a scale | Standard Deviation 28.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C17D1 | 0.00 unit on a scale | Standard Deviation 11.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C18D1 | 0.00 unit on a scale | Standard Deviation 12.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C18D22 | -3.33 unit on a scale | Standard Deviation 10.54 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C19D1 | 2.22 unit on a scale | Standard Deviation 15.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C19D22 | -3.03 unit on a scale | Standard Deviation 10.05 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C20D1 | 0.00 unit on a scale | Standard Deviation 12.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C2D22 | 10.56 unit on a scale | Standard Deviation 31.01 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C3D1 | 9.35 unit on a scale | Standard Deviation 30.53 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C3D22 | 13.51 unit on a scale | Standard Deviation 31.31 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C4D1 | 15.94 unit on a scale | Standard Deviation 34.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C4D22 | 16.01 unit on a scale | Standard Deviation 35.1 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C5D1 | 15.05 unit on a scale | Standard Deviation 29.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C5D22 | 16.52 unit on a scale | Standard Deviation 30.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C6D1 | 15.70 unit on a scale | Standard Deviation 26.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C6D22 | 10.87 unit on a scale | Standard Deviation 28.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C7D1 | 9.18 unit on a scale | Standard Deviation 23.83 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C7D22 | 10.50 unit on a scale | Standard Deviation 24.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C8D1 | 10.70 unit on a scale | Standard Deviation 22.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C8D22 | 11.28 unit on a scale | Standard Deviation 22.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C9D1 | 12.37 unit on a scale | Standard Deviation 28.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C9D22 | 11.52 unit on a scale | Standard Deviation 27.38 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C10D1 | 8.33 unit on a scale | Standard Deviation 21.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C10D22 | 9.30 unit on a scale | Standard Deviation 23.37 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C11D1 | 7.25 unit on a scale | Standard Deviation 20.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C11D22 | 8.60 unit on a scale | Standard Deviation 24.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C12D1 | 8.13 unit on a scale | Standard Deviation 17.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C12D22 | 16.00 unit on a scale | Standard Deviation 27.42 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C13D1 | 10.48 unit on a scale | Standard Deviation 25.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C13D22 | 22.22 unit on a scale | Standard Deviation 30.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C14D1 | 14.44 unit on a scale | Standard Deviation 27.24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C14D22 | 12.28 unit on a scale | Standard Deviation 22.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C15D1 | 6.17 unit on a scale | Standard Deviation 18.58 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C15D22 | 3.92 unit on a scale | Standard Deviation 20.01 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C16D1 | 4.55 unit on a scale | Standard Deviation 18.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C16D22 | 4.76 unit on a scale | Standard Deviation 22.1 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C17D1 | 5.56 unit on a scale | Standard Deviation 20.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C18D1 | 4.17 unit on a scale | Standard Deviation 20.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C18D22 | 6.67 unit on a scale | Standard Deviation 26.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C19D1 | 4.44 unit on a scale | Standard Deviation 17.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C19D22 | 6.06 unit on a scale | Standard Deviation 25.03 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C20D1 | 6.67 unit on a scale | Standard Deviation 22.54 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C20D22 | 0.00 unit on a scale | Standard Deviation 15.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C21D1 | 0.00 unit on a scale | Standard Deviation 13.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C22D1 | 5.56 unit on a scale | Standard Deviation 23.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste C23D1 | 5.13 unit on a scale | Standard Deviation 22.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste 30 day follow up | 15.93 unit on a scale | Standard Deviation 32.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble with taste 90 day follow up | 13.82 unit on a scale | Standard Deviation 32.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image Baseline | 24.90 unit on a scale | Standard Deviation 30.8 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C1D22 | -0.96 unit on a scale | Standard Deviation 26.6 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C2D1 | 0.00 unit on a scale | Standard Deviation 31 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C2D22 | 2.78 unit on a scale | Standard Deviation 30.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C3D1 | -0.51 unit on a scale | Standard Deviation 29.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C3D22 | -0.90 unit on a scale | Standard Deviation 28.02 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C4D1 | -4.35 unit on a scale | Standard Deviation 28.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C4D22 | -3.41 unit on a scale | Standard Deviation 26.84 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C5D1 | -3.01 unit on a scale | Standard Deviation 26.42 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C5D22 | -2.32 unit on a scale | Standard Deviation 34.69 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C6D1 | -1.93 unit on a scale | Standard Deviation 28.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C6D22 | -4.71 unit on a scale | Standard Deviation 29.06 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C7D1 | -2.72 unit on a scale | Standard Deviation 31.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C7D22 | -5.48 unit on a scale | Standard Deviation 34.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C8D1 | -2.88 unit on a scale | Standard Deviation 30.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C8D22 | -6.15 unit on a scale | Standard Deviation 29.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C9D1 | -8.06 unit on a scale | Standard Deviation 32.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C9D22 | -8.48 unit on a scale | Standard Deviation 32.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C10D1 | -4.17 unit on a scale | Standard Deviation 33.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C10D22 | -10.08 unit on a scale | Standard Deviation 31.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C11D1 | -5.07 unit on a scale | Standard Deviation 31.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C11D22 | -7.53 unit on a scale | Standard Deviation 33.01 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C12D1 | -7.32 unit on a scale | Standard Deviation 30.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C12D22 | -4.00 unit on a scale | Standard Deviation 26.03 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C13D1 | -5.71 unit on a scale | Standard Deviation 27.4 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C13D22 | -12.70 unit on a scale | Standard Deviation 32.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C14D1 | -11.11 unit on a scale | Standard Deviation 33.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C14D22 | -12.28 unit on a scale | Standard Deviation 33.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C15D1 | -12.35 unit on a scale | Standard Deviation 33.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C15D22 | -17.65 unit on a scale | Standard Deviation 33.58 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C16D1 | -10.61 unit on a scale | Standard Deviation 37.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C16D22 | -14.29 unit on a scale | Standard Deviation 33.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C17D1 | -7.41 unit on a scale | Standard Deviation 26.95 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C18D1 | -4.17 unit on a scale | Standard Deviation 31.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C18D22 | -20.00 unit on a scale | Standard Deviation 28.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C19D1 | -4.44 unit on a scale | Standard Deviation 30.52 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C19D22 | -12.12 unit on a scale | Standard Deviation 34.23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C20D1 | -8.89 unit on a scale | Standard Deviation 29.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C20D22 | -16.67 unit on a scale | Standard Deviation 32.39 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C21D1 | 2.38 unit on a scale | Standard Deviation 40.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble Talking C20D22 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C21D1 | -2.38 unit on a scale | Standard Deviation 8.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C22D1 | 0.00 unit on a scale | Standard Deviation 14.21 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking C22D22 | 0.00 unit on a scale | Standard Deviation 13.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C22D1 | -13.89 unit on a scale | Standard Deviation 36.12 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image C23D1 | -5.13 unit on a scale | Standard Deviation 35.61 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image 30 day follow up | 5.56 unit on a scale | Standard Deviation 31.7 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Body Image 90 Day follow up | 8.94 unit on a scale | Standard Deviation 29.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva Baseline | 9.08 unit on a scale | Standard Deviation 20.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C1D22 | -2.40 unit on a scale | Standard Deviation 19.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C2D1 | -3.44 unit on a scale | Standard Deviation 24.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C2D22 | -2.41 unit on a scale | Standard Deviation 24.16 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C3D1 | -2.89 unit on a scale | Standard Deviation 22.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C3D22 | -2.25 unit on a scale | Standard Deviation 21.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C4D1 | -3.11 unit on a scale | Standard Deviation 21.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C4D22 | 0.26 unit on a scale | Standard Deviation 21.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C5D1 | -2.78 unit on a scale | Standard Deviation 19.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C5D22 | -1.45 unit on a scale | Standard Deviation 21.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C6D1 | -0.55 unit on a scale | Standard Deviation 20.63 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C6D22 | -1.45 unit on a scale | Standard Deviation 20.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C7D1 | -1.70 unit on a scale | Standard Deviation 18.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C7D22 | -0.91 unit on a scale | Standard Deviation 20.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C8D1 | -2.47 unit on a scale | Standard Deviation 18.09 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C8D22 | -3.59 unit on a scale | Standard Deviation 22.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C9D1 | -2.15 unit on a scale | Standard Deviation 19.9 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C9D22 | -2.42 unit on a scale | Standard Deviation 20.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C10D1 | -2.38 unit on a scale | Standard Deviation 19.96 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C10D22 | -0.78 unit on a scale | Standard Deviation 21.19 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C11D1 | 1.45 unit on a scale | Standard Deviation 23.26 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C11D22 | 4.30 unit on a scale | Standard Deviation 11.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C12D1 | 0.00 unit on a scale | Standard Deviation 21.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C12D22 | 2.67 unit on a scale | Standard Deviation 16.44 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C13D1 | 0.00 unit on a scale | Standard Deviation 22.87 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C13D22 | 0.00 unit on a scale | Standard Deviation 25.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C14D1 | -3.33 unit on a scale | Standard Deviation 20.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C14D22 | -3.51 unit on a scale | Standard Deviation 24.58 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C15D1 | -6.17 unit on a scale | Standard Deviation 20.75 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C15D22 | -5.88 unit on a scale | Standard Deviation 24.25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C16D1 | -3.03 unit on a scale | Standard Deviation 22.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C16D22 | -7.14 unit on a scale | Standard Deviation 26.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C17D1 | -5.56 unit on a scale | Standard Deviation 23.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C18D1 | -6.25 unit on a scale | Standard Deviation 25 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C18D22 | 3.33 unit on a scale | Standard Deviation 10.54 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C19D1 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C19D22 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C20D1 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C20D22 | 3.33 unit on a scale | Standard Deviation 10.54 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C21D1 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C22D1 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva C23D1 | 0.00 unit on a scale | Standard Deviation 0 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva 30 Day follow up | -0.37 unit on a scale | Standard Deviation 24.73 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble swallowing saliva 90 Day follow up | -1.63 unit on a scale | Standard Deviation 24.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing Baseline | 6.10 unit on a scale | Standard Deviation 15.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C1D22 | -1.28 unit on a scale | Standard Deviation 16.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C2D1 | -1.05 unit on a scale | Standard Deviation 13.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C2D22 | -1.30 unit on a scale | Standard Deviation 16.29 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C3D1 | -0.34 unit on a scale | Standard Deviation 15.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C3D22 | -2.93 unit on a scale | Standard Deviation 16.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C4D1 | -1.86 unit on a scale | Standard Deviation 16.77 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C4D22 | -0.26 unit on a scale | Standard Deviation 17.57 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C5D1 | -2.08 unit on a scale | Standard Deviation 15.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C5D22 | 0.29 unit on a scale | Standard Deviation 18.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C6D1 | 0.83 unit on a scale | Standard Deviation 17.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C6D22 | -2.90 unit on a scale | Standard Deviation 14.54 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C7D1 | -2.04 unit on a scale | Standard Deviation 15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Choked when swallowing C7D22 | -1.37 unit on a scale | Standard Deviation 16.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking 30 day follow up | 2.59 unit on a scale | Standard Deviation 15.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Trouble talking 90 Day follow up | 4.88 unit on a scale | Standard Deviation 14.93 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss Baseline | 34.24 unit on a scale | Standard Deviation 31.38 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C1D22 | -2.72 unit on a scale | Standard Deviation 28.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C2D1 | -7.92 unit on a scale | Standard Deviation 28.33 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C2D22 | -6.11 unit on a scale | Standard Deviation 30.41 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C3D1 | -9.35 unit on a scale | Standard Deviation 30.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C3D22 | -9.46 unit on a scale | Standard Deviation 29.62 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C4D1 | -13.87 unit on a scale | Standard Deviation 29.71 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C4D22 | -12.34 unit on a scale | Standard Deviation 29.04 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C5D1 | -12.04 unit on a scale | Standard Deviation 28.32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C5D22 | -13.33 unit on a scale | Standard Deviation 32.08 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C6D1 | -11.02 unit on a scale | Standard Deviation 30.24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C6D22 | -15.58 unit on a scale | Standard Deviation 30.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C7D1 | -15.31 unit on a scale | Standard Deviation 28.38 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C7D22 | -21.00 unit on a scale | Standard Deviation 31.18 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C8D1 | -13.58 unit on a scale | Standard Deviation 27.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C8D22 | -14.87 unit on a scale | Standard Deviation 27.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C9D1 | -13.98 unit on a scale | Standard Deviation 25.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C9D22 | -19.39 unit on a scale | Standard Deviation 28.47 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C10D1 | -16.07 unit on a scale | Standard Deviation 31.78 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C10D22 | -20.93 unit on a scale | Standard Deviation 30.88 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C11D1 | -15.94 unit on a scale | Standard Deviation 32 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C11D22 | -17.20 unit on a scale | Standard Deviation 29.65 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C12D1 | -18.70 unit on a scale | Standard Deviation 28.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C12D22 | -20.00 unit on a scale | Standard Deviation 30.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C13D1 | -21.90 unit on a scale | Standard Deviation 33.28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C13D22 | -25.40 unit on a scale | Standard Deviation 23.34 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C14D1 | -21.11 unit on a scale | Standard Deviation 29.66 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C14D22 | -26.32 unit on a scale | Standard Deviation 30.59 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C15D1 | -23.46 unit on a scale | Standard Deviation 34.36 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C15D22 | -23.53 unit on a scale | Standard Deviation 38.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C16D1 | -18.18 unit on a scale | Standard Deviation 38.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C16D22 | -23.81 unit on a scale | Standard Deviation 27.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C17D1 | -20.37 unit on a scale | Standard Deviation 30.55 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C18D1 | -16.67 unit on a scale | Standard Deviation 32.2 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C18D22 | -30.00 unit on a scale | Standard Deviation 29.19 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C19D1 | -17.78 unit on a scale | Standard Deviation 33.01 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C19D22 | -27.27 unit on a scale | Standard Deviation 32.72 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C20D1 | -17.78 unit on a scale | Standard Deviation 27.79 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C20D22 | -30.00 unit on a scale | Standard Deviation 33.15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C21D1 | -23.81 unit on a scale | Standard Deviation 30.46 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C22D1 | -16.67 unit on a scale | Standard Deviation 36.24 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss C23D1 | -15.38 unit on a scale | Standard Deviation 37.55 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight loss 30 day follow up | -9.63 unit on a scale | Standard Deviation 33.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Weight Loss 90 Day follow up | -6.91 unit on a scale | Standard Deviation 37.31 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss Baseline | 14.14 unit on a scale | Standard Deviation 29.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C1D22 | 4.07 unit on a scale | Standard Deviation 29.05 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C2D1 | 3.10 unit on a scale | Standard Deviation 28 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C2D22 | 3.45 unit on a scale | Standard Deviation 24.14 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C3D1 | 2.70 unit on a scale | Standard Deviation 30.81 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C3D22 | 0.00 unit on a scale | Standard Deviation 27.22 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C4D1 | 7.78 unit on a scale | Standard Deviation 34.67 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C4D22 | 11.59 unit on a scale | Standard Deviation 21.58 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C5D1 | 10.67 unit on a scale | Standard Deviation 26.74 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C5D22 | 0.00 unit on a scale | Standard Deviation 37.27 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C6D1 | 9.52 unit on a scale | Standard Deviation 28.17 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C6D22 | 4.76 unit on a scale | Standard Deviation 38.91 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C7D1 | 7.84 unit on a scale | Standard Deviation 30.11 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C7D22 | 5.56 unit on a scale | Standard Deviation 37.15 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C8D1 | 0.00 unit on a scale | Standard Deviation 30.86 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C8D22 | 2.78 unit on a scale | Standard Deviation 26.43 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C9D1 | 0.00 unit on a scale | Standard Deviation 36.51 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C9D22 | 0.00 unit on a scale | Standard Deviation 40.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C10D1 | 6.67 unit on a scale | Standard Deviation 40.98 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C10D22 | -9.52 unit on a scale | Standard Deviation 53.45 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C11D1 | 0.00 unit on a scale | Standard Deviation 43.64 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C11D22 | 4.76 unit on a scale | Standard Deviation 23 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C12D1 | -5.56 unit on a scale | Standard Deviation 49.07 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C12D22 | -16.67 unit on a scale | Standard Deviation 40.82 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C13D22 | 4.76 unit on a scale | Standard Deviation 29.99 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss C14D1 | 6.67 unit on a scale | Standard Deviation 27.89 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Hair loss 30 day follow up | 18.18 unit on a scale | Standard Deviation 22.92 |
| mFOLFOX6+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire | Dysphagia C12D1 | -4.34 unit on a scale | Standard Deviation 18.9 |
Secondary
Duration Of Response (DOR)
DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.PD was defined as development of new, or progression of existing metastases to the primary cancer under the sudy.
Time frame: From date of first response (CR/PR) until 62 months and 18 day
Population: FAS - All Objective Responders
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Duration Of Response (DOR) | 9.00 Months |
| mFOLFOX6+ Placebo | Duration Of Response (DOR) | 8.11 Months |
p-value: 0.072195% CI: [0.573, 1.087]Log Rank
Secondary
Number of Participants With Anti-drug Antibodies (ADA)
Immunogenicity will be measured by the number of participants that are ADA positive.
Time frame: Predose on C1D1, C1D22, C3D1, C5D1, C7D1, C9D1, 30-day follow up, 90-day follow up
Population: Participants who were randomized to zolbetuximab + mFOLFOX6 Arm with at least One Valid Result for ADA.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | 90 day follow up | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | C1D1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | C1D22 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | C3D1 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | C5D1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | C7D1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | C9D1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Anti-drug Antibodies (ADA) | 30 day follow up | 4 Participants |
Secondary
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.
Time frame: Baseline, cycle (C) 1 day (D) 22, D1 and D22 of C2 through C39
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 1 | 97 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 2 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 2 | 5 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 0 | 94 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 1 | 118 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 2 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 0 | 78 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 1 | 118 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 0 | 78 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 0 | 49 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 1 | 84 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 2 | 6 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 0 | 70 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 1 | 101 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 2 | 8 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 0 | 57 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 1 | 67 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 2 | 5 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 0 | 66 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 1 | 82 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 2 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 3 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 0 | 51 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 1 | 67 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 0 | 65 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 1 | 70 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 2 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 3 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 0 | 46 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 1 | 56 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 2 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 0 | 53 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 1 | 62 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 0 | 37 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 1 | 47 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 2 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 0 | 45 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 1 | 48 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 2 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 0 | 33 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 0 | 40 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 1 | 41 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 0 | 29 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 1 | 38 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 1 | 39 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 2 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 0 | 26 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 1 | 35 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 0 | 28 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 1 | 37 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 2 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 0 | 24 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 1 | 25 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 0 | 26 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 1 | 34 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 1 | 29 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 0 | 23 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 1 | 24 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 0 | 18 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 0 | 19 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 1 | 24 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 0 | 15 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 1 | 21 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 0 | 20 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 0 | 14 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 1 | 18 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 0 | 15 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 1 | 18 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 0 | 9 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 0 | 13 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 1 | 17 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 0 | 11 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 0 | 9 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 1 | 17 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 0 | 9 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 1 | 12 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 0 | 9 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 1 | 16 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 0 | 7 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 1 | 11 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 0 | 8 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 1 | 14 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 0 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 0 | 6 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 0 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 1 | 7 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 0 | 5 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 0 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 1 | 9 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 0 | 6 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 0 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 0 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 0 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 1 | 9 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 0 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 1 | 6 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 0 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 1 | 10 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 0 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 1 | 7 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 0 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 1 | 9 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 0 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 1 | 7 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 0 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 1 | 6 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 1 | 5 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 0 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 1 | 7 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D22 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 0 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 1 | 5 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 1 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 1 | 5 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D22 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D22 Score 1 | 4 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 1 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D22 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D22 Score 1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D22 Score 0 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D22 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D22 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D22 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D22 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D22 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D22 Score 0 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D22 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 2 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 2 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 1 | 42 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 0 | 36 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 0 | 23 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 1 | 19 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 1 | 21 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 1 | 13 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 1 | 7 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 0 | 3 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 0 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D22 Score 1 | 6 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D22 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 1 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 1 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 2 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 0 | 125 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 1 | 153 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 2 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 3 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 0 | 83 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 1 | 116 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 2 | 8 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 3 | 2 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 0 | 103 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 1 | 127 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 2 | 8 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 3 | 1 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 4 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 5 | 0 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 0 | 64 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 1 | 113 Participants |
| mFOLFOX6 + Zolbetuximab | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 2 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 1 | 7 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 1 | 59 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 1 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 2 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 0 | 43 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 1 | 28 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 0 | 27 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 0 | 10 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 2 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 0 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 1 | 9 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 0 | 8 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 0 | 5 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 0 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 0 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 0 | 8 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 1 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 1 | 9 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 0 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 0 | 115 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 1 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 1 | 163 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 0 | 6 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 0 | 102 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 1 | 133 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 1 | 5 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 2 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 1 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C1D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 0 | 112 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 1 | 144 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 2 | 6 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 1 | 7 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 0 | 78 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 0 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 1 | 123 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 2 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 0 | 91 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 1 | 132 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 2 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 0 | 6 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 1 | 6 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 0 | 65 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 1 | 104 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 2 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 1 | 115 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 0 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 0 | 79 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 2 | 5 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 0 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 0 | 8 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 0 | 54 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 1 | 8 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 1 | 89 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 1 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 2 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 3 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 0 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 1 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 0 | 70 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 1 | 101 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 1 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 2 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 3 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 0 | 7 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 0 | 53 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 1 | 82 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 2 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 1 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 0 | 57 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 1 | 84 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 2 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 0 | 9 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 0 | 50 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 1 | 7 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 0 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 0 | 55 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 1 | 58 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 0 | 45 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 0 | 5 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 1 | 45 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 0 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 0 | 52 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 1 | 46 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 1 | 35 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 1 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 0 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 0 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 1 | 9 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 0 | 40 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 1 | 34 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 1 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 0 | 37 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 0 | 5 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 0 | 34 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 1 | 29 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 0 | 25 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 1 | 23 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 0 | 23 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 0 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 1 | 29 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 0 | 5 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 1 | 8 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 1 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 0 | 22 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 1 | 17 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 1 | 19 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 0 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 2 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 0 | 17 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 1 | 16 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 0 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 0 | 22 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 1 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 1 | 17 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 0 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 1 | 6 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 0 | 14 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 1 | 12 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 0 | 18 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 0 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 1 | 17 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 0 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 1 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 0 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 0 | 12 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 1 | 10 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 0 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 0 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 1 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 0 | 15 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 0 | 3 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 1 | 15 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 1 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 1 | 5 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D22 Score 0 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 0 | 12 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 1 | 8 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D22 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 1 | 1 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 0 | 13 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 1 | 12 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 0 | 2 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 1 | 4 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 4 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 2 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 5 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 3 | 0 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D22 Score 0 | 9 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D22 Score 3 | 0 Participants |
Secondary
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or notconsidered related to the medicinal product. TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.
Time frame: From first dose until 62 months and 18 days
Population: Safety analysis set (SAF) included all participants who received at least 1 dose of any study drug (zolbetuximab/placebo and mFOLFOX6).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 278 Participants |
| mFOLFOX6+ Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 277 Participants |
Secondary
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.
Time frame: From the date of randomization until 62 months and 18 days
Population: FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Objective Response Rate (ORR) | 48.1 Percentage of participants |
| mFOLFOX6+ Placebo | Objective Response Rate (ORR) | 47.5 Percentage of participants |
p-value: 0.4536Cochran-Mantel-Haenszel
Secondary
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Overall Survival (OS) | 18.23 Months |
| mFOLFOX6+ Placebo | Overall Survival (OS) | 15.57 Months |
p-value: 0.007595% CI: [0.644, 0.954]Log Rank
Secondary
Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)
Ctrough was defined as the predose concentration at the end of dosing interval.
Time frame: Predose on C1D22, C3D1, C5D1, C7D1, C9D1
Population: PKAS consisted of the subset of the SAF for which at least 1 zolbetuximab concentration measurement was available. Participants with available data at each timepoint were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| mFOLFOX6 + Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C1D22 | 40.9 micrograms/mililiter (ug/mL) | Standard Deviation 37.2 |
| mFOLFOX6 + Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C3D1 | 70.1 micrograms/mililiter (ug/mL) | Standard Deviation 49.8 |
| mFOLFOX6 + Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C5D1 | 97.4 micrograms/mililiter (ug/mL) | Standard Deviation 50.8 |
| mFOLFOX6 + Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C7D1 | 118.0 micrograms/mililiter (ug/mL) | Standard Deviation 64.9 |
| mFOLFOX6 + Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C9D1 | 135.0 micrograms/mililiter (ug/mL) | Standard Deviation 56.2 |
Secondary
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30
TTCD: time from randomization to first CMD that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items were scored 1 (not at all) to 4 (very much) except for the items contributing to the global health status/QoL, which were scored 1 (very poor) to 7 (excellent). All raw domain scores were linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -10. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | 15.44 Months |
| mFOLFOX6+ Placebo | Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | 11.83 Months |
p-value: 0.168595% CI: [0.874, 1.492]Log Rank
Secondary
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25
TTCD: time from randomization to first CMD that was confirmed at next scheduled visit. EORTC QLQ-OG25 evaluated gastric and GEJ cancer specific symptoms. A 25 item instrument with 6 scales: dysphagia (3 items), eating restrictions (4 ), reflux (2), odynophagia (2), pain and discomfort (2), anxiety (2), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight and hair loss. Items were scored:1: not at all; 2: a little, 3: quite a bit, 4: very much, and were transformed linearly into scores (0 to 100) with higher scores indicating worse symptoms. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of 16.67. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 | NA Months |
| mFOLFOX6+ Placebo | Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 | NA Months |
p-value: 0.050895% CI: [0.475, 1.071]Log Rank
Secondary
Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)
TTCD: time from randomization to first clinically meaning full deterioration (CMD) that was confirmed at next scheduled visit. EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical,role,emotional,social & cognitive), 9 symptom scales (fatigue, nausea/vomiting,general pain,dyspnea,insomnia,appetite loss,constipation,diarrhea,financial difficulties) & global health status scale. Most items were scored 1(not at all) to 4(very much) except for items contributing to global health status/QoL, which were scored 1(very poor) to 7(excellent). All raw domain scores were linearly transformed to 0-100scale with higher scores on symptoms indicate worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -13. This was derived from an Exit Survey conducted using Patient Global Impression of Severity/Change(PGIS/PGIC) questionnaires as an anchor for estimating meaningful change. KM estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| mFOLFOX6 + Zolbetuximab | Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | 9.89 Months |
| mFOLFOX6+ Placebo | Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | 12.32 Months |
p-value: 0.02895% CI: [0.994, 1.687]Log Rank